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ABSTRACT
Macrophage inflammatory protein-1 alpha (MIP-la) is a pro-inflammatory 
cytokine and a regulator of haemopoiesis. Little is currently known regarding the 
network of regulatory factors controlling the expression of MIP-la, within the bone 
marrow microenvironment. This study was therefore initiated to further understand 
how expression of this gene is regulated by haemopoietic growth factors. 
Macrophages are likely to be an important source of MIP-la within the bone marrow 
and this study has therefore used primary murine bone marrow-derived macrophages 
and Northern blot analysis to examine the expression of MIP-la following treatment 
with various growth factors.
The results presented in this thesis show that treatment of bone marrow- 
derived macrophages with granulocyte-macrophage colony-stimulating factor (GM- 
CSF) results in a striking increase in MIP-la mRNA levels, relative to control cells. 
This increase in MIP-la mRNA expression was also followed by an increase in MIP- 
la  protein levels in these cells, suggesting that the potent stimulatory effect of GM- 
CSF on macrophage-derived MIP-la expression may be of physiological or 
pathological significance. Since GM-CSF, interleukin- (IL-) 3 and IL-5 all share a 
common p-chain subunit in their receptors and can functionally substitute for each 
other in certain cell types, primary macrophages were also treated with IL-3 or IL-5. A 
similar increase in mRNA levels was found when macrophages were treated with IL- 
3, but not IL-5. An increase in the expression of mRNAs for three other CC 
chemokines: MIP-lp, JE and MARC, was also found following treatment with GM- 
CSF or IL-3, implying that the potent stimulatory effects of GM-CSF and IL-3 are not 
restricted to MIP-la and may therefore also have an impact on the expression of other 
CC chemokines.
Previous work from our group has provided evidence of an endogenous 
reciprocal relationship in macrophages, between MIP-la and transforming growth 
factor-beta (TGF-p), in which TGF-p acts to suppress MIP-la expression. To 
investigate the potential effect of GM-CSF and IL-3 on the relationship between 
TGF-p and MIP-la, the effect of TGF-p on the GM-CSF-or IL-3-induced expression 
of MIP-la mRNA was assessed. TGF-p was able to suppress the GM-CSF-or IL-3-
Vinduced expression of MIP-la mRNA, but this suppression was not complete. These 
results suggest that GM-CSF and IL-3 may therefore be two potential stimulatory 
signals, that may be sufficiently potent to overcome the TGF-p mediated block on 
MIP-la expression. Similar effects on the expression of the GM-CSF or IL-3 induced 
expression of MIP-ip, JE and MARC were also observed. The significance of this is 
unclear, but may reflect the widely recognised function of TGF-p as an immuno­
suppressive molecule.
A previous study in our laboratory suggested that TGF-P reversibly 
downregulated the expression of MIP-la receptors on the murine FDCPmix cell line. 
Therefore, the effect of GM-CSF and IL-3 on the expression of various receptors for 
MIP-la on bone marrow-derived macrophages was also examined and an increase in 
the expression of CCR1 mRNA levels was observed, but no change was seen in the 
level of mRNA for CCR5. This suggests that CCR1 and CCR5 expression may be 
differently regulated in bone marrow-derived macrophages. TGF-p was observed to 
have only a minimal suppressive effect on the expression of CCR1 and CCR5 mRNA. 
Binding studies revealed that treatment of bone marrow macrophages with GM-CSF 
also resulted in an increase in the overall levels of MIP-la receptors on these cells. 
Scatchard analysis showed that GM-CSF increased the number of MIP-la receptors 
with no change in the affinity of the remaining receptors for MIP-la ligand. The Kd’s 
for the receptors detected in this study are similar to those previously reported for 
murine CCR1, but different to those for CCR5. This observation, together with the 
lack of effect of GM-CSF on CCR5 expression suggests, that this increase in MIP-la 
receptor numbers probably reflects an increase in the cell surface expression of CCR1. 
To investigate the functional significance of this increase in MIP-la receptors, the 
effect of GM-CSF on the ability of macrophages to mobilise calcium in response to 
MIP-la was examined. In one experiment, treatment of bone marrow-derived 
macrophages with GM-CSF appeared to result in a slight increase in the ability of 
these cells to respond to MIP-la. In most cases however, their ability to flux was 
highly variable, suggesting they were not an ideal choice for calcium flux analysis and 
therefore the pro-monocytic human THP-1 cell line was used instead. GM-CSF 
stimulation of THP-1 cells resulted in an increase in the expression of CCR1 mRNA, 
similar to that observed in bone marrow-derived macrophages, but no increase in
calcium mobilisation was observed in GM-CSF treated THP-1 cells in response to 
MIP-la. The functional significance of the observed GM-CSF-induced increase in 
CCR1 expression therefore remains to be determined.
Using RT-PCR analysis, a preliminary investigation of MIP-la expression in 
tissues derived from a GM-CSF transgenic mouse, revealed that an increased 
expression of MIP-la occurred in samples from the eye (and perhaps also the bone 
marrow) of a GM-CSF transgenic mouse. Although preliminary, these results suggest 
that increased expression of MIP-la may occur under circumstances in which elevated 
GM-CSF expression occurs.
The data presented in this thesis suggest that expression of GM-CSF or IL-3 
may be one mechanism through which the levels of MIP-la and other p chemokines 
produced within the bone marrow by macrophages is increased. Indeed, the 
observation that TGF-P was only partially able to inhibit the induction of MIP-la by 
GM-CSF and IL-3, implies that GM-CSF and IL-3 may be sufficiently potent to 
overcome the proposed TGF-p mediated block on MIP-la expression. Although it is 
impossible to say with certainty, whether these observations reflect an involvement in 
stem cell proliferative control or in inflammatory responses, these results clearly have 
implications for both. In summary, the results presented in this thesis suggest that the 
expression of MIP-la and other chemokines in bone marrow macrophages, is 
regulated through the combined interaction of the positive stimuli exerted by GM-CSF 
and IL-3 and the negative stimulus of TGF-p.
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PART I: INTRODUCTION
1CHAPTER 1: The Haemopoietic System
1.1 The Haemopoietic System: An Overview
The haemopoietic system is essential for the maintained viability of an 
individual. It can be considered as a highly complex cellular system that enables the 
derivation of mature immuno-haemopoietic cells, through the processes of 
proliferation, commitment and differentiation. There are at least eight mature blood 
cell types, functionally distinct from each other, but which are ultimately derived from a 
single self-renewing pluripotent stem cell that differentiates via various different 
committed progenitor cells (some of which are summarised in figure 1.1). This 
complex system has evolved to cope with the on-going production of the vast 
numbers of cells needed on a daily basis, simply to maintain the stasis of the mature 
immuno-haemopoietic system. In fact it is estimated that as many as 3.7 x 1011 
haemopoietic cells are needed per day to maintain human homeostasis. In addition to 
this homeostatic role, the haemopoietic system must also be able to respond rapidly 
with a dramatic increase in cell numbers, in order to be able to combat infection and 
disease (inducible haemopoiesis). The many processes involved in regulating the 
haemopoietic system are likely to be complex and elaborate and yet they must also be 
remarkably efficient because despite the enormous scope for abnormalities, diseases 
such as leukaemia and anaemia are relatively rare.
1.2 The Stem Cell Compartment
One can consider the stem cell compartment in its simplest form, as “a 
heterogeneous compartment consisting of cells displaying varying degrees of self­
renewal capacity and/or differentiation potential” (Graham and Pragnell 1992a). This is 
perhaps best illustrated by considering the haemopoietic system as a three-tiered 
hierarchical system, analagous to a pyramid, which forms an ordered continuum. At the 
apex of this pyramid are the most primitive cells with a high capacity for self-renewal, 
the greatest repopulating ability and which are most resistant to proliferation and 
differentiation stimuli. As one moves further down the hierachy, the cells exhibit a 
reduced capacity for self-renewal and increased tendency for differentiation. At the 
base of this pyramid are the mature cells. It is this remarkable ability to undergo self-
Figure 1.1: Overview of the Haemopoietic System
This figure summarises the ability of the haemopoietic system to generate all the 
necessary different mature blood cell types. Shown is a single pluripotent stem cell, as 
well as the various different progenitor cells and their lineages. Progenitors are defined 
by in vitro assays, according to the cell type to which they give rise and are known as 
colony-forming units (CFU) or burst-forming units (BFU). Abbreviations: E=Erythroid, 
Meg=Megakaryocyte, GM=Granulocyte/Macrophage. For example, CFU-GM represents 
a progenitor giving rise to granulocytes and macrophages.
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renewal and generate differentiated progeny which defines a stem cell. Stem cells 
constitute only a tiny proportion of the total haemopoietic system, probably between 
0.01 and 0.1 % of the total bone marrow of an adult mouse, and it is believed that the 
majority of these are held in a quiescent or Go state (Hodgson et al 1982, Harrison and 
Lemer 1991). Stem cells are triggered into an actively cycling state in order to 
replenish progenitor and mature cell compartments, as a result of stress to the system 
(e.g. following chemotherapy, or during infection). Following replenishment, the stem 
cells re-enter quiescence.
Significant progress in understanding the nature of haemopoietic stem cells 
came from a series of experiments in which it was discovered that transplanted murine 
bone marrow contained progenitor cells that were able to give rise to individual 
macroscopic colonies of myeloid, erythroid and megakaryocytic cells on the surface of 
spleens of lethally irradiated recipient mice (Till and McCulloch 1961). This seminal 
experiment, defined the first in-vivo stem cell assay (the CFU-S assay) and produced 
the first evidence for primitive quiescent stem cells with a capacity for self-renewal 
and differentiation. Due to the difficulty in distinguishing stem cells on the basis of 
their morphology, much of what we now know about stem cells has been derived 
through the development and usage of such in vivo and other, in vitro, assays.
1.3 The In Vivo CFU-S Assay
The aforementioned colony forming unit-spleen (CFU-S) assay (Till and 
McCulloch 1961) was also important in demonstrating that stem cells are in fact a 
heterogeneous population of cells. In this assay, transplantation of donor bone marrow 
cells to a lethally irradiated mouse resulted in the reconstitution of the ablated 
haemopoietic system and enabled the mouse to survive an otherwise potentially lethal 
dose of radiation. During reconstitution, colonies formed on the spleen that were 
donor-derived and which could be detected at various stages of maturity, depending 
upon when the CFU-S assay was read (Siminovich et al 1964). Colonies were first 
visible on the spleen at day 7 or 8 and other colonies were visible at a later time, 
around day 12. Subsequent studies, in which individual day 7/8 spleen colonies were 
transplanted into a similarly lethally irradiated mouse, demonstrated very little 
secondary CFU-S colony formation and indicated that the early appearing (day 7/8) 
colonies were derived from cells with a limited self-renewal/differentiation potential.
4Cells derived from individual day 12 colonies were however able to generate multiple 
secondary CFU-S colonies on serial transplantation, indicating that cells within these 
later-derived colonies had a greater capacity for self-renewal (Wolf and Priestly, 
1986). Put more simply, colonies appearing early at day 7/8 were derived from more 
mature cells, whilst the later appearing day 12 colonies were derived from more 
primitive cells. Originally it was assumed that the day 12 colonies, since they appeared 
later, were derived directly from the earlier appearing day 7/8 colonies by 
differentiation and self-renewal. However studies have shown that 50 % of the day 7/8 
colonies (mostly erythroid in morphology) subsequently regressed, following which, 
colonies were observed at day 12, which had a multi-lineage constitution (Magli et al 
1982). The precise origin of the day 12 colonies remains in controversy, with three 
possible explanations. They may have arisen as a result of re-circulation of CFU-S 
cells that originally seeded in the bone marrow, but which subsequently moved to the 
spleen (Van Zant 1984), or a second explanation is that some stem cells have migrated 
out of the day 7/8 colonies and formed de novo colonies, that appear later at day 12. 
The third and simplest explanation is that the day 12 colonies simply take longer to 
appear. Additional evidence for the heterogeneity of stem cells, at least within the 
CFU-S compartment, has arisen through studies using cell cycle specific toxic drugs, 
such as 5-fluorouracil (5-FU). These studies demonstrated that the day 7/8 CFU-S 
cells were extremely sensitive to the lethal effects of these drugs, whereas the later day 
12 CFU-S cells were less sensitive (Hodgson et al 1982). This suggests that the day 
7/8 cells are largely in cycle, whilst the day 12 cells are in a more quiescent state and 
accordingly represent a more primitive population of stem cells.
Following the early work on the CFU-S assay, it was believed that the day 12 
CFU-S cell could be the ‘ultimate’ or ‘totipotent’ haemopoietic stem cell in vivo. 
Since then however, various lines of evidence have emerged suggesting that the day 
12 CFU-S cell is not the ultimate haemopoietic stem cell. Perhaps most obviously, is 
the inability of the day 12 CFU-S cell to give rise to cells of the lymphopoietic 
lineages. Also, despite the importance of donor CFU-S cells in the reconstitution of 
short-term haemopoiesis in a lethally irradiated mouse (Jones et al 1989), these cells 
are unable to establish long-term in vitro or in vivo haemopoiesis (van der Sluijs et al 
1990). This would suggest the existence of another more primitive or ‘pre-CFU-S’ 
cell, the existence of which was previously suggested (Hodgson and Bradley 1979).
5This pre-CFU-S stem cell would have the ability to give rise to both lymphoid and 
myeloid lineages (from which the more mature CFU-S cell would be derived as a 
myeloid committed stem cell). To date this cell has not been purified to homogeneity, 
but it has been further characterised. Pre-CFU-S cells have been enriched for and 
separated from, CFU-S cells on the basis of its ability to retain the dye Rhodamine 123 
(Ploemacher and Brons 1988, 1989). These cells have been termed long-term 
repopulating cells (LTRC), for their ability to maintain long-term haemopoiesis. These 
cells alone are not sufficient however, to effectively establish haemopoietic 
repopulation in a lethally irradiated animal, nor are they radioprotective. CFU-S cells 
alone will initiate reconstitution, but this will only persist for a short time and mice die 
within about 4 weeks. Full, long-term reconstitution only occurs with transplantation 
of both more mature CFU-S type stem cells, as well as the primitive pre-CFU-S stem 
cells (Jones et al 1990). Therefore, in simplistic terms one can subdivide the stem cell 
compartment into two subcompartments, comprised of the more primitive long-term 
engrafting stem cells and the short-term or transiently engrafting stem cells (reviewed 
by Graham and Wright 1997).
1.4 In vitro Culture of Haemopoietic Stem Cells
1.4.1 In vitro stem cell assays
As mentioned in previous sections, much of what is known about the stem cell 
compartment has been derived from the development of in vitro assays. The basis for 
these assays is the fact that clonogenic bone marrow cells cultured in the presence of 
appropriate growth factors give rise to colonies in semi-solid culture, without the 
addition of supporting stromal cells. The precise combination of cytokines and their 
concentrations vary from assay to assay. The size, morphology and composition of 
these colonies can then be assessed to give an indication of the level of primitiveness 
of the cell from which they were derived. In general, only differentiation along 
myeloid and erythroid lineages is observed.
A number of in vitro assays have been reported, that detect a range of cells 
within the haemopoietic stem cell compartment. The precise role that many of these 
cells play in normal steady-state haemopo iesis in vivo is still uncertain. These assays 
have however, enabled identification of several primitive stem cell types and
6haemopoietic stem cell regulatory factors. Some of these assays are outlined briefly 
below and were recently reviewed by Graham and Wright (1997).
The high proliferative potential colony-forming cell (HPP-CFC) was originally 
identified by Bradley and Hodgson (1979), using a clonal in vitro assay that detected 
macroscopic colonies in agar culture. These HPP-CFC differ from more mature 
haemopoietic cells, by virtue of their relative resistance to 5-fluorouracil, their 
requirement for a combination of regulatory growth factors and their ability to form 
large colonies (>0.5 mm) in agar culture. HPP-CFC have been further defined and 
now form three distinct populations of stem cells, known as HPP-CFC 1, 2 and 3. 
Studies with 5-fluorouracil have suggested that HPP-CFC 1 cells are the more 
primitive, whilst HPP-CFC 2 and 3 are more mature in phenotype. It is believed that 
the HPP-CFC population forms part of the stem cell compartment detected by the in 
vivo CFU-S assay (reviewed by Bertoncello 1992, Graham and Wright 1997).
The CFU-A assay is an in vitro assay that enables detection of primitive 
progenitor cells, that are HPP-CFC-like and which are believed to be equivalent to the 
population of cells detected by the in vivo day 12 CFU-S assay. The CFU-A assay 
detects a cell with an incidence of approximately 200 per 1 x 105 cells in normal bone 
marrow and which forms colonies >2 mm in diameter (Pragnell et al 1988, Lorimore 
etal 1990).
1.4.2 The stromal microenvironment
The most accurate in vitro culture model, of in vivo haemopoietic stem cell 
activity, is obtained through the use of stromal or long-term bone marrow cultures 
(LTBMC). The bone marrow microenvironment is a complex 3-dimensional structure 
consisting of a meshwork of heterogeneous cell types and extracellular matrix 
proteins. It provides an environment that allows the maintenance, self-renewal, 
proliferation and differentiation of haemopoietic stem cells and ultimately their 
migration to the circulation (Dexter 1982, Deryugina and Muller-Sieberg 1993). Bone 
marrow stromal cells are a crucial component in this micro-environment and include 
macrophages, fibroblasts, adipocytes, and endothelial cells (Gordon et al 1980, Mori 
et al 1990, Greenberger 1991). Stromal cells can be grown from freshly isolated bone 
marrow as in vitro cultures and will, under the appropriate conditions, form confluent 
adherent layers that will support the proliferation, differentiation and limited self­
renewal of haemopoietic progenitors in the absence of added haemopoietic growth 
factors. The first stromal cultures were developed using murine haemopoietic tissue 
(Dexter et al 1977a, 1977b) and were subsequently adapted to human cells (Gartner 
and Kaplan 1980). Whilst cells with long-term repopulating ability in vivo can be 
maintained for several weeks in vitro (Fraser et al 1991), both human and murine 
stromal-dependent LTBMCs have a limited life span. In these LTBMCs, committed 
progenitor cells rapidly undergo terminal differentiation and within 4-5 weeks these 
initial committed progenitor cells have disappeared and at this time, other clonogenic 
progenitors are detected. These cells are derived from primitive cells, termed long­
term culture initiating cells (LTC-IC) (Sutherland et al 1989). These LTC-IC appear to 
be present in normal bone marrow at a frequency of approximately 1-5 per 1 x 104 cells 
and were recently shown to be capable of self-renewal and expansion in vitro (Petzer et 
al 1996). Despite their limitations, LTBMC have provided a useful in vitro culture 
system for modelling the structure of the stromal microenvironment and its interactions 
with haemopoietic stem cells.
1.5 Progenitor Cells and Lineages
Haemopoietic stem cells are able to undergo self-renewal, and this has been 
postulated to be of two types. 1) Symmetric self-renewal, which results in the 
generation of two identical daughter stem cells and 2) asymmetric self-renewal, that 
results in an identical daughter stem cell and a daughter cell that is committed to 
differentiation along a specific lineage(s). As shown previously in figure 1.1, 
differentiation occurs through various lineages and via a variety of morphologically 
identifiable intermediate progenitor cells, ultimately giving rise to terminally 
differentiated mature cells. These haemopoietic progenitor cells (HPCs) have only a 
limited capacity for self-renewal and are defined through the ability to give lineage 
specific progeny in in vitro assays. These assays, as those used for HSCs, are based on 
the ability of progenitor cells to form colonies upon culture in semi-solid agar or upon 
methylcellulose, in the presence of the appropriate haemopoietic growth factors. These 
“colony assays” led first to the growth and clonal differentiation of macrophages and 
granulocytes from their progenitor cells (Paran et al 1970, Pike and Robinson 1970) 
and subsequently to the in vitro generation of the majority of other blood cell lineages 
(Stephenson et al 1971, Metcalf et al 1975). The HPCs are defined according to the
8precursor cell type to which they give rise and are known as colony-forming units 
(CFU) or burst-forming units (BFU). So for example, cells from early and late 
progenitors giving rise to colonies containing erythroid cells are known as BFU-E or 
CFU-E, respectively, whilst those progenitors giving rise to granulocytes or 
macrophages are called CFU-GM.
These assays have enabled the identification, characterisation and cloning of a 
multitude of regulatory factors, that have been implicated in the process of stem cell 
function. The function of some of these regulatory factors and their overall importance 
to the regulation of haemopoiesis will be discussed in greater detail in chapter 2.
1.6 Inhibition of Haemopoiesis
The existence of a multitude of positively acting or stimulatory haemopoietic 
growth factors and cytokines, and their potential importance in regulating 
haemopoiesis, is well documented. What is less certain however, is the role inhibitory 
molecules play in haemopoiesis. One can argue that the action of positive regulators 
alone, is sufficient to control the proliferation of haemopoietic stem cells. There are 
however several problems with this argument. On a superficial level, one can question 
if this arrangement would provide a sufficiently rapid and tightly controlled 
regulation. Under normal steady state conditions, it is estimated that only 10 % or 
fewer of the haemopoietic stem cells are in active cell cycle, with the remainder in a 
quiescent or Go phase. One can envisage that stress to the system, such as that of 
inflammation, could result in inducible haemopoiesis (see section 1.7) and activation 
of previously quiescent stem cells. Under circumstances of extreme stress, such as 
bone marrow regeneration following chemotherapy or radiotherapy, even the most 
primitive stem cells are actively cycling (Harrison and Lemer 1991). Following 
activation, the majority of the cells within the haemopoietic stem cell compartment 
then return to their normal quiescent state. The existence of a variety of inhibitory 
molecules, that actively inhibit the cell cycle have been proposed to be responsible for 
the return to, or even maintenance of, stem cell quiescence. Whilst it is possible that 
the action of stimulatory regulators alone may be sufficient to control haemopoietic 
stem cell proliferation, the existence of both positive and negatively acting regulators 
would allow for a far more flexible and responsive system of control. In such a model, 
positive and negative regulators could both operate, and the relative balance between
9their opposing actions would ultimately control the state of haempoietic stem cell 
proliferation.
Further support for the existence of negative regulators comes from the 
identification of molecules that have the ability to inhibit stem cell proliferation 
(reviewed in Axelrad 1990, Graham and Pragnell 1990, Graham 1997). Both novel 
inhibitory molecules, such as the Tetrapeptide (AcSDKP), and Haemoregulatory 
peptide (pEEDCK) (both reviewed in Graham and Pragnell 1990, Guigon and Bonnet 
1995, Graham 1997) have been identified, as well as previously described molecules 
such as TGF-pl, MIP-la and TNF-a. Interestingly some of these ‘cytokines’ appear 
to be able to function bi-directionally, in that they can both stimulate as well as inhibit, 
the growth of some cell types (Keller et al 1994). This will be discussed further in 
sections 2.14.6 and 3.6.5, with regard to the known functions of TGF-pl and MIP-la 
respectively.
1.7 The Stromal Microenvironment and the Production of Soluble Mediators
As mentioned previously, the stromal microenvironment is crucial to the 
regulatory processes involved in haemopoiesis in the bone marrow. Much of what is 
known about the potential role of stromal regulation of haemopoiesis has been 
determined through the investigation of LTBMC and other in vitro culture systems 
designed to mimic the stromal microenvironment. A multitude of studies has been 
reported, particularly with regard to further understanding the relationship between the 
stromal cell network and the various cytokines and other soluble mediators implicated 
in regulating haemopoiesis. At this point, it is worth mentioning inducible 
haemopoiesis (as opposed to constitutive haemopoiesis), which can be defined as 
haemopoiesis induced as a result of an increased need for mature blood cells (e.g. 
during infection and inflammatory responses). Whilst these two forms of 
haemopoiesis may operate under different circumstances and via different mechanistic 
routes, a complex network of interacting cytokines and growth factors has been 
implicated in both. Regardless of which model(s) of haemopoiesis one subscribes to 
(stochastic or instructive; see sections 2.15.1 and 2.15.2), this network of cytokines is 
strongly implicated in a multitude of roles, such as the control of mobilisation, self­
renewal, survival, proliferation, commitment, differentiation and migration of cells
10
within the haemopoietic system. Further discussion of the potential role of this 
network in the control of haemopoiesis is detailed in chapter 2.
1.7.1 Bone marrow and stromal production of cytokines and growth factors
Steady state or constitutive haemopoiesis is regulated in the bone marrow by 
direct cell-cell contact between bone marrow stroma and haemopoietic stem and 
progenitor cells, and by locally produced soluble mediators (see figure 1.2).
Direct cell-cell contact may not be a pre-requisite in LTBMC, which mimic the 
stromal microenvironment, since stromal cells separated from haemopoietic cells by a 
thin porous mesh can still support haemopoiesis (Verfaillie 1992). This suggests that 
these stromal cells can produce soluble mediators that enable haemopoiesis to be 
maintained (Verfaillie 1993, Verfaillie et al 1994). Many studies have examined 
production of such soluble factors both in vivo and in vitro, as discussed below.
Attempts to detect mRNA expression and protein production has been 
complicated by the difficulty in detection of these factors and to date the results are 
still very confused and sometimes even contradictory. Constitutive expression of 
macrophage colony-stimulating factor (M-CSF) and granulocyte-macrophage colony- 
stimulating factor (GM-CSF) by a variety of cell types, including fibroblasts and bone 
marrow stromal cells in long-term culture, have been widely reported (Piersma et al 
1984, Sieff et al 1988, Schaafsma et al 1989, Kittler et al 1992). Detection of 
constitutive expression of granulocyte colony-stimulating factor (G-CSF), stem cell 
factor (SCF) and interleukin (IL)-6 mRNA has also been documented (Kittler et al 
1992, Guba et al 1992). The role of IL-3 in the regulation of constitutive haemopoiesis 
is however, still very confused. Whilst the ability of IL-3 to function as a multilineage 
colony-stimulating factor during the earlier stages of haemopoietic stem cell 
differentiation in vitro are well documented (Sonoda et al 1988, Koike et al 1987) 
attempts to detect constitutive IL-3 expression, without the addition of inducing 
stimuli, have been largely unsucessful (Guba et al 1992, Cluitmans et al 1995). 
Expression of IL-3 has however, been detected in irradiated stromal cells using the 
sensitive technique of polymerase chain reaction (PCR) amplification and addition of 
IL-3 specific antibodies resulted in the abrogation of the ability of these stromal cell 
lines to support the growth of factor dependent cell lines (Kittler et al 1992). These 
results suggest that whilst the presence of growth factors in LTBMC stromal cells and
11
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bone marrow may be undetectable by techniques such as Northern blotting and PCR, 
their actual presence (albeit at extremely low levels) can not be excluded.
Whilst many reports have documented the constitutive expression of GM-CSF 
and G-CSF by a variety of cell types crucially important to the bone marrow 
microenvironment, Cluitmans and his collegues were unable to detect their 
constitutive expression in normal human bone marrow (Cluitmans et al 1995). This 
study suggested that whilst constitutive expression of the cytokines M-CSF, SCF, IL- 
lp, IL-4, IL-6, IL-7, tumour necrosis factor-beta (TNF-P), transforming growth factor- 
beta (TGF-P) and macrophage inflammatory protein-1 alpha (MIP-la) was detectable 
in human bone marrow, expression of G-CSF and GM-CSF was not. This raises the 
question of whether or not GM-CSF and G-CSF play a role in uninduced/normal 
steady-state haemopoiesis. However, it should be noted that although Cluitmans et al 
were unable to detect constitutive GM-CSF expression in normal bone marrow, this 
does not preclude their expression at subliminal levels. Indeed, evidence from studies 
on mice deficient for GM-CSF, suggest that GM-CSF is critical for the homeostasis of 
normal lung physiology and resistance to local infection (Stanley et al 1994) and 
indicates that at least some subliminal GM-CSF expression must occur in vivo. 
Likewise, studies on mice deficient for G-CSF indicate at least some role for G-CSF 
in the in vivo production of granulocytes (Lieschke et al 1994)-
1.7.2 Localisation of growth factors
Many soluble and insoluble mediators are produced by the stromal 
microenvironment, though in many cases, detection of these has proved extremely 
difficult. This suggests that if some of these factors are indeed produced within the 
bone marrow, they may be at extremely low levels (perhaps even below levels 
detectable with current techniques). One possible explanation for this may lie with the 
apparent existence of growth factor localisation. It is now evident that some cytokines 
and growth factors (such as SCF, M-CSF and IL-1) exist not just as soluble forms, but 
also as biologically active membrane or extra-cellular membrane (ECM) bound forms 
(Kurt-Jones et al 1985, Stein et al 1990). Other growth factors, e.g. GM-CSF, IL-3 
and leukemia inhibitory factor (LIF) are also able to bind to components of the ECM 
(Gordon et al 1987, Roberts et al 1988). The ability to bind components of the ECM, 
as found within the stromal microenvironment, would enable these growth factors to
13
be held in an active, but highly localised fashion. There is some intriguing evidence 
that certain components of the ECM, such as heparan sulphate and other 
glycosaminoglycan (GAG) derivatives, can function directly on their own to regulate 
growth factor expression (Wrenshall et al 1991, Yang and Yang 1995). With the 
possible exception of fibroblast growth factor (Spivak-Kroizman et al 1994), these 
proteoglycan interactions are clearly not essential for growth factor function as 
exogenous soluble growth factors will function in the absence of such interactions. 
This does not however exclude their involvement in a localised niche within the stem 
cell microenvironment, perhaps in the sequestration or presentation of growth factors.
1.8 Haemopoietic Regulators and the Cytokine Network: Redundancy or 
Eloquent Control ?
There are a vast number of cytokines and growth factors and some of these, are 
summarised in table 1.1. Whilst not all play a direct role in regulating haemopoiesis, a 
large number of them clearly do. Given the known complexity and precision of 
haemopoiesis, it is not really a surprise that a large number of regulatory molecules 
have been identified to date and indeed further regulators continue to be identified. 
What is perhaps surprising, is the seemingly overlapping actions or redundancy of 
many regulators.
There does at first sight appear to be a great deal of evidence supporting the 
notion of redundancy (reviewed in Metcalf 1993). It is clear for instance, that more 
than one factor can stimulate the formation of the same type of colony, e.g. G-CSF, 
GM-CSF, IL-3, and IL-6 can all function to stimulate formation of granulocytes 
(Metcalf 1993). A similar number of factors can also stimulate the formation of 
eosinophil and mast cell colonies. Such an arrangement is seemingly wasteful and 
redundant, as well as offering a greatly increased risk of dysregulation. A second 
argument is that certain regulators, particularly LIF, IL-6 and IL-11 (Metcalf 1991, 
Kishimoto et al 1995), appear to have an unusually wide range of target cells. In many 
cases these cytokines also exhibit (at least partial) overlaps in their actions.
It is now evident that the receptors for these cytokines and growth factors can 
be subdivided into 3 major categories (reviewed in Park et al 1990a, Ullrich and 
Schlessinger 1990, Cosman et al 1990, Bazan 1990, Hara et al 1996, Bagley et al 
1997), as follows: 1) Receptors belonging to the immunoglobulin superfamily, e.g.
14
Table 1.1: Summary of Cytokines and Growth Factors 
Interleukins and Colony-Stimulating Factors
IL-la IL-10 G-CSF
IL-ip IL-11 GM-CSF
IL-2 IL-12 M-CSF
IL-3 IL-13 SCF
IL-4 IL-14 LIF
IL-5 IL-15 Epo
IL-6 IL-16 TPO
IL-7 IL-17 TNF-a
IL-8 IL-18 TNF-P
IL-9 Ftl3L
CNTF
OSM
TGF-B superfamilv Interferons Other Growth Factors
TGF-pl IFN-a EGF
TGF-p2 IFN-P TGF-a
TGF-p3 IFN-y acidic FGF
Inhibin basic FGF
Activin PDGFa
Bone Morphogenetic Proteins (BMPs) PDGFP
IGF-I
IGF-II
NGF
HGF
Chemokines
See Table 3.1 for a full list of Chemotactic cytokines (Chemokines)
Abbreviations used:
IL-, interleukin; CNTF, ciliary neurotrophic factor; EGF, epidermal growth factor; Epo, erythropoietin; FGF, fibroblast growth 
factor; Ftl3L, Ftl3 ligand; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating 
factor; HGF, hepatocyte growth factor; IGF, insulinlike growth factor; IFN, interferon; LIF, leukemia inhibitory factor; M-CSF, 
macrophage colony-stimulating factor; NGF, nerve growth factor; OSM, oncostatin M; PDGF, platelet-derived growth factor; 
SCF, stem cell factor; TGF, transforming growth factor; TNF, tumour necrosis factor; TPO, thrombopoietin.
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IL-1R; 2) the tyrosine kinase receptors, which include receptors for M-CSF and SCF; 
and 3) receptors belonging to the “cytokine receptor superfamily”, that are subdivided 
further on the basis of homology and which includes the haemopoietin receptors. 
Given their homology, it is almost certain that evolution of some of these receptors, 
has arisen through duplication of a common ancestral gene. This is most evident in the 
structure of the haemopoietin receptors. Many are heterodimers, with an a-chain 
specific for the cytokine cognate to that receptor and a (3-chain that is shared among 
members of the same subfamily. For instance GM-CSF, IL-3 and IL-5 share a 
common (3-chain (reviewed in Miyajima et al 1993). This p-chain is proposed to 
transduce the signal from the receptor complex to the intracellular compartment and 
may explain why GM-CSF, IL-3 and IL-5 all show the overlapping ability to stimulate 
eosinophil proliferation and functions. A similar situation exists for IL-6, IL-11, 
oncostatin M (OSM) and LIF, which share a common subunit chain (the gpl30 
subunit) and this is a probable explanation for the appearance of many of the 
overlapping pleiotropic functions of these cytokines (reviewed in Kishimoto et al 
1995).
A multitude of studies has now been reported in which individual (and even 
combinations of) specific growth factors or cytokines have been deleted in mice. The 
various phenotypes of these mice, suggest that whilst some facets of their function 
may overlap, others are clearly unique. As indicated above, M-CSF, G-CSF, IL-3, 
SCF and IL-6 can all stimulate the formation of granulocytes. However, the gene for 
each of these has been separately deleted in mice and each shows a very distinct 
phenotype. Such deletion analysis has suggested functions for these molecules in both 
constitutive and inducible haemopoiesis, i.e. distinct and non-redundant roles. This 
suggests, that to say that some factors are redundant is over simplistic. Indeed, there is 
another alternative to redundancy as an explanation for the plethora of regulatory 
immuno-haemopoietic cytokines. A complex system such as haemopoiesis must be 
inherently flexible, in order to be able to respond rapidly to a multitude of sudden 
stresses to the system. A network of interacting cytokines allows such flexibility and 
enables rapid, yet controlled responses. From an evolutionary point of view this makes 
more sense too, as a lack of such flexibility could prove lethal. A network with 
overlapping functions also provides a fail-safe mechanism, by which one cytokine can 
substitute for another should that one not function properly.
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There are clearly many other logical reasons why a such a complex interactive 
network makes sense. It can provide an in built amplification mechanism, whereby 
one cytokine has the ability to induce the expression of other cytokines and even 
autoregulate its expression (Lotem and Sachs 1991).
An additional level of control exists, with the potential to couple cytokine 
expression to that of cytokine receptor expression (Walker et al 1985). For instance 
IL-6 induces expression of receptors for M-CSF and IL-3 (Lotem et al 1989) and 
TGF-p downregulates expression of receptors for GM-CSF, G-CSF and IL-3 
(Jacobsen et al 1991a).
Clearly, inducing or stimulating factors are only part of the cytokine network 
and the network is in fact likely to be a balance between these positive signals and 
those exerted by molecules with inhibitory functions, such as TGF-p, TNF-a and 
MIP-la. The role of inhibitory regulators in haemopoiesis was briefly discussed in 
section 1.6, whilst a discussion of the inhibitory roles of TGF-p and MIP-la can be 
found in sections 2.14.6 and 3.6.5 respectively. The following sections of chapter 2 
summarise the roles and importance of some of the growth factors and cytokines 
(previously indicated in table 1.1), which together fonn an interacting network of 
regulatory molecules implicated in the survival, growth, differentiation and function of 
cells within the immuno-haemopoietic system.
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CHAPTER 2: Growth Factors and Cytokines
This chapter will focus on some of the key regulators of the immuno- 
haemopoietic system and discuss some of their known functions. This can not possibly 
be an exhaustive review, due to the overwhelming literature available. Instead, it is 
intended to familiarise the reader with some of the most important points concerning 
the role of specific growth factors and cytokines, in the network of cytokines that is 
implicated in the regulation of the immuno-haemopoietic system.
2.1 Interleukin-1 (IL-1)
IL-1 is a cytokine responsible for mediating a variety of processes in host 
defence, inflammation and haemopoiesis. EL-1 is most closely related to tumour 
necrosis factor (TNF), but is a member of a small cytokine subfamily that includes IL- 
la , EL-ip and IL-1 receptor antagonist (IL-IRa). IL-1 was originally described as a 
product of macrophages, but is now known to be produced by a variety of cell types, 
including fibroblasts, keratinocytes, T and B lymphocytes, astrocytes and microglial 
cells. IL-1 a  and IL-ip are two related, but distinct molecules, that are synthesised as 
31 kD precursors (proIL-la and proIL-lp). Unlike proIL-la, pro-IL-lp requires 
cleavage for optimal secretion and activity and this occurs through the action of IL-1 P 
converting enzyme (ICE) (Thomberry et al 1992, Wilson et al 1994). Whilst both IL- 
l a  and EL-lp exist as extracellular proteins, IL-1 a  can also exist as a membrane bound 
form, that is also biologically active (Matsushima et al 1986, Kurt-Jones et al 1985). In 
most tissues, IL-1 p mRNA predominates over IL -la mRNA and in fact IL -la is rarely 
found in the circulation. The many inflammatory functions of IL-1 will not be discussed 
further and the reader is referred to reviews on this subject, such as that by Dinarello 
(1994).
IL-1 affects various levels of haemopoiesis and its direct haemopoietic effects 
were first identified as hemopoietin-1, an activity that modulated the response of very 
primitive progenitor cells to colony-stimulating factors (Stanley et al 1986, Mochizuki 
et al 1987). IL-1 induces the production of GM-CSF, G-CSF, M-CSF and IL-3 and 
other cytokines, particularly from bone marrow stromal cells (Zucali et al 1986). IL-1 
has been shown to act synergistically with IL-3, IL-6, G-CSF and GM-CSF^ to induce
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single and multi-lineage colony formation (Moore et al 1987, Bradley et al 1989). In 
vivo, IL-1 has been shown to protect stem cells and promote granulopoiesis following 
cytotoxic drug treatment or irradiation (Fibbe et al 1989, Oppenheim et al 1989). IL- 
1 p also appears to stimulate platelet production in vivo, as shown in a murine model 
(Williams and Morrissey 1989). In vivo experiments have also suggested that IL-1 can 
function as an inhibitor of progenitor cell proliferation. IL-la reversibly inhibits late- 
stage erythropoiesis (Johnson et al 1989) and prolonged administration of IL-1 p has 
been shown to inhibit the formation of granulocyte-macrophage (GM) colonies, albeit 
indirectly through induction of TNF-a, a known inhibitor (Gasparetto et al 1989).
2.2 Interleukin-3 (IL-3)
During the search for colony-stimulating activities, several activities were 
found in spleen conditioned medium. These activities were designated by various 
names, including erythroid burst (colony)-promoting activity (BPA), mast cell growth 
factor (MCGF), Thy-1-inducing activity, hemopoietin-2, 20ahydroxysteroid 
dehydrogenase (20aSDH) inducing activity, and interleukin-3. These activities were 
suggested in fact, to be the result of a single colony-stimulating factor and were 
subsequently re-named multi-CSF, which is now more commonly known as IL-3. 
Unusually, IL-3 appears to be potentially involved in regulating the production of all 
the major myeloid blood cell types, including macrophages, megakaryocytes, mast 
cells, eosinophils, neutrophils and erythrocytes.
The major source of IL-3 appears to be antigen or mitogenically activated T 
lymphocytes. However, in addition to activated T cells, NK cells, (Cuturi et al 1989), 
mast cell lines (Wodner-Filipowicz et al 1989), megakaryocytic cell lines (Avaraham 
et al 1992) and thymic epithelial cells (Dalloul et al 1991) have been shown to express 
IL-3. Reports of IL-3 expression in cells within the bone marrow microenvironment, 
such as fibroblasts and endothelial cells have largely been negative (Cluitmans et al
1995) although one study, using a sensitive PCR-based detection method, did report 
the detection of IL-3 expression in irradiated bone marrow (Kittler et al 1992). The 
persistent failure to detect IL-3 in either bone marrow or normal serum has led to the 
suggestion, that IL-3 does not in fact play a role in constitutive haemopoiesis. Instead,
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some researchers have suggested that it functions as a mediator of inflammation, due 
to its immune cell-derived sources.
Whilst the precise role of IL-3 in vivo remains controversial, the in vitro ability 
of IL-3 to function as a multilineage colony-stimulating factor is well documented. In 
vitro, recombinant IL-3 induces the formation of colonies in cultures of bone marrow 
cells in soft agar. It promotes the formation of mixed erythroid/myeloid, macrophage, 
neutrophil, eosinophil and basophil colonies (Hapel et al 1985, Rennick et al 1985). 
IL-3 has also been reported to support the growth of erythroid and megakaryocyte 
lineages, but the formation of mature cells does not occur in the absence of 
erythropoietin or thrombopoietin. A number of reports have provided evidence that 
IL-3, along with GM-CSF, is more specific for early stages of haemopoietic 
development. For instance, IL-3 is required for the proliferation and differentiation of 
multipotential haemopoietic progenitors in culture, though IL-3 does not appear to 
promote the entry of these quiescent progenitor cells into active cell cycle (Suda et al
1985). It has also been reported that multipotent progenitors become less sensitive to 
IL-3 as they mature into multilineage colonies (Koike et al 1986). Taken together 
these, and other studies, suggest that in vitro, IL-3 acts primarily on multipotent 
progenitors in the earlier stages of haemopoietic development.
IL-3 can clearly also function through synergy with other growth factors. For 
example, IL-3 synergises with M-CSF, to enhance M-CSF receptor levels and 
generate ‘giant’ macrophage colonies from HPP-CFCs, a progenitor cell with high 
proliferative potential (see section 1.4.2) (McNiece et al 1984, Bartelmez et al 1985). 
IL-3 has also been reported to act in synergy with IL-6 to enhance IL-3 dependent 
proliferation of multipotential haemopoietic progenitors (Ikebuchi et al 1987) and 
with IL-4 to enhance mast cell growth (Smith et al 1986). Interestingly, further insight 
into the role of IL-3 synergy with other growth factors has come from the study of 
particular mouse strains (mostly A/J, AKR and NZB), which appear to be less 
responsive or ‘hyporesponsive’ to IL-3 (Kincade et al 1979, Morris et al 1990). 
Progenitor cells from these mice strains are defective in their ability to form colonies 
or proliferate in response to IL-3, and yet they are still able to exhibit a synergistic 
response to IL-3 in combination with M-CSF, indicating that responses to IL-3 are not 
totally absent in these strains. (Breen et al 1990, Morris et al 1990). The genetic basis 
for this hyporesponsiveness has recently been identified, as being due to a defect in the
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gene encoding the a  chain for the IL-3 receptor (IL-3Ra). Unusually however, this 
defect is not absolute and some functional receptors do appear to be expressed by 
haemopoietic bone marrow derived mast cells. (Leslie et al 1996). Further study of 
such hyporesponsive strains may well provide further insight into mechanisms by 
which IL-3 is able to synergise with other growth factors.
As discussed above, IL-3 is almost undetectable under most circumstances and 
many in vivo studies have proved confusing and difficult to interpret. Some have 
however, proved useful and suggest that there is at least some potential role for IL-3 
in vivo. For instance, continuous infusion of IL-3 into mice was shown to result in 
increased numbers of progenitor and myeloid committed precursor cells in the spleen, 
but not in the bone marrow (Kindler et al 1986). Similar results were obtained by 
intraperitoneal injection of IL-3, which resulted in large increases in macrophage, 
eosinophil and neutrophil cell numbers, as well as enhanced peritoneal phagocytic 
activity (Metcalf et al 1986). It is possible however, that these changes could be 
attributable to chemotaxis and mobilisation of cells from the circulation in response 
to an IL-3 induced mediator, suggesting a role for IL-3 in inflammatory processes. 
Some evidence for a role for IL-3 to function in vivo in constitutive haemopoiesis 
came from studies using mice that had been pre-treated with purified lactoferrin, 
(Broxmeyer et al 1987a) which has been shown to suppress release of some 
haemopoietic growth factors in vitro and to inhibit myelopoiesis in vivo. In this way, 
the authors were able to suppress the background of normal haemopoiesis and 
demonstrate that a small infusion of IL-3 resulted in an change in cell cycle status and 
increased the number of progenitor cells in both the bone marrow and the spleen. In 
another study, the authors were also able to demonstrate that IL-3 could synergise with 
GM-CSF and M-CSF in vivo, to increase the number of progenitor cells and the 
absolute number of progenitor cells (Broxmeyer et al 1987b).
Whilst the effects of IL-3 appear to predominantly affect the early stages of 
haemopoiesis, effects on mature, fully differentiated cells are also evident. For 
instance, IL-3 can potentiate mature eosinophil functions, such as degranulation 
(Fujisawa et al 1990) and stimulate histamine release from basophils (Kurimoto et al 
1989). IL-3 has also been reported to affect the functions of mature monocytic 
phagocytes, such as cytotoxicity (Cannistra et al 1988), as well as stimulating 
macrophage growth outside the bone marrow (Chen et al 1988).
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The in vivo role of IL-3 may however not be essential, as mice deficient in the 
pc or Pil-3 components of the IL-3 receptor exhibit apparently normal haemopoiesis 
(Nicola et al 1996), as do mice completely lacking IL-3 functions (Nishinakamura et 
al 1996a). The role of IL-3 in vivo therefore remains controversial.
2.3 Interleukin-4 (IL-4)
IL-4 was initially characterised as B cell growth factor (BCGF), subsequently 
renamed B-cell stimulatory factor and is now known as IL-4. The main function of IL- 
4 appears to be in regulating the switch in immunoglobulin (Ig) synthesis to IgE (and 
IgGl in mice), although it clearly has many other pleiotropic functions (reviewed in 
Paul 1991). Besides regulation of Ig class-switching, IL-4 can also function as a 
haemopoietic regulator. It has been shown to enhance the IL-3 mediated growth of 
mast cells (Mosmann et al 1986). IL-4 acts as a co-stimulator with other haemopoietic 
growth factors, such as G-CSF, erythropoietin (Epo) and IL-6, inducing the 
proliferation of CFU-GM, BFU-E and CFU-GEMM (Rennick et al 1987, Peschel et al 
1987, Sonoda et al 1990).
Several inhibitory actions have been described for IL-4, such as macrophage 
colony formation (Jansen et al 1989) and IL-4 has also been shown to induce 
expression of a reversible inhibitory activity from bone marrow stromal cells (Peschel 
et al 1989). Taken together, these studies suggest that IL-4 has a potential role in the 
regulation of various stages of haemopoiesis.
2.4 Interleukin-5 (IL-5)
IL-5 is an unusually specific growth factor, directed to cells of the eosinophilic 
and basophilic lineage. In fact, IL-5 appears to be the most important, if not only 
cytokine involved in eosinophilia (elevated level of eosinophils). Eosinophils are 
cytotoxic cells capable of killing larger organisms such as helminths, parasitic 
protozoa, as well as tumour cells and normally constitute a very small population 
within the immuno-haemopoietic system. In addition to its many eosinophil specific 
functions (reviewed by Sanderson 1992), IL-5 also has actions on mature basophils 
(reviewed by Denburg 1992).
IL-5 was first identified as eosinophil differentiation factor and subsequently 
re-named IL-5. In comparison to GM-CSF and IL-3, IL-5 is a poor stimulator of
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colony formation in semi-solid assays, whereas IL-5 is much better at stimulating 
precursor formation in liquid cultures than either GM-CSF or IL-3. In fact whilst GM- 
CSF and IL-3 can both generate precursors for several different lineages, including 
eosinophils (see sections 2.2 and 2.11), only IL-5 is specific for eosinophil progenitor 
formation (Lopez et al 1986, Clutterbuck et al 1988). It is speculated that IL-5 is only 
a late acting factor, as suggested by several studies (Sanderson et al 1985). GM-CSF 
and IL-3 can synergise with IL-5 to induce eosinophils (Lu et al 1990, Clutterbuck et 
al 1990, Ema et al 1990b).
Whilst in vitro studies have been unable to demonstrate conclusively, at what 
stage of progenitor cell IL-5 acts upon, other studies have clearly demonstrated the 
fundamental importance of IL-5 in vivo. Administration of anti-IL-5 antibody to 
parasite or helminth infected mice prevented the associated eosinophilia completely 
(Coffman et al 1989), whilst another study showed that retrovirally mediated 
overexpression of IL-5 resulted in long-lasting eosinophilia (Vaux et al 1990). Several 
studies with IL-5 transgenic mice have also determined the in vivo importance of IL-5 
to eosinophil production (Dent et al 1990, Tominaga et al 1991). The study of IL-5 
transgenic mice has also supported the notion that IL-5 may act upon B lymphocyte 
development in the mouse system. Mouse IL-5 had previously been reported to 
function as a promoter of B cell growth and differentiation (Matsumoto et al 1987). 
Transgenic mice with IL-5 coupled to the metallothionein promoter (mMT-I), showed 
eosinophilia, but in addition had elevated levels of serum IgM and IgA and an 
expansion of Ly-1+ and Ly-ldull B220+ cells in the spleen (Tominaga et al 1991). Ly- 
1+ cells are a minor population of B cell lineage cells, showing a restricted Ig 
repertoire. In contrast to mouse IL-5, human IL-5 has not been reported to act on B- 
cells (Clutterbuck et al 1987).
Deletion of both the IL-3 ligand and pc common receptor subunit in mice, 
removes all ability to respond to GM-CSF, IL-3 and IL-5. Analysis of such mice 
revealed that these mice exhibited a reduced number of eosinophils and eosinophilic 
responses to parasitic infections and this was attributable solely to the absence of IL-5 
(Nishinakamura et al 1996a).
Many questions concerning the role of IL-5 in haemopoiesis remain to be 
answered and in particular, whether IL-5 is sufficient on its own to stimulate
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eosinophil progenitor formation or if it must act in synergy with the earlier acting 
growth factors, GM-CSF and IL-3.
2.5 Interleukin-6 (IL-6)
IL-6, like many other cytokines, exhibits many pleiotropic functions. It was 
originally identified as a B-cell differentiation factor (BSF-2), that induced maturation 
of B cells into antibody producing cells (Hirano et al 1985, 1986). As well as effects 
on B cells, IL-6 also acts on T cells, hepatocytes and neuronal cells (reviewed in 
Kishimoto 1989, Kishimoto et al 1992). IL-6’s functions as a potent growth factor for 
human myeloma cells and as a potential autocrine regulator of myeloma, have also 
been particularly well studied (reviewed in Klein et al 1995).
In addition to its roles in human myeloma, IL-6 has also been well 
characterised as a regulator of haemopoietic progenitor cells. IL-6 synergises with IL- 
3, to induce the expansion of haemopoietic progenitor cells (Ikebuchi et al 1987, 
Leary et al 1988). IL-6 has also been shown to interact with IL-4 or G-CSF to increase 
GM colony formation (Rennick et al 1989), suggesting that IL-6 is able to interact 
with a variety of factors to regulate the growth of progenitor cells at different stages of 
lineage commitment and maturation. A role for IL-6 has also been proposed, in the 
maturation and production of megakaryocytes (Ishibashi et al 1989, Suematsu et al
1989) and in vivo administration of recombinant IL-6 in primates has been 
demonstrated to result in an increase in the number of platelets (Asano et al 1990).
Interestingly, analysis of IL-6 deficient mice has shown that they exhibit 
defective leukocyte recruitment, and this appears to be associated with a reduced level 
of chemokine expression (Romano et al 1997). This implies that IL-6 may also be 
involved in amplifying leukocyte accumulation at sites of inflammation in vivo.
2.6 Interleukin-7 (IL-7)
IL-7 is a cytokine that is more restricted in its effects, than most other 
haemopoietic growth factors. IL-7 was originally described as a stroma-derived pre-B 
cell growth factor (Hunt et al 1987). Subsequently to this, IL-7 has been demonstrated 
to exert it’s proliferative effects on B cell progenitors (Namen et al 1988, Suda et al 
1989, Tushinski et al 1991), as well as stimulating T cell progenitors (Conlon et al
1989) and mature T cells (Morrissey et al 1989). For a long time therefore, IL-7 was
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regarded as being purely a lymphoid-lineage-restricted cytokine. Only recently has a 
role for IL-7 in myelopoiesis emerged, with the demonstration that IL-7 directly 
enhances colony-stimulating factor and SCF-induced in vitro myeloid colony 
formation from murine bone marrow progenitor cells (Jacobsen et al 1993, 1994a and 
1994b). IL-7 has also been shown to induce cytokine secretion from monocytes 
(Alderson et al 1991) and bone marrow macrophages have also been reported to 
express high numbers of IL-7 receptors (Park et al 1990b), suggesting that IL-7 may 
exert effects on more mature myeloid cells and its effects may therefore be more 
pleiotropic than originally thought.
2.7 Interleukin-8 (IL-8)
IL-8 although designated an interleukin, is actually a member of the 
chemokine superfamily of cytokines and will therefore be discussed later in section 
3.2.1.
2.8 Interleukin-11 (IL-11)
IL-11 was originally cloned from a primate stromal cell line (Paul et al 1990) 
and appears relatively pleiotropic in its effects, on a wide range of cell types. Only a 
brief synopsis is detailed here and the reader is refered to the various reviews on IL-11 
(Du and Williams 1994, 1997).
IL-11 acts synergistically with other early and late acting growth factors, such 
as IL-3, IL-4, SCF, flt3 ligand (ftl3L) and GM-CSF (Musashi et al 1991, Leary et al 
1992, Lemoli et al 1993, Jacobsen et al 1995a), to stimulate various stages and 
lineages of haemopoiesis. It acts with IL-3, thrombopoietin (TPO) or SCF to 
synergistically stimulate both murine and human megakaryocytopoiesis and 
thrombopoiesis (Broudy et al 1995). IL-11 can also stimulate various stages of 
erythropoiesis either on its own, or in synergy with IL-3, SCF or Epo (Quesniaux et al 
1992). IL-11 has also been shown to affect the differentiation and maturation of 
myeloid progenitor cells. A protective role for IL-11 has also been well documented. 
For instance, IL-11 has been shown to provide protection of small intestinal 
clonogenic stem cells against 5-fluorouracil treatment and irradiation (Potten 1995,
1996). In combination with growth factors such as SCF, IL-13, IL-4 and G-CSF, IL-11 
effects on B cell growth have also been reported (Hirayama et al 1992, 1994).
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2.9 Macrophage Colony-Stimulating Factor (M-CSF)
Colony-stimulating factor-1 (CSF-1) or M-CSF, was originally purified on the 
basis of its ability to stimulate the growth and differentiation of macrophages (Stanley 
and Heard 1977). M-CSF is somewhat more complex in its gene structure and 
regulation of expression at RNA and protein levels, than most other cytokines. Soluble 
M-CSF is a homodimeric glycoprotein and human M-CSF is encoded by a single gene 
that is transcribed to give a primary mRNA transcript, that is in turn subsequently 
alternatively spliced and results in mRNAs encoding different forms of M-CSF. 
These precursor forms of M-CSF are then proteolytically processed to give various 
forms of the soluble growth factor (Ladner et al 1987). At least two different forms of 
precursor protein exist, the larger of these is rapidly processed and does not give rise 
to cell surface M-CSF (Wong et al 1987, Rettenmier and Roussel 1988). The smaller 
precursor is processed however (Kawasaki et al 1985), but does not always undergo 
efficient cleavage and may instead be stably expressed on the cell surface (Rettenmier 
et al 1987). The membrane expressed precursor is then slowly cleaved to yield the 
soluble homodimeric growth factor. The cell surface form also appears to be 
biologically active (Stein et al 1990).
M-CSF stimulates the growth, differentiation and proliferation of cells of the 
monocyte/macrophage lineage (Ralph and Nakoinz 1987). Recombinant M-CSF has 
been shown to stimulate differentiation of progenitor cells into monoblasts (Becker et 
al 1987) and also to induce maturation into promonocytes and monocytes (Rosenfeld 
et al 1990). The effects of M-CSF on human macrophage colony formation in vitro do 
however appear somewhat limited, as GM-CSF and other growth factors have been 
shown to be necessary for optimal colony formation (Caracciolo et al 1987, Zhou et al
1988). A role for M-CSF does appear to exist in vivo however, as demonstrated by 
studies using mice with a homozygous null mutation for the op mutation. These 
{op!op) or osteopetrotic mice, suffer congenital osteopetrosis as a result of a deficiency 
in osteoclasts and macrophages. It is now clear that this deficiency in osteoclast 
formation, lies with a complete absence of M-CSF (Wiktor-Jedrzejczak et al 1990) 
and furthermore, that the op mutation lies within the coding region for the M-CSF 
gene (Yoshida et al 1990). Addition of recombinant M-CSF has been shown to correct 
the haemopoietic abnormalities (Wiktor-Jedrzejczak et al 1991), which are also 
progressively corrected as the mice age (Begg and Bertoncello 1993). There is also
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evidence that M-CSF has roles in reproduction, as female op/op mice show impaired 
fertility (Pollard et al 1987, 1991).
In addition to its roles on progenitor cells, M-CSF also exerts a variety of 
actions on mature cells of the monocyte/macrophage lineage, including phagocytic 
activity and microbial killing (Karbassi et al 1987) and macrophage-mediated tumour 
cell cytolysis (Wing et al 1982). M-CSF also induces expression of many cytokines 
from monocytes and macrophages, including G-CSF, GM-CSF, IFN-y, TNF and DL-1 
(Moore eta l 1980, Warren and Ralph 1986, Motoyoshi et al 1989).
2.10 Granulocyte Colony-Stimulating Factor (G-CSF)
G-CSF is a growth factor that regulates the production of neutrophilic 
granulocytes. These are a critical component to the host defence system and it is 
estimated that as many as 120 billion granulocytes are produced each day, simply to 
maintain normal numbers and this number may increase ten-fold during infection 
(Demetri and Griffin 1991). Whilst G-CSF activity was identified by many researchers, 
it was not until 1983 that G-CSF was purified and characterised (Nicola et al 1983) 
and the cDNA for a human G-CSF subsequently cloned (Souza et al 1986). G-CSF is 
produced, in many cases constitutively, by various cell types. Cells of the 
monocyte/macrophage lineage are a particularly dominant source of G-CSF, along with 
cells such as vascular endothelial cells and fibroblasts. G-CSF production can be 
induced by a variety of stimuli, including lipopolysaccharide (LPS) and many other 
growth factors (Oster et al 1989, Vellenga et al 1988). Evidence for the role of G-CSF 
in vivo, has come from analysis of mice carrying a homozygous null mutation for G- 
CSF. These mice have chronic neutropenia, with only approximately 20 % of normal 
circulating neutrophils and a reduced number of neutrophilic granulocyte and 
macrophage precursors in their bone marrow (Lieshcke et al 1994). This study, 
suggests that some role for G-CSF in the production of granulocytes does exist in 
vivo, although it is one which can be at least partially fulfilled by another factor(s), 
since G-CSF'7’ mice are viable and do still have some neutrophils. This role may be 
minimal and G-CSF might function instead, to increase neutrophil production during 
periods of stress, such as during infection. In normal haemopoiesis, the effects of G- 
CSF are limited to cells of the neutrophilic lineage. These effects will be discussed
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only briefly here and the reader is referred to the many reviews on G-CSF (Nicola 
1990, Demetri and Griffin 1991).
In vitro, G-CSF stimulates proliferation and differentiation of neutrophil 
colony-forming cells, as well as affecting several functions of mature neutrophils 
(Metcalf and Nicola 1983). G-CSF, acts on a relatively mature progenitor cell 
population, that is mostly committed to neutrophilic differentiation (Ema et al 1990a). 
Whilst the effects of G-CSF alone are relatively limited, in combination with other 
growth factors, G-CSF can stimulate the survival and proliferation of multi-lineage 
progenitor cells in vitro (Metcalf and Nicola 1983, McNiece et al 1989). In fact, G- 
CSF was originaly described as a multi-lineage-stimulating or pluripotent growth 
factor. However, when accessory cells were depleted from culture this pluripotent 
activity was shown to disappear (Strife et al 1987). G-CSF has been shown to exert 
synergistic or enhancing actions with IL-3 (Ikebuchi et al 1988), IL-4 (Rennick et al 
1987, Peschel et al 1987), IL -la (Moore and Warren 1987), and IL-6 (Rennick et al
1989).
In addition to stimulating proliferation of progenitor cells, G-CSF also 
enhances the functions of mature neutrophil effector cells. These range from ‘priming’ 
of cells for receptor-mediated responses (Yuo et al 1989), production of cytokines 
such as interferon-a (Shirafuji et al 1990), and enhancement of cytotoxic functions 
(Lopez et al 1983).
G-CSF is now widely used clinically to increase neutrophil numbers and to 
enhance neutrophil responses, during or following chemotherapy or radiotherapy, or 
following bone marrow transplantation, thus providing a protective role against 
opportunistic infections.
2.11 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
GM-CSF, along with G-CSF, M-CSF and IL-3, is one of a number of colony 
stimulating factors identified to date. It derives its name from the ability to stimulate 
formation of macroscopic colonies containing neutrophilic granulocytes (neutrophils), 
eosinophilic granulocytes (eosinophils), and macrophages, or a mixture of these cell 
types. GM-CSF stimulates the proliferation and maturation of myeloid progenitor cells, 
as well as having many actions on mature neutrophils, eosinophils and macrophages.
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Many different cell types have been reported to produce GM-CSF. These 
include both immune cells such as T lymphocytes, macrophages and mast cells, as well 
as adherent cells within the bone marrow microenvironment such as macrophages, 
fibroblasts and endothelial cells. B lymphocytes and natural killer (NK) cells have also 
been reported to synthesise GM-CSF (Pistoia et al 1987, 1989). The precise nature of 
this expression is sometimes contradictory, but in most cases GM-CSF does not appear 
to be constitutively expressed and is instead induced by a variety of stimuli. LPS, IL-1 
and TNF-a are amongst the most prevalent and dramatic inducers of GM-CSF 
expression (Broudy et al 1986, Chan et al 1986, Siefif et al 1988), particularly within 
the bone marrow microenvironment. In addition to growth factors, other stimuli such 
as FCS, phagocytosis (Thorens et al 1987), and FcsRI triggerring by IgE plus antigen 
in mast cells (Wodnar-Filipowicz et al 1989) have also been demonstrated to induce 
GM-CSF expression.
GM-CSF was first purified from mouse lung-conditioned medium and found to 
stimulate proliferation and differentiation of myelomonocytic progenitors (Burgess et 
al 1977). Following identification of the complementary cDNA and generation of 
recombinant protein, the actions of GM-CSF on hemopoietic cells have been studied in 
great detail (reviewed in Gough and Nicola 1990, Gasson 1991, Baldwin 1992). In 
vitro, GM-CSF is now known to be a mutilineage stimulator for CFU-granulocyte 
(CFU-G), CFU-GM, CFU-macrophage (CFU-M), and CFU-eosinophil (CFU-Eo) 
(Tomonaga et al 1986). GM-CSF may also support the growth of erythroid and 
megakaryocytic progenitors in vitro (Sieff et al 1985, Emerson et al 1989).
The effects of GM-CSF on differentiation and maturation are however, less 
clear. Several studies have suggested that GM-CSF can function to induce 
differentiation, for instance towards monocytic and eosinophilic lineages in the human 
myeloid leukemia cell line HL60 (Tomonaga et al 1986, Ellias et al 1988), and in co­
operation with Epo to induce erythroid differentiation in the erythroleukemic cell line 
K562 (Tawhid eta l 1989).
In addition to its effects on haemopoietic progenitor cells, GM-CSF also exerts 
a wide variety of actions on mature, fully differentiated neutrophils, eosinophils and 
macrophages. These actions can be either 1) direct effects, such as increasing cell 
survival (Begley et al 1986); or 2) indirect or so-called ‘priming’ effects that occur in
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conjunction with a secondary stimulus, such as enhancement of neutrophil oxidative, 
phagocytic and cytolytic functions (Baldwin et al 1989), and priming of basophils for 
enhanced histamine release (Hirai et al 1988). As well as granulocyte-directed effects, 
GM-CSF also has a wide variety of macrophage directed functions, such as increased 
release of inflammatory mediators and growth factors (Oster et al 1992, Takamatsu et 
al 1996). These various effects on mature cells, are too numerous to discuss in full 
here, and the reader is refered to the excellent review by Baldwin (1992) for a full 
overview.
Many groups have attempted to examine the role of GM-CSF in vivo. One of 
the most interesting of these was that of Lang et al (1987), who overexpressed the 
GM-CSF gene in mice, under a retroviral promoter. These mice had a very unexpected 
compound phenotype, in that they were bom with accumulations of macrophages in 
their eyes and striated muscle. In fact, the eyes were opaque, with extensive retinal 
damage that resulted in blindness. Many GM-CSF transgenic mice subsequently died 
after 2-4 months, with a chronic wasting syndrome. The ocular defects were attributed 
to autostimulation of macrophages, that are required for normal developmentally 
programmed tissue remodelling in the mouse eye (Cuthbertson et al 1989, Lang and 
Bishop 1993). Stanley et al (1994) later reported that GM-CSF was in fact dispensable 
for haemopoiesis, since GM-CSF deficient mice exhibited apparently normal 
haemopoiesis. These mice did however, develop an abnormal lung pathology that was 
characterised by infiltration of lymphocytes and large intraalveolar macrophages and 
which was reminiscent of the human disease, pulmonary alveolar proteinosis (PAP). 
Many GM-CSF deficient mice also developed inflammatory lung infections. A similar 
phenotype has been reported in mice deficient for the common component shared by 
the GM-CSF, IL-3 and IL-5 receptors, the pc component (Nishinakamura et al 1995). 
This phenotype is reversed following bone marrow transplantation, suggesting a 
haemopoietic origin (Nishinakamura et al 1996b). In fact, human PAP was recently 
reported to be associated with a defect in the GM-CSF/IL-3/IL-5 common chain (Pc) 
(Dirksen et al 1997). Taken together, these reports suggest that GM-CSF is probably 
dispensible (or even redundant) for normal constitutive haemopoiesis, but that GM- 
CSF may be important for pro-inflammatory functions in vivo.
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2.12 Stem Cell Factor (SCF)
SCF is a pleiotropic cytokine (reviewed in Broudy 1997), that functions 
primarily in the early stages of haemopoiesis. It was previously known as kit ligand, 
mast cell growth factor, or steel factor. The gene for SCF is encoded within the Steel 
or SI locus (Zsebo et al 1990), whilst the gene for the SCF receptor, c-kit, is encoded 
by the white spotted or W locus (Huang et al 1990). A host of naturally occuring 
mutations at the W or SI loci have been identified, and these have led to the 
identification and further characterisation of both SCF and its receptor. The absence of 
either SCF or Kit receptor results in death in utero, or perinatally as a result of severe 
anaemia (Besmer et al 1993). This, together with evidence from embryonic expression 
patterns for SCF (Orr-Urtrger et al 1990, Matsui et al 1990), suggests a developmental 
role for SCF.
SCF exists in two forms generated by alternative splicing of mRNA (Flanagan 
et al 1991); as a soluble form and also as a transmembrane form, which are both 
biologically active (Anderson et al 1990). Mice with deleted transmembrane and 
cytoplasmic domains (which results in only the soluble form of SCF) are viable but 
show several phenotypic abnormalities (Flanagan et al 1991, Brannan et al 1991), 
suggesting the transmembrane form does play a role in vivo. Recently, it was reported 
that overexpression of the membrane associated form of human SCF in mice (which 
in murine cells acts as an antagonist, through interference with the interaction between 
murine SCF and its receptor), resulted in impaired melanocyte development. 
Moreover, compound heterozygous mice that carried both a mutated W or SI allele and 
the transgene for hSCF (hSCF220) (i.e hSCF220 / +; W /+ or hSCF220 / +; SI / +), 
showed a significantly reduced number of dermal mast cells, and defective thymocyte 
development (Kapur et al 1997). This study suggests that transmembrane SCF is 
required for the migration or survival/proliferation of melanocytes and dermal mast 
cells, and that c-kit may be involved in thymocyte differentiation. In fact, the ratio of 
soluble to transmembrane SCF varies considerably between different tissues (Huang et 
al 1992). In the bone marrow, stromal fibroblasts predominantly express the soluble 
form of SCF (Heinrich et al 1993a, Linenberger et al 1995). In addition to expression 
by fibroblasts, SCF is constitutively expressed by endothelial cells, another important 
cell type in the stromal microenvironment. Keratinocytes and gut epithelial cells have 
also been reported to express SCF (Longley et al 1993, Klimpel et al 1995) and SCF
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mRNA has also been detected in enriched populations of stem cells and progenitor 
cells (Ratacjczak et al 1995). Whilst inflammatory stimuli such as IL-1 and TNF are 
strong inducers of many growth factors from the bone marrow (Broudy et al 1986), 
they are much less potent at stimulating the expression of SCF (Heinnich et al 1993a, 
Linenberger et al 1995).
SCF exhibits a wide variety of haemopoietic functions. It has been reported to 
accelerate the entry of haemopoietic stem cells into cell cycle (Leary et al 1992) and 
has been suggested to maintain the survival of long-term repopulating cells in vivo (Li 
and Johnson 1994). SCF, in conjunction with IL-3, also enhances the production of 
CFU-S cells (see section 1.3) in vitro (de Vries et al 1991). Addition of a blocking 
antibody to Kit receptor was shown to reduce the survival of CFU-S cells (Kodama et 
al 1992) but still allowed the survival of LTC-IC (see section 1.4.1), suggesting that 
SCF is dispensible for LTC-IC survival. Several studies have reported that SCF can 
act upon very primitive pre-CFU-C type cells, that give rise to colony forming cells. In 
addition, SCF in conjunction with IL-3 and other haemopoietic growth factors 
enhanced the number of BFU-E, CFU-GM and CFU-GEMM in vitro (Bernstein et al 
1991, Migliaccio et al 1992). In fact, SCF now forms the basis for an increasing 
number of ex vivo expansion protocols (Brandt et al 1992), in conjunction with a 
number of different cytokines. In such protocols, enriched populations of primitive 
precursor cells are removed from the donor and the number of resulting progenitor 
cells is expanded in vitro with a cocktail of growth factors, before re-infusion. This 
can result in as much as a 200-fold expansion of BFU-E, CFU-GM, and CFU-GEMM 
from enriched haemopoietic stem cells (Brugger et al 1993). It is also suggested that 
SCF can promote haemopoietic progenitor cell survival, in the absence of cell division 
(Keller et al 1995).
In vitro, SCF has been reported to have many synergistic actions with other 
growth factors to support direct colony formation (McNiece et al 1991, Metcalf and 
Nicola 1991). SCF can synergise with factors, such as Tpo and IL-3, to promote the 
growth (but not differentiation) of megakaryocyte progenitors and cell lines (Broudy et 
al 1995).
SCF appears to be particularly important for mast cell production. The tissues 
of mice with mutations in the SI locus (Sl/Sf) or W locus (W/W*) contain less than 1 
% of the normal numbers of mast cells (Kitamura et al 1978, 1979), although mast
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cell progenitors have been identified in the bone marrow of these mice. The most 
primitive mast cell progenitor, the pro-mastocyte, proliferates and differentiates in 
response to SCF plus IL-3 (Rodewald et al 1996) and mast cells can be cultured in 
vitro from a variety of sources, using SCF in conjunction with IL-3 (Durand et al 
1994).
Evidence also exists for a role for SCF in B and T lymphocyte development. 
SCF can synergise with IL-7 to stimulate proliferation of pre-B cells (Billips et al 
1992), but it does not enhance the proliferation of the more primitive pro-B cells. 
(Faust et al 1993). Actions of SCF on NK and dendritic cell progenitors have also 
been documented (Shibuya et al 1995, Szabolcs et al 1995).
In addition to its many effects on haemopoietic stem and progenitor cells, SCF 
also exerts many functions on mature cells of the mast cell lineage and to a lesser 
extent, basophil lineage. For instance, SCF enhances secretion of mediators from mast 
cells, as well as their chemotaxis and adhesion (Columbo et al 1992, Dastych et al 
1994) and also induces IgE-dependent histamine release from basophils (Columbo et 
al 1992).
SCF therefore, is a haemopoietic growth factor that acts primarily during the 
earlier stages of haemopoiesis, interacts with a variety of growth factors to regulate 
stem / progenitor cell proliferation and which is particularly important to cells of the 
mast cell lineage.
2.13 Leukemia Inhibitory Factor (LIF)
LIF is an unusual factor, that exerts its actions on haemopoietic and mature 
cells. LIF was characterised by several groups under various different names; such as 
differentiation inducing factor (DIF or D-factor), differentiation inhibitory activity 
(DIA), human interleukin for DA cells (HILDA) and cholinergic neuronal 
differentiation factor (CNDF), but these are now more commonly known as LIF 
(reviewed in Metcalf 1991). LIF shows sequence homology with OSM, IL-6, IL-11 
and CNTF, and like LIF these all signal through the common gpl30 subunit. LIF 
receptors are found on cells of the monocyte/macrophage lineage (Hilton et al 1991) 
and the number of LIF receptors was found to increase with maturation. LIF receptors 
are also found on megakaryocytes and on a subclass of T lymphocytes (Hilton et al
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1991), as well as on osteoblasts (but not osteoclasts), fibroblasts, endothelial cells, 
adipocytes and embryonic stem cells (reviewed in Metcalf 1991).
LIF expression is normally almost undetectable. No expression can be detected in 
normal serum by bioassay, nor in tissues by northern blot analysis. One consistent 
exception to this, is the expression of LIF by metrial gland cells developing in the uterine 
wall at the site of blastocyst implantation (Croy et al 1991). LIF has however, been 
reported to be expressed by a variety of cell types following induction by a variety of 
stimulae, such as IL-1, TNF-a, and TGF-p (Wetzler etal 1990). Fibroblasts (Tomida et al 
1984), T lymphocytes (Gearing et al 1987), monocytes and macrophages (Anegon et al
1990), stromal cells (Wetzler et al 1990) and astrocytes (Wesselingh et al 1990) have all 
been reported to express LIF.
The reported effects of LIF on haemopoietic stem cells in vitro, are relatively 
limited. LIF was originally reported not to have any effect on the survival or proliferation 
of adult haemopoietic cells (Metcalf et al 1988). It has however been reported to stimulate 
the proliferation of murine myeloid DA-1 cells (Moreau et al 1988) and also to promote 
the IL-3 induced proliferation of megakaryocytes and BFU-E cells (Leary et al 1990). The 
origin of the name, leukemia inhibitory factor, lies with the ability of LIF to suppress the 
self-renewal of clonogenic murine Ml leukemic cells (Metcalf et al 1988, Metcalf 1989). 
This suppression occurred in conjunction with the simultaneous differentiation of Ml cells 
by LIF. These cells differentiated into cells with macrophage morphology, expressed Fc 
receptors and exhibited other macrophage-like characteristics such as phagocytosis and an 
increased dependency upon M-CSF for their survival. (Metcalf 1989, Metcalf et al 1988). 
In addition to Ml cells, LIF can also suppress colony formation from HL-60 or U937 
cells, but with negligible changes in differentiation (Maekawa et al 1989). More recent 
studies have however, suggested that LIF can in fact effect the survival of haemopoietic 
progenitor cells (Escary et al 1993). LIF deficient mice were generated, which showed 
dramatically decreased numbers of stem cells in the spleen and bone marrow. In the 
spleen, pluripotent stem cells (CFU-S), committed erythroid progenitors (BFU-E), and 
GM progenitors (GM-CFC) were all reduced by 70-90 %. In the bone marrow CFU-S 
numbers were decreased by 60 %, whilst the BFU-E and GM-CFC were less affected. 
This decrease in the CFU-S pool could be restored by addition of exogenous LIF. 
Primitive stem cells from LIF deficient mice were able to reconstitute the
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haemopoietic systems of lethally irradiated normal mice, suggesting that LIF was not 
affecting the differentiation potential of stem cells and was instead required to 
maintain stem cell numbers. Female LIF deficient mice were also infertile, due to a 
defect in embryo implantation. It has since been reported, that LIF is able to directly 
synergise with growth factors to promote the proliferation of purified progenitor cells 
(Keller et al 1996). These reports support previous in vivo studies on LIF and suggest 
that the roles of LIF in vivo, may be more extensive than originally envisaged (Metcalf 
et al 1990).
The most striking function of LIF however, is perhaps its ability to prevent 
differentiation commitment of murine embryonic stem (ES) cells. ES cells are 
normally totipotent and will give rise to cells of all murine tissues when injected into a 
blastocyst, but in culture ES cells undergo differentiation and lose their totipotency. 
LIF was believed to be unique in its ability to block this predisposed differentiation, 
yet still maintain the totipotent abilities of ES cells (Williams et al 1988), but it is now 
evident that IL-6, IL-11, CNTF and OSM can all prevent ES cell differentiation 
(Conover et al 1993, Nichols et al 1994). LIF has proved of immense use in the 
development of ES cell based technologies, such as those employed in the generation 
of transgenic and knockout mice.
2.14 The Transforming Growth Factor Beta (TGF-p) Superfamily
The TGF-p superfamily consists of over 20 factors involved in the growth, 
differentiation and morphogenesis of cells from almost all lineages. This superfamily 
can be divided into several different sub-families; the TGF-P family, the activins and 
inhibins, Mullerian inhibitory substance and the DVR group that includes the bone 
morphogenetic proteins (reviewed in Massague 1990). The various members of this 
superfamily are structurally related to the prototypic TGF-p 1 molecule, sharing a 
common precursor structure and conservation of seven or nine cysteine residues in the 
mature sequence. There is considerable variation at the level of sequence identity with 
members within a subfamily showing considerable sequence identity e.g. TGF-p 1, P2 
and p3 share a 64-82 % homology in their amino acid sequence, whilst the homology 
between members in different subfamilies is more disparate. As a full discussion of all
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the members of the TGF-p superfamily is beyond the scope of this work, only the 
TGF-P subfamily will be discussed hereafter, with a particular emphasis on TGF-p 1.
2.14.1 The TGF-P family
This subfamily consists of at least five members at present. Three distinct 
mammalian forms of TGF-P (TGF-p 1, p2 and P3) have been identified from various 
species. Two other non-mammalian forms have also been reported, TGF-p4 in 
chickens (Jakowlew et al 1998) and TGF-p5 in Xenopus Laevis (Kondaiah et al
1990). The TGF-ps are amongst the most pleiotropic of cytokines, and their functions 
include proliferative and inhibitory effects upon cell growth and differentiation, 
wound repair and fibrosis, and inflammation. The most abundant form of TGF-p in 
mammals is TGF-p 1.
2.14.2 Structure of TGF-p: TGF-P exists in a latent form
TGF-p 1 is considered to be the prototypic form of TGF-p. The mature form of 
TGF-p 1 is a 25 kD disulphide linked polypeptide, composed of two 12.5 kD 
homodimers. TGF-P 1 is expressed as a precursor, 412 amino acids (412aa) in length 
(Derynck et al 1985), which then undergoes intracellular proteolytic cleavage. The 
precursor is composed of an N-terminal signal sequence, a pro-region, and a C- 
terminal region that contains the active domain. TGF-p is synthesised in the form of a 
latent complex which is inactive and unable to bind to TGF-p receptors (Pircher et al
1986). This latent TGF-P complex can exist in two forms, either as a small latent 
TGF-p complex or as large latent TGF-P complex (Wakefield et al 1988, and 
reviewed in Harpel et al 1992).
The active form of TGF-P 1 consists of a disulphide-bonded dimer of the C- 
terminal 112aa of the TGF-p 1 precursor polypeptide. In the small latent TGF-p 1 
complex, the active TGF-p 1 dimer complex is non-covalently associated with a dimer 
of the amino-terminal remnant from the proteolytically cleaved precursor (the pro­
region) (Gentry et al 1988, Wakefield et al 1989). This remnant is known as the 
latency associated peptide (LAP) and purified LAP can reassociate with mature TGF- 
p and inactivate it (Gentry et al 1987). In vitro, small latent TGF-P complex has been 
reported to be expressed in the culture medium of several cell types, including bone
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cultures (Jennings and Mohan 1990, Bonewald et al 1991) and an erythroleukaemic 
cell line (Lioubin et al 1991).
In addition to the small latent complex, latent TGF-p also exists in the form of 
large latent TGF-p complex. Platelets have been shown to express this (Wakefield et 
al 1988), it has also been found in cell conditioned medium from several cell lines 
(Olofsson et al 1992, Lioubin et al 1991) and in cultures of smooth muscle and 
endothelial cells (Flaumenhaft et al 1993). This large latent TGF-p complex has been 
purified from platelets (Miyazono et al 1988) and is a 235 kD complex, composed of 
the small latent TGF-P complex (as described above) and an additional 125-160 kD 
protein called the latent TGF-p binding protein (LTBP). This LTBP is linked to the 
small latent TGF-p complex via disulphide bonds (Kanzaki et al 1990). The precise 
function of LTBP is unclear, although roles in assisting assembly and secretion of the 
large latent TGF-p complex (Miyazono et al 1991), activation of the latent TGF-p 
complex (Flaumenhaft et al 1993), assisting in the association of TGF-p to the ECM 
(Taipale et al 1994), or in stability (Brown et al 1990) have all been proposed.
The complex system that appears to have evolved to prevent TGF-p activation, 
strongly suggests that inappropriate expression of TGF-p is highly undesirable. 
However, the in vivo mechanisms by which the latent forms of TGF-p are converted 
to the mature, active form have yet to be fully elucidated. In vitro, latent TGF-p can be 
activated by a variety of chemical and physical treatments, including extreme changes 
of pH, heating, urea, or by the use of detergents (Lawrence et al 1985, Brown et al
1990). Many reports have also demonstrated that various enzymatic treatments will 
also activate latent TGF-P (Lyons et al 1988). Indeed proteolysis of latent TGF-p 
remains the most likely mechanism for activation and several mechanistic models 
have been proposed (reviewed in Harpel et al 1992). One of these proposed 
mechanisms suggests that the activation of TGF-p may involve the activation of 
plasminogen to plasmin. Apolipoprotein (a) inhibits the activation of plasminogen to 
plasmin and this was shown to result in the suppression of TGF-P activation (Grainger 
et al 1993). Further evidence for this came from the observation that the activation of 
TGF-p was inhibited in mice overexpressing the human apolipoprotein (a) gene 
(Grainger et al 1994).
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One interesting twist to the functioning of TGF-P is the observation that 
almost all mature active TGF-p found in plasma, is associated with a 2-macroglobulin 
((X2M) (O’ Connor-McCourt and Wakefield 1987). 0C2M is a highly abundant serum 
glycoprotein that is secreted by the liver and other cells, such as macrophages and 
which interacts with other cytokines (reviewed in James 1990). (X2M binds only to 
mature TGF-p and its function remains uncertain. Several mechanisms have been 
proposed, for example ot2M could simply function as a mechanism to remove excess 
TGF-p from the circulation (Lamarre et al 1991), alternatively it may actively 
scavenge active TGF-p.
2.14.3 Expression of TGF-p
TGF-p has been reported to be expressed by a very wide variety of cells in 
culture. The expression of the different mammalian isoforms of TGF-p varies 
according to the cell type. The widespread expression of TGF-p during many stages of 
embryonic development suggests an important role for TGF-p during development 
and morphogenesis (Lehnert and Akhurst 1988, Wilcox and Derynck 1988). 
Expression of TGF-p is also widespread in the adult system, with expression of TGF- 
p l, P2 or P3 mRNA detectable in most tissues and organs (Thompson et al 1989).
The predominant source of TGF-p is platelets (Assoian et al 1983), but a 
number of other mature haemopoietic cell types have also been shown to synthesise 
TGF-p, including activated macrophages (Assoian et al 1987) and B and T 
lymphocytes (Kehrl et al 1986a, 1986b).
2.14.4 The role of TGF-P as an immunoregulator
As indicated above, the expression of TGF-p appears widespread across the 
course of embryonic development. The production of TGF-p by mature immune cells 
such as macrophages suggests however, that TGF-p may also act as an immunological 
mediator. In fact, TGF-p is a very potent chemotactic agent for neutrophils (Brandes et 
al 1991, Reibman et al 1991) as well as for monocytes and macrophages (Wahl et al
1987), fibroblasts (Postelwaite et al 1987) and mast cells (Gruber et al 1994). The 
immunological functions of TGF-p appear to be mostly anti-inflammatory. TGF-p 
inhibits the activation of T cells and macrophages (Wahl et al 1988, Tsunawaki et al
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1988) and inhibits the production of cytokines (Musso et al 1990), as well as inhibiting 
the production and secretion of IgM and IgG antibodies from B cells ( Kehrl et al 
1986a, 1991).
TGF-P has been reported to provide a protective effect in animal models of 
certain autoimmune diseases. Administration of TGF-P 1 was shown to protect against 
collagen induced arthritis and experimental autoimmune encephalomyelitis (models for 
reactive arthritis and multiple sclerosis respectively) (Kuruvilla et al 1991, Racke et al 
1991, Johns et al 1991). TGF-P has also been implicated in the impaired immune 
response associated with autoimmune deficiency syndrome (AIDS), where elevated 
TGF-P levels were observed in cultures of peripheral blood mononuclear cells derived 
from HIV-infected donors (Kekow et al 1990). In addition, TGF-P has also been 
suggested to suppress HIV expression and replication in infected 
monocyte/macrophages (Poli et al 1991), suggesting that TGF-P may be involved both 
in modulating viral infection and in facets of the immune dysfunction associated with 
AIDS.
The most compelling evidence for a direct role for TGF-p in vivo has come 
from studies in which mice were generated with a homozygous deletion of the TGF-P 1 
allele (TGF-P I'7’) (Shull et al 1992, Kulkami et al 1993). In these initial studies, 
approximately 50 % of TGF-P I'7' embryos experienced prenatal lethality, but the 
remainder survived and were bom normally with no apparent developmental 
abnormalities. Subsequent reports have examined the reasons for the observed prenatal 
lethality and have suggested that TGFpi null embryos do in fact show some defects in 
haemopoiesis, as well as in embryonic vasculogenesis (Dickson et al 1995). The 
observed lethality may however, be dependent upon the genetic background (Dickson 
et al 1995). After approximately 2 weeks, perinatally surviving mice begin to develop a 
progressive wasting syndrome that results in death with 3-4 weeks of age. Histological 
analysis revealed that this wasting syndrome was accompanied by a multifocal, mixed 
inflammatory cell infiltrate and tissue necrosis. The infiltrate was observed in many 
organs including heart, lungs and liver. Comparative analysis of wild type and 
homozygous TGF-P I"7' mice revealed that several pro-inflammatory cytokines were 
upregulated, including TNF-a, IFN-y and M IP-la (Shull et al 1992). Furthermore, 
elevated levels of MHC class I and class II expression have also been
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observed in TGF-P I'7' mice (Geiser et al 1993, Nakabayashi et al 1997). Recently, it 
was shown that treatment of TGF-p I'7' mice with the immunosuppressive agent 
lapunycin led to ablation of the wasting syndrome, gain of weight and an almost 
complete inhibition of inflammation (Borkowski et al 1996), supporting the notion 
that some of the defects observed in the compound phenotype of TGF-p"7‘ mice are 
cttr.buted to an inflammatory role for TGF-P in vivo.
Although some mice do die in utero, the survival of the remainder initially 
suggested that TGF-P 1 was at least partially dispensible for normal development, or 
was compensated for, by another isoform. However it is now clear' that this postnatal 
survival is in fact due to maternal transfer of TGF-p 1 (Letterio et al 1994). TGF-p 1 
can be detected in homozygous null mice derived from a heterozygous mother, but 
none can be detected in null mice derived from a homozygous null mother. Moreover, 
homozygous null pups bom to homozygous null females (that were kept alive by 
administration of dexamethasone) died perinatally due to severe cardiac abnormalities, 
suggesting a role for TGF-p 1 in cardiac development. Furthermore, the authors 
demonstrated that TGF-P 1 was able to cross the placenta and was taken up by 
homozygous null foetal cells. Additional evidence for an in vivo role for TGF-P 1 has 
arisen from the observation that TGF-p I’7' mice have a complete absence of epidermal 
Langerhans cells and suggests that TGF-p 1 may also be involved inLangerhans cell 
generation (Borkowski et al 1996, 1997). Additional evidence that TGF-p may be 
involved in the development of Langerhans cell, is suggested by recent in vitro studies 
in which TGF-p 1 promoted the development of dendritic cells from CD34+ 
progenitors, by blocking apoptosis (Strobl et al 1996, Riedl et al 1997).
2.14.5 TGF-p as a regulator of cell proliferation
Perhaps more study has been directed towards the role of TGF-p in the control 
of cell proliferation, than any other of its many functions. TGF-p can act either to 
inhibit or to stimulate cell proliferation, though it appears to mostly function as an 
inhibitor. In fact TGF-p is one of the most potent growth inhibitors identified to date 
and shows activity on a wide variety of both normal and transformed cell types. These 
include epithelial cells, endothelial cells, fibroblasts, keratinocytes, T and B 
lymphocytes, neuronal cells and haemopoietic progenitor cells (Tucker et al 1984,
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Moses et al 1985, Roberts et al 1985, Shipley et al 1986, Kehrl et al 1986a, Kehrl et 
al 1986b, Ohta et al 1987). The degree of inhibition is highly variable between cell 
types, ranging from induction of apoptosis (Bursch et al 1993, Alam et al 1994a)* to 
either almost complete growth arrest in lung epithelial cells (Tucker et al 1984) or a 
lengthening of the G1 phase of the cell cycle (reviewed in Massague et al 1992, or in 
Alexandrow and Moses 1995).
2.14.6 The role of TGF-p in haemopoiesis
TGF-p functions as a bidirectional regulator of haemopoiesis, inhibiting 
proliferation of primitive multipotential progenitors (Keller et al 1988, 1990) and yet 
also synergising with specific growth factors to enhance proliferation of more 
committed progenitors (Keller et al 1991). Autocrine production of TGF-p has been 
demonstrated to inhibit the growth factor-induced proliferation of haemopoietic 
progenitors (Hatzfeld et al 1991, Ploemacher et al 1993). TGF-p can induce the 
apoptosis of myeloid leukaemic cells, which can be reversed by certain haemopoietic 
growth factors (Lotem and Sachs 1992, Taetle et al 1993). TGF-p has also been 
reported to induce apoptosis of primitive murine haemopoietic progenitor cells 
(Jacobsen et al 1995b). This effect appears to be at least partially reversible, since a 
combination of IL-1, IL-6 and IL-11 reduced the negative effects of TGF-p and 
supported previous studies, demonstrating that TGF-P-induced inhibition can be 
overcome by a combination of growth factors (Jacobsen et al 1994c).
As mentioned above, TGF-p can also function as a stimulator of more 
committed progenitor cells. Keller et al (1991) showed that TGF-p stimulated GM- 
CSF-induced granulopoiesis by enhancing the proliferation and differentiation of 
progenitor cells. In general the effects of the three different mammalian isoforms of 
TGF-p on haemopoietic progenitors tend to be fairly similar. One reported exception 
is the study by Jacobsen et al (1991b) that showed TGF-pl and -p2 were both able to 
bidirectionally modulate the proliferation of human progenitor cells, whilst TGF-p3 
was unable to stimulate the proliferation of granulopoiesis (but it was a more potent 
inhibitor of human haemopoiesis than TGF-pl or -p2).
It is now evident that the control of stem cell proliferation is regulated through 
a balance of both positive and negative regulators. Some regulators such as TGF-p
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and MUM a  appear to be able to function as both inhibitors and stimulators, depending 
upon the state of maturity and the growth factors present. Thus, adding yet another 
twist to understanding interactions occuring within the complex network of regulatory 
cytokines.
2.15 The Role of Growth Factors in the Regulatory Control of Haemopoiesis
Clearly it is impossible to discuss all the haemopoietic growth factors outlined 
in table 1.8.1, in detail. In addition to those already discussed, many others have more 
lineage-restricted effects such as erythropoietin on erythroid cells (reviewed in Krantz 
1991), whilst the actions of other recently identified factors such as ftl3 ligand (Lyman 
et al 1993) and thrombopoietin (reviewed in Kaushansky 1995) are only just beginning 
to be understood. However, as outlined in the preceding sections of this chapter, 
growth factors and cytokines exert a wide variety of functions on cells of various 
stages of differentiation, from uncommitted progenitors through to mature terminally 
differentiated cell types. Whilst many of these have been strongly implicated in the 
control of haemopoiesis, their precise role remains highly controversial. At one 
extreme it has been proposed that these haemopoietic growth factors (HGFs) may only 
function as survival factors. At the other extreme, these HGFs have been suggested to 
actively instruct the haemopoietic differentiation program. One can summarise these 
mechanisms as being either stochastic or instructive, though there are clearly many 
variations on these two models. It is beyond the scope of this work to provide a 
detailed explanation of the various models for haemopoietic differentiation. Therefore, 
the following sections are merely meant to give a very brief summary of the potential 
role of HGFs in haemopoietic differentiation.
2.15.1 The stochastic model of differentiation
In this model, proposed in its original form by Till et al (1964), stem cells 
undergo self-renewal and differentiate in a random or stochastic manner. Ogawa and 
colleagues have proposed models involving either random restriction of a stem cell to a 
monopotential lineage, or through random lineage restriction of oligopotential 
progenitors (reviewed by Ogawa 1993). The role of HGFs within this stochastic model 
is proposed to be restricted to the survival and proliferation of stem cells and their
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progenitors. Therefore in this model, the process of differentiation must occur through 
the action of intrinsic factors. Indeed, studies have shown that cytokines can prevent 
cells from apoptotic death and therefore act as “happiness factors” (Williams et al
1990). As also discussed previously in chapter 2, other studies have clearly implicated 
HGFs in the control of the cycling status of stem cells and their progenitors. One of the 
strongest pieces of evidence in support of a stochastic mechanism involving intrinsic 
control factors is that of Fairbaim et al (1993), using the IL-3 dependent murine 
FDCPmix cell line. These cells have the capacity to undergo differentiation along 
multiple myeloid lineages, but in the absence of IL-3 these cells undergo apoptosis. 
However, introduction of the gene for the anti-apoptotic factor bcl-2 into these cells,
' resulted in a significant delay in the time taken for the onset of apoptosis to occur. 
Moreover, this was accompanied by a spontaneous differentiation of cells along a 
variety of haemopoietic lineages. This suggests that in FDCPmix cells, IL-3 may act to 
maintain cell viability and to block differentiation. Recently it was reported that 
monocytes may have an intrinsic program of differentiation toward macrophages, that 
can occur in the absence of M-CSF (Lagasse and Weissman 1997). In this study op/op 
mice lacking functional M-CSF and exhibiting depressed macrophage levels, were 
crossed with mice engineered to overexpress Bcl-2 in the myeloid lineage. Suppression 
of monocyte apoptosis in serum-free and cytokine-free medium in vitro was sufficient 
to allow complete macrophage differentiation. In addition, this Bcl-2 overexpression 
also rescued diverse macrophage populations in vivo and resulted in a less severe form 
of osteopetrosis in these mice. This suggests that M-CSF acts to augment monocyte 
survival and allows them to respond to an intrinsic differentiation program.
2.15.2 The instructive or deterministic model of differentiation
In contrast to the above stochastic model, other researchers subscribe to an 
instructive or deterministic model (reviewed by Morrison et al 1997). In this model it is 
proposed that HGFs directly influence the differentiation program. Evidence in support 
of this model was eloquently provided by studies on the G-CSF receptor (G-CSF R). 
Dong et al (1994) reported the existence of a nonsense mutation in the G-CSF R, in 
patients with chronic neutropenia. The authors demonstrated that this mutation caused 
a truncation in a differentiation-promoting domain within the G-CSF R, resulting in the 
ablation of G-CSF induced differentiation but not G-CSF induced proliferation. Further
i
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support for a direct effect of HGFs on differentiation (as opposed to indirect effects 
such as induction or promotion of cell survival, or proliferation of a progenitor cell 
after commitment) have been reported by Shah et al (1994, 1996). In these reports it 
was shown that glial growth factor or TGF-p superfamily members acted in an 
instructive manner, to restrict multipotent neural progenitors to a glial lineage. Johe et 
al (1996) have also reported the involvement of instructive mechanisms in the 
differentiation of CNS stem cells to astrocytes. Therefore strong evidence exists for 
instructive mechanisms, particularly in the differentiation of cells within the CNS.
2.16 Summary
Clearly the processes involved in the regulatory control of haemopoiesis are 
highly complex. As indicated in the above sections, various models have been proposed 
to explain the involvement of growth factors and a large amount of evidence exists to 
support each model. As to which model is correct, remains uncertain and in 
controversy? Indeed they may not be mutually exclusive, as it is theoretically feasible 
for aspects of both stochastic and instructive mechanisms to be involved in this 
regulation. However, regardless of whether haemopoiesis is the result of intrinsic 
factors operating in a stochastic manner or is the result of an instructive environment, 
an interacting network of cytokines and their receptors is implicated in the regulation 
of haemopoiesis. This network may or may not exhibit redundancy and clearly shows 
many overlapping actions, whilst others may be unique to individual cytokines. It is 
evident that the balance of actions between the different members of this network, is 
important for the survival, proliferation, differentiation and maturation of haemopoietic 
cells and thus the normal running of the immuno-haemopoietic system.
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CHAPTER 3: MIP-la and the Chemokine Superfamily
The role of MIP-la as a haemopoietic stem cell regulator was first identified 
in 1990, when Graham et al (1990) purified a reversible inhibitor of CFU-A and CFU- 
S stem cell proliferation from the J774.2 murine macrophage cell line. They called this 
activity Stem Cell Inhibitor (SCI) and sequence analysis demonstrated that it was 
identical to a previously described molecule, macrophage inflammatory protein-la 
(MIP-la).
MIP-la is a member of a rapidly expanding family of chemotactic cytokines, 
known as the chemokines. The biological functions of these chemokines are diverse 
and range from haemopoietic regulation to proinflammatory functions. The field has 
recently become a focus of attention and excitement, following the discovery of the 
critical role certain chemokines and their receptors play in the pathogenesis of HIV. 
An overview of chemokine biology (including recent advances), with a particular 
emphasis on the role of MIP-la in the immuno-haemopoietic system follows.
3.1 The Chemokine Superfamily: Structure and Family Subdivision
As indicated above, MIP-la belongs to the chemokine superfamily, which has 
expanded in a little under a decade from a handful of family members (Schall 1991, 
Oppenheim et al 1991) to now number in excess of 30-40 members (reviewed by 
Rollins 1997, Mackay 1997). In fact some researchers estimate that as many as 50-100 
unique chemokines may eventually be identified. Table 3.1 lists the chemokines 
identified to date. The chemokines are all small inducible proteins, 8-18 kDa in size 
and are related to each on the basis of sequence homology and the presence of a 
characteristic cysteine motif in their N-terminus. Originally the family was subdivided 
into 2 classes, on the basis of the spacing of the first two N-terminal cysteine residues. 
Thus, in the “CC” or p subfamily these two cysteines are adjacent to each other, whilst 
in the “CXC” or a  subfamily they are separated by a single residue. More recently, 
this designation has been complicated by the identification of unique members of two 
novel putative chemokine subfamilies. These are designated the C subfamily, with a 
sole member Lymphotactin (Kelner et al 1994), due to the presence of only a single N- 
terminal cysteine and the CX3C subfamily with its sole member
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Table 3.1 : The Chemokine Superfamily....so far
c-x-c c-c c
IL-8 MIP-la Lymphotactin
Groa MIP-lp
GroP RANTES
Groy MCP-1
NAP-2 MCP-2
ENA-78 MCP-3
GCP-2 MCP-4
SDF-1 MCP-5
PF-4 1-309
IP-10 Eotaxin
Mig Eotaxin 2 (=MPIF-2)
HCC-1
TARC
MIP-3a (=LARC=Exodus)
MIP-3P (=ELC=Exodus-3)
DC-CK1 (=PARC)
MDC (=STCP-1)
MIP-3
MIP-ly (=HCC-2=MIP-5=Lkn-l) 
C-10 (=MRP-1)
MPIF-1 (=MRP-2=CCF18)
I
CX3C
Fractalkine
(=Neurotactin)
TECK (=TCA4)
6-Ckine (=Exodus-2=SLC)
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Fractalkine/Neurotactin (Bazan et al 1997, Pan et al 1997), in which the two amino 
terminal cysteines are separated by three amino acid residues. Members of each these 
four subfamilies, will be discussed in more detail in the following sections.
3.2 The CXC Chemokines
The CXC family of chemokines numbers at least 11 members to date (listed in 
table 3.1) and includes IL-8, PF-4, IP-10, Mig, the GRO proteins, NAP-2, ENA-78 
and SDF-1. It is possible to further subdivide the CXC chemokines, based on the 
presence or absence of a so-called “ELR-motif’, located in the N-terminal region just 
prior to the CXC motif. The ELR-chemokines such as IL-8, NAP-2, the GRO 
proteins, ENA-78, and GCP-2 are all potent neutrophil chemoattractants, whilst the 
non-ELR chemokines include PF-4, IP-10, Mig, and SDF-1 and show little or no 
neutrophil directed actions. Modification of these ELR residues prevents receptor 
binding and thus also neutrophil chemotaxis (Beall et al 1992, Clark-Lewis et al 1993) 
and insertion of an ELR motif into the N-terminus of non-ELR chemokines enables 
them to become neutrophil chemoattractants (Clark-Lewis et al 1993).
3.2.1 Interleukin-8 (IL-8)
IL-8 or neutrophil activating protein (NAP)-l as it was originally called, is 
perhaps considered to be the prototypic CXC chemokine and is certainly the most 
extensively studied. To date, no rat or murine homologue of IL-8 has been identified. 
However, antibodies to human IL-8 inhibit lung inflammation in rats, suggesting a 
rodent IL-8 homologue does exist in vivo. Human IL-8 is produced by a wide variety 
of cell types, including monocytes, neutrophils, fibroblasts, endothelial cells, epithelial 
cells, and T lymphocytes and can be induced by a number of inflammatory stimuli 
such as IL-1, TNF, and LPS (reviewed by Stoekle and Barber 1990, Oppenheim et al
1991). IL-8 was originally identified as an activity that was directed towards 
neutrophils, but not monocytes (Yoshimura et al 1987, Shroeder et al 1987) and 
which may also chemoattract T lymphocytes (Larsen et al 1989). In addition to 
chemoattraction of neutrophils, IL-8 also induces degranulation and the respiratory 
burst in neutrophils (Walz et al 1987). IL-8 has also been suggested to play a role in 
angiogenesis (Koch et al 1992, Smith et al 1994a).
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There is increasing evidence that IL-8 may also function as an inhibitor of 
haemopoietic stem cell proliferation. Broxmeyer et al (1993) showed that in addition 
to MIP-la, other chemokines such as PF-4, IL-8 and MCP-1 can all function to 
suppress colony formation from GM-CSF plus SCF stimulated progenitor cells. 
Laterveer et al (1995, 1996a) reported that a single injection of IL-8 rapidly mobilised 
haemopoietic progenitors and that SCF augmented this mobilisation (Laterveer et al 
1996b). Although no murine homologue of IL-8 has been identified to date, a putative 
murine IL-8 receptor homologue (mIL-8Rh) has, and mice have been generated with a 
homozygous null mutation in this gene (Cacalano et al 1994). These IL-8Rh7' mice 
had an increased number of neutrophils, suggesting a negative role for the IL-8Rh in 
regulating neutrophil numbers. In addition, there was also an increased number of B 
cells in their lymph nodes, as well as enlarged spleens due to enhanced proliferation of 
specific myeloid elements and megakaryocytes. There also appeared to be enhanced 
myelopoiesis in the bone marrow. Thus, providing further evidence supporting a 
possible role for IL-8 or related chemokines in the regulation of haemopoiesis in vivo. 
Further evidence for the involvement of the IL-8Rh in the negative regulation of 
myeloid progenitor cells, was also reported in a more recent study (Broxmeyer et al
1996). This study compared normal mice and mice deficient in mIL-8Rh (mIL-8Rh7') 
that were raised in either a normal or a germ-free environment. Myeloid progenitors 
from mIL-8Rh7' mice were insensitive to inhibition by hIL-8 and MIP-2, a ligand for 
mIL-8Rh. A large expansion of myeloid progenitors was observed in these mice and 
this expansion was decreased in mice raised under germ-free conditions, suggesting 
that it was environmentally inducible.
3.2.2 Stromal Cell Derived Factor-1 (SDF-1)
The chemokine SDF-1 was originally cloned from a ‘signal sequence trap 
library’ (designed to enrich for proteins containing a signal peptide sequence) (Tashiro 
et al 1993). It was also cloned from a stromal cell line, as pre-B-cell growth- 
stimulating factor (PBSF) and as the name suggests, it stimulated the growth of B-cell 
progenitors in vitro (Nagasawa et al 1994). Unusually for a chemokine it is 
constitutively expressed in a broad range of tissues. The importance and apparent 
uniqueness of SDF-1 is only just beginning to emerge. Although SDF-1 is grouped 
with the CXC chemokines, it is equally distant/related to both CC and CXC
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chemokines. Furthermore it has a unique degree of conservation with the murine and 
human homologues sharing 99 % amino acid identity, suggesting that of all the 
chemokines to date, SDF-1 is the least diverged from any prospective primordial 
ancestor.
An insight into the probable role of SDF-1 in vivo has come from the 
generation of mice in which the gene for SDF-1 has been disrupted (Nagasawa et al 
1996a). These SDF-l'7' mice died perinatally, showing a severe reduction in the 
number of B cell progenitors in both the fetal liver and bone marrow and a reduction 
in myelopoietic progenitors in the bone marrow (but not the fetal liver), thus 
suggesting SDF-1 is a regulator of B cell lymphopoiesis and bone marrow 
myelopoiesis. These SDF-l_/‘ mice also exhibited a defect in the development of the 
cardiac ventricular septum. It has since been reported that SDF-1 is a low-potency, 
high efficacy lymphocyte chemoattractant in vitro (Bleul et al 1996a) and that it also 
chemoattracts monocytes, but not neutrophils (it is a non-ELR chemokine). Most 
recently, Aiuti et al (1997) demonstrated that SDF-1 was a chemoattractant for human 
CD34+ progenitor cells. These progenitors consisted of both moderately primitive and 
more lineage-committed CD34+ cells. This suggests that SDF-1 may be important in 
the migration and homing of bone marrow CD34+ progenitors to different organs 
during development and to different niches during the differentiation and maturation 
of haemopoietic progenitor cells. Such a role certainly provides a feasible explanation 
for the myelopoietic defects observed in the SDF-1 ^  mice. The role of SDF-1 in HIV 
pathogenesis is discussed in section 3.9.
3.2.3 IP-10 and Mig
Interferon-inducible Protein-10 (IP-10) was originally isolated in 1985, as an 
IFN-y induced product from U937 cells (Luster et al 1985). IP-10 is expressed by a 
variety of cell types, including monocytes, keratinocytes, fibroblasts, endothelial cells 
and T lymphocytes (Luster et al 1985). IP-10 is a non-ELR chemokine and this is in 
keeping with its poor neutrophil activity (Dewald et al 1992), but it does appear to be 
chemotactic for monocytes (Taub et al 1996) and smooth muscle cells (Wang et al
1996). At the moment there is conflicting evidence as to whether IP-10 does, or does 
not chemoattract T lymphocytes (Taub et al 1996, Luster and Leder 1993, Roth et al 
1995). In addition to chemotactic functions, IP-10 also appears to be an inhibitor of
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angiogenesis (Angiolillo et al 1995), in contrast to IL-8 which appears to stimulate 
angiogenesis (Smith et al 1994a).
Monokine Induced by Interferon-y (Mig) is a recently identified chemokine 
and like IP-10, it is also an IFN-y inducible protein that was isolated from 
macrophages (Liao et al 1995). Mig is a chemoattractant in vitro for tumour 
infiltrating lymphocytes (TIL) and for peripheral blood lymphocytes (PBLs) (Liao et 
al 1995).
Mig and IP-10 can cross-desensitise each other in receptor activation (Liao et 
al 1995) and in fact, they appear to share the same receptor, CXCR3 (Loetscher et al 
1996a). Like IL-8 (see section 3.2.1), both Mig and IP-10 have also been reported to 
act as inhibitors of haemopoietic progenitor cell proliferation (Sarris et al 1993, Sarris 
et al 1996, Schwartz et al 1997).
3.2.4 Other CXC Chemokines
The early study of PF-4 as an immunoregulator has been well documented 
(Stoekle et al 1990). PF-4 has also been reported to inhibit megakaryocytopoiesis 
(Gewirtz et al 1989, Han et al 1990, Gewirtz et al 1995) and more recently it was 
proposed that PF-4 (and IL-8 and NAP-2) supported the viability and survival of 
normal (but not leukaemic) progenitor cells (Han et al 1997). Little is known about the 
functions of other CXC chemokines like ENA-78 (Walz et al 1991) or some of the 
more recently identified members such as LIX (Smith and Herschman 1995) and 
granulocyte chemotactic protein-2 (GCP-2) (Proost et al 1993), beyond the initial 
reports of their isolation and characterisation.
3.3 The CC Chemokines
The number of CC chemokines appears to be much larger and their effects 
more diverse, than those of the CXC chemokine subfamily. Whilst many members 
were initially characterised as monocyte/macrophage chemoattractants, it is now 
evident that they act upon an extremely wide range of cell types, including basophils, 
mast cells, eosinophils, B and T lymphocytes and NK cells (reviewed by Rollins 
1997). In general they do not exert neutrophil directed effects, although there are a few 
examples of specific chemokines that may be exceptions to this.
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3.3.1 The Monocyte Chemotactic Proteins
3.3.1.1 Monocyte Chemotactic Protein-1 (MCP-1) / JE
Human monocyte chemotactic protein-1 or MCP-1 was first isolated in 1989 
from monocytic cell lines and activated monocytes (Yoshimura et al 1989) and its 
amino acid sequence found to be identical to that of the previously cloned human 
homologue of the mouse JE gene (Rollins et al 1989). JE was originally reported as a 
gene that was highly inducible by platelet-derived growth factor (PDGF) in the 3T3 
fibroblast cell line (Rollins et al 1988). It is now generally assumed that JE is the 
murine homologue of the human MCP-1 gene and JE is therefore often commonly 
also refered to as MCP-1 (although as discussed in section 3.3.1.3, recent evidence 
suggests this may not necessarily be the case).
MCP-1 is an extremely potent monocyte chemoattractant (Yoshimura et al
1989), but has also been reported to function in vitro as a chemoattractant for activated 
T lymphocytes (Carr et al 1994) and NK cells (Taub et al 1995a). MCP-1 is also a 
potent inducer of mast cell migration (but not degranulation) (Taub et al 1995b). In 
addition, MCP-1 has also been reported to induce IL-1 and IL-6 expression in 
monocytes (Jiang et al 1992). Interestingly, a very recent report suggested that MCP-1 
may also be involved in vivo with other CXC and CC chemokines in neutrophil 
recruitment (but does not appear to do so on its own), suggesting the existence of a co­
operative chemokine network in vivo (Tessier et al 1997). In an elegant study, Weber 
et al (1996) demonstrated that MCP-1 could be converted from a potent inducer of 
mediator release from basophils to an eosinophil chemoattractant, by deleting the N- 
terminal amino acid residue from full length mature MCP-1. They also demonstrated 
that deletion of another residue led to inactivity with both basophils and eosinophils, 
whilst deletion of three or four residues resulted in mutants that were active on both 
cell types. This strongly suggests that N-terminal processing is a potential mechanism 
for regulating MCP-1 cell selectivity and function. Interestingly, an antagonist of MCP- 
1 (9-76) derived by deletions in the N-terminus was recently shown to inhibit arthritis in 
the MRL-//?r model, a murine model in which mice spontaneously develop a chronic 
inflammatory arthritis similar to human RA (Gong et al 1997).
Several laboratories are currently trying to address the true in vivo role of 
MCP-1, through the generation and study of MCP-1 transgenic and “knockout” mice.
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In one recent report the murine MCP-1 gene was coupled to the strong mouse 
mammary tumour virus (MMTV) promoter, resulting in mice (MMTV-MCP-1) with a 
high level of MCP-1 expression that corresponded to an increased susceptibility to 
intracellular pathogens (Rutledge et al 1995). No monocyte infiltrates were observed in 
any of these transgenic mice and this was proposed to be the result of monocyte 
unresponsiveness to locally produced MCP-1, due either to receptor desensitisation or 
disruption of monocyte chemoattractant gradients. In a second study by this same 
group, transgenic mice expressing MCP-1 under the control of the rat insulin promoter 
(RIP) were reported to elicit monocyte recruitment into pancreatic islets without the 
development of insulitis (diabetes) (Grewal et al 1997). When these RIP-MCP-1 
transgenic mice were crossed with the MMTV-MCP-1 mice discussed above (thus 
generating mice expressing both transgenes), the resulting mice did develop a mild 
form of insulitis. This suggests that high systemic levels of MCP-1 prevent monocytes 
from responding to local MCP-1 and therefore the ability of MCP-1 to elicit monocyte 
infiltration will be dependent on its expression at lows levels and in it being restricted 
to the appropriate site.
There is increasing evidence that MCP-1 (and other chemokines) may be 
critically important mediators of inflammation in the central nervous system (CNS). 
Chemokine expression, particularly that of MCP-1 and MIP-la, have been reported in 
many animal models of CNS inflammation (Berman et al 1996, reviewed by Ransohoff 
eta l 1996)......................................................................................................................
3.3.1.2 MCP-2 and MCP-3
MCP-2 and MCP-3 are part of a small subgroup of CC chemokines with 
extensive sequence homology to MCP-1 (>60 %). In comparison to MCP-1 and MCP- 
3, MCP-2 action is still poorly understood. MCP-2 and MCP-3 were both identified 
through their monqcyte chemoattractant abilities (Van Damme et al 1992) and they are 
both as effective as MCP-1 in this respect. Like MCP-1, they have both been reported 
to function as T lymphocyte chemoattractants. It appears that the biological effects of 
MCP-2 and MCP-3 partially overlap with those of MCP-1, yet others are clearly 
distinct. They often appear however, to be less effective and are produced at lower 
levels than MCP-1 (reviewed by Proost et al 1996). Whilst all three MCPs 
chemoattract basophils, MCP-3 is a particularly effective stimulator of basophil
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chemotaxis and release (Alam et al 1994b). The putative murine homologue of human 
MCP-3 has been identified (Minty et al 1993), and was originally cloned as MARC 
from an IgE plus antigen stimulated mast cell line (Kulmburg et al 1992) and 
subsequently from 3T3 fibroblasts as fibroblast induced cytokine (fie) (Heinrich et al 
1993b).
3.3.1.3 MCP-4 and MCP-5
MCP-4 and MCP-5 are the two most recently described MCPs. MCP-4 shares 
closest homology to MCP-3 and another CC chemokine, eotaxin. In fact MCP-4 
appears to share similar functional properties to MCP-3 and eotaxin. Like MCP-3 and 
eotaxin it is also a strong chemoattractant for eosinophils, as well as for monocytes 
and T lymphocytes (Uguccioni et al 1996) and it is also reported to stimulate 
histamine release from basophils (Garcia-Zepeda et al 1996).
To date, only murine MCP-5 has been identified (Jia et al 1996, Sarafi et al
1997). MCP-5 appears to share greatest homology with human MCP-1 (66 % amino 
acid identity) and is also structurally very similar too. In fact this similarity is even 
greater than that shown between human MCP-1 and the supposed murine homologue, 
JE (55 % identity). This suggests that JE may not in fact be the murine homologue of 
human MCP-1, although Jia et al (1996) did find evidence for a potential human 
MCP-5 gene that was not MCP-1.
3.3.2 RANTES
RANTES (Regulated on Activation Normal T-cell Expressed and Secreted) 
was identified by Schall et al in 1988, and found to be a gene inducible by antigenic or 
mitogenic stimulation in a variety of T cell lines and circulating T lymphocytes (Schall 
et al 1988). RANTES is produced by a variety of cell types including platelets 
(Kameyoshi et al 1992) and eosinophils (Lim et al 1996). RANTES is a potent 
chemoattractant of monocytes and subsets of T lymphocytes, particularly of the CD4+, 
CD45RO+ memory phenotype (Schall et al 1990), but is also a very potent 
chemoattractant of CD8+ T cells (Roth et al 1993). RANTES has also been reported to 
chemoattract and activate eosinophils (Rot et al 1992) and basophils (Bischoff et al
1993), as well as NK cells (Taub et al 1995a).
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3.3.3 Other CC Chemokines
There are now over twenty known, distinct CC chemokines, many only recently 
discovered and no doubt others remain to be identified still. Briefly, others include 
Eotaxin and Eotaxin-2 (also known as MPIF-2), which are potent chemoattractants 
and activators of only eosinophils and basophils (Jose et al 1994, Forssmann et al
1997). 1-309 and its putative murine homologue TCA-3 (Miller et al 1989, Burd et al 
1987) are produced by activated mast cells and T cells and are unusual in having an 
extra pair of cysteines. TCA-3 is activated on a wide variety of cell types, including 
neutrophils. Other novel chemokines include CIO (Orlofsky et al 1991), MLP-ly 
(Mohamadzadeh et al 1996), CCF18 or MIP-related protein-2 (MRP-2) (Youn et al 
1995, Hara et al 1995). Recently two laboratories isolated a novel chemokine with an 
extended C-terminus that includes two extra cysteines, known as 6C-Kine (Hedrick 
and Zlotnick 1997) or Exodus-2 (Hromas et al 1997a). Another interesting recent 
discovery, was that of a novel chemokine known as thymus expressed chemokine or 
TECK, that appears to be specifically expressed by thymic dendritic cells and which 
may be involved in T cell development (Vicari et al 1997). In most cases the functions 
of these novel chemokines are unknown.
3.4 The C Subfamily: Lymphotactin
To date Lymphotactin (Lptn) is the only member of the so called C subfamily. 
It only has 2 cysteines, which correspond to cysteines 2 and 4 in the CXC and CC 
chemokines. Lptn was originally cloned from activated pro-T cells (Kelner et al 1994) 
and the human homologue, SCM-1, was subsequently isolated (Yoshida et al 1995). 
Lptn was shown initially to attract T lymphocytes, particularly of type CD4+ and CD8+, 
as well as thymocytes (with the exception of CD4+CD8+ thymocytes) (Kelner et al 
1994). More recently, Lptn has also been reported to chemoattract NK cells both in 
\itro and in vivo (Hedrick et al 1997). In addition to pro-T cells and activated T cells, 
Lptn is now known to be produced by NK cells (Hedrick et al 1997) and IgE plus 
antigen activated mast cells (Rumsaeng et al 1997).
3.5 The CX3C Subfamily: Fractalkine / Neurotactin
The recent identification of a putative fourth chemokine subfamily has caused 
considerable interest. This is because fractalkine, the only member identified to date,
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appears unique in being the only known membrane-anchored chemokine. Fractalkine 
was cloned by Bazan et al (1997) from non-haemopoietic cells and shown to be a 373- 
amino acid glycoprotein that carried a chemokine domain on a long extended mucin­
like stalk. Fractalkine exists either in a membrane bound form or as a secreted protein. 
The secreted form attracts T cells and monocytes, whilst the anchored form promotes 
leukocyte adhesion. The expression of fractalkine is also unique amongst 
chemokines, with little or no expression detectable in peripheral blood leukocytes. 
Fractalkine can however, be strongly induced by IL-1 and TNF. Fractalkine was also 
cloned independently as neurotactin and shown to be predominantly expressed in 
mouse brain, with elevated expression in mice with EAE or in LPS treated mice (Pan 
et al 1997). However, in contradiction to Bazan et al, neurotactin was reported to 
attract neutrophils. The precise function of fractalkine / neurotactin is still uncertain, 
but it may well be involved in leukocyte adhesion and CNS inflammation.
3.6 MIP-la
MIP-la and MIP-ip are clearly distinct molecules. However, they do share 
some striking similarities in their functions, barring a few specific exceptions. 
Therefore, the following discussion is largely limited to that of MIP-la, unless stated 
otherwise.
3.6.1 Characterisation of MIP-la
MIP-la and MIP-lp were originally isolated as MIP-1 from the macrophage 
cell line RAW264.7, stimulated by LPS (Wolpe et al 1988). MIP-1 ran as a doublet 
composed of two peptides with very similar molecular weights of ~8 kDa. This 
doublet was subsequently found to comprise two distinct proteins, which were 
renamed MIP-la and MIP-1 p (Sherry et al 1988). The cDNA previously cloned as 
MIP-1 corresponded to that of MIP-la (Davatelis et al 1988). The amino acid 
sequences of MIP-la and MIP-1 p are 59.8 % identical, whilst their cDNAs share 56.7 
% identity. The human homologues of MIP-la and MIP-lp had previously been 
identified as LD78 (Obaru et al 1986) and Act-2 (Lipes et al 1988) respectively. The 
MIP-1 proteins are encoded for by distinct genes and clustered on chromosome 17 in 
humans, and on chromosome 11 in mice, along with most other CC chemokines.
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One of the original observations made during the isolation of MIP-1 was its 
propensity to undergo self-aggregation (Wolpe et al 1988). In fact this self aggregation 
is a phenomenon noted for both human and murine MIP-la and MIP-lp. The 
aggregation results from non-covalent and electrostatic interactions between 
molecules and occurs to such an extent that multimers may result with molecular 
masses in excess of 100 kDa in physiological buffers in vitro (Graham et al 1992) and 
even greater aggregation occurs at higher concentrations (>106 kDa). Further 
understanding of this aggregation has been achieved through the derivation of three 
MIP-la mutants, in which the C-terminal acidic amino acids have been sequentially 
neutralised, resulting in the generation of non-aggregating forms of MIP-la (Graham 
et al 1994). These three mutants formed tetramers, dimers and monomers respectively, 
which were equipotent to each other and to wild type MIP-la, in both stem cell 
inhibition assays and monocyte shape-change assays. This suggested that aggregation 
was not necessary for the function of MIP-la in these assays and implied that the 
aggregated forms spontaneously disaggregate and are ultimately functional as 
monomers, as has been confirmed in more recent studies. However, it should be noted 
that these results are in contrast to those obtained by Mantel et al (1993) in a previous 
study. In this study, it was proposed that the inhibitory activity of aggregated MIP-la 
resided in small amounts of monomeric MIP-la in the aggregated preparations and it 
was further suggested, that the monomeric MIP-la therefore had 1000-fold higher 
activity per unit weight than the aggregated forms. Graham et al (1994) reported 
however, that the aggregated form (separated from any monomeric MIP-la) was as 
active as the monomeric form and therefore concluded that the aggregated form 
spontaneously disaggregated under the assay conditions used.
Recently, the actions of stem cell inhibition and monocyte chemoattraction 
have been uncoupled. A MIP-la mutant has been generated in which the proteoglycan 
binding domain had been disrupted by mutagenesis of two basic amino acids within 
this site (Graham et al 1996). This mutant (HepMut) was unable to bind proteoglycans 
or bind to the human or murine MIP-la receptor, CCR1, and was also severely 
compromised in its ability to function in the monocyte shape change assay. In contrast 
however, HepMut was still fully active in both human and murine stem cell inhibition 
assays. Therefore, it appears that the proteoglycan binding region mutated in this study
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is critical for binding of MIP-la to CCR1, but not for inhibition of stem cell 
proliferation and suggests, that inhibition may occur through another receptor distinct 
from CCR1.
3.6.2 Normal Expression of MIP-la
MIP-la mRNA has been reported to be expressed by a wide variety of 
haemopoietic cell-types, including monocytes and macrophages (Davatelis et al 1988), 
T lymphocytes (Obaru et al 1986), mast cells (Burd et al 1989), eosinophils (Costa et 
al 1993), basophils (Li et al 1996), neutrophils (Kasama et al 1993), NK cells 
(Bluman et al 1996) and epidermal langerhans cells (Heufler et al 1992). In addition, 
several non-haemopoietic cell-types such as fibroblasts (Nakao et al 1990) and 
microglial cells (Hayashi et al 1995) have also been reported to express MIP-la.
MIP-la has been reported to be an inhibitor of haemopoietic stem cell 
proliferation (Graham et al 1990) and although expression of MIP-la mRNA is 
detectable by PCR based techniques in normal bone marrow, the levels of MIP-la are 
low. This is a situation which is in fact common for other haemopoietic cytokines (see 
section 1.6.1). One explanation for these low levels, is that MIP-la protein is 
sequestered and held in a local microenvironment through interactions with 
proteoglycans and therefore only a low level of expression is necessary for an effect 
within a localised microenvironment. Although as indicated above, such proteoglycan 
interaction is not apparently necessary for stem cell inhibition. Another explanation, is 
that under normal circumstances the expression of MIP-la is held in check and is only 
released under conditions of stress, such as inflammation. One possible candidate for 
the in vivo suppression of MIP-la, is TGF-p. Reports from our laboratory (Maltman 
et al 1993, 1996) have defined an endogenous reciprocal relationship in bone marrow 
derived macrophages between MIP-la and TGF-p, whereby elevation of MIP-la will 
lead to the increased expression of TGF-p, which in turn will result in a suppression 
of MIP-la expression. Thus, in the bone marrow, where levels of TGF-p are readily 
detectable, TGF-p would act as the predominant partner and keep the expression of 
MIP-la in check. Outside of the bone marrow, several other cytokines have also been 
shown to downregulate the expression of MIP-la, including IL-10 (Kasama et al
1994) and IL-4 (Standiford et al 1993a).
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MIP-la was originally identified as an LPS-inducible gene in macrophages, 
but a number of other stimuli also induce MIP-la expression. These include IgE in 
mast cells (Burd et al 1989) and IL-1, IL-2, and IL-6 in monocytes (Maciejewski et al
1992). Several studies have tried to address the transcriptional elements involved in 
inducible MIP-la expression, but with limited success. Comparative analysis of the 
promoters for murine MIP-la and p revealed a conserved CK-1 element (Widmer et 
al 1993) previously identified in the murine GM-CSF gene (Stanley et al 1985), whilst 
Ritter et al (1995) demonstrated that a novel transcription factor named MIP-la 
nuclear protein (MNP) was required for transcription of human MIP-la. Analysis of 
LPS induction has revealed that members of the C/EBP, NF-KB, and c-ets 
transcription factor families may be involved in LPS induced MIP-la transcription 
(Grove and Plumb 1993). Another report, by Proffitt et al (1995), suggested that 
ATF/CREB and AP-1 related proteins may be involved in regulating MIP-1 p 
expression following LPS induction, implying that whilst MIP-la and MIP-1 p are co­
expressed in many cell types they may exhibit differential transcription under certain 
circumstances.
3.6.3 Expression in Disease and Inflammation
Elevated MIP-la expression has been observed in a number of disorders and 
disease states. For instance, a significant increase in MIP-la mRNA expression was 
observed in bone marrow nucleated cells derived from patients with aplastic anaemia 
(AA) and myelodysplastic syndrome (MDS) (Maciejewski et al 1992). It is probable 
that this aberrant expression results from dysregulated expression of other cytokines 
within the bone marrow as a result of the disease state, though it is also possible that 
aberrant MIP-la expression might play an etiological role in the development of AA 
and MDS.
Increased expression of MIP-la has been observed in both human interstitial 
lung disease (Standiford et al 1993b) and also in a murine model of interstitial lung 
disease (Smith et al 1994b), as well as in several other animal models of human 
diseases such as murine endotoxemia (a model for sepsis) (Standiford et al 1995).
MIP-la expression is also elevated in TGF-p 7’ mice (Shull et al 1992). This 
finding is certainly in keeping with the known endogenous reciprocal relationship with
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TGF-p (see previous section) and suggests that this interaction may indeed occur in 
vivo. It is not clear however, whether MIP-la is a direct mediator of the multifocal 
inflammation observed in these mice or if it is merely a secondary consequence of it.
In addition to classical inflammatory disease, MIP-la has also been implicated 
in several auto-immune diseases, most notably in rheumatoid arthritis (RA), as well as 
in inflammatory neurological disease. RA is characterised by elicitation and activation 
of various leukocyte populations within the synovial space and in joint tissue. These 
recruited leukocytes are known to be critical participants in the resulting pathology. A 
number of chemokines have been implicated in the recruitment of leukocytes in RA 
(reviewed by Kunkel et al 1996), one of these being MIP-la (Koch et al 1994). 
Aberrant MIP-la expression has also been documented by many researchers in a 
variety of inflammatory neurological disease states. One of the most intensively 
studied areas has been that of multiple sclerosis (MS), characterised by focal T cell 
and macrophage infiltration into white matter and resulting demyelination. Significant 
elevation of MIP-la has been reported in MS patients undergoing relapse (Miyagishi 
et al 1995). Experimental allergic encephalomyelitis (EAE) is an experimental model 
frequently used to study MS. Investigation of EAE, has revealed that the kinetics of 
MIP-la expression (and certain other chemokines) parallels that of leukocyte 
recruitment and disease severity (Miyagishi et al 1997). MIP-la has been reported to 
be produced by microglial cells within the central nervous system (CNS) (Hayashi et 
al 1995) and by glial and neuronal cells within the brain (Ishizuka et al 1997). Perhaps 
most conclusive, is the report by Karpus et al (1995), in which they demonstrated that 
administration of anti-MIP-la antibodies prevented the development of EAE. Taken 
together these studies strongly implicate MIP-la (and other chemokines) as important 
mediators of inflammation within the CNS.
3.6.4 Pro-inflammatory Functions of MIP-la
During the initial characterisation of MIP-la, as MIP-1, Wolpe et al (1988) 
reported that injection of MIP-1 into the footpads of mice resulted in inflammation, 
characterised primarily by a neutrophil infiltrate. MIP-1 was also shown to attract 
neutrophils and induce a respiratory burst in vitro. Since that initial report the precise 
relationship between MIP-la and neutrophils has remained confused. Firstly, the
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report of Wolpe et al (1988) used a supraphysiological dose of MIP-1. A later report 
by McColl et al (1993) suggested that human MIP-la had only very minimal effects 
on neutrophil attraction and activation. In contrast however, was a later report that 
murine MIP-la was a mediator of neutrophil recruitment in murine endotoxemia 
(Standiford et al 1995). One possible explanation is that MIP-la does not play a role 
in neutrophil function in humans, but that it does in rodents. In support of this is the 
observation that rodent, but not human, neutrophils express abundant CCR1, a MIP- 
la  receptor. In addition, IL-8 which is a potent neutrophil chemoattractant has not 
been identified in rodents, nor has its receptor CXCR1 been detected on rodent 
neutrophils. It is possible therefore that in rodents, MIP-la and CCR1 can fulfil the 
roles played by IL-8 and CXCR1 in humans. This notion is however, difficult to 
reconcile with the identification of a putative murine IL-8Rh that has been implicated 
in neutrophil function (Cacalano et al 1994). At present the role of MIP-la in 
neutrophil function is unclear, but it does underline the fact that caution that should be 
used in assuming that there is a direct correlation between human and murine 
chemokines, their receptors, and their functions.
MIP-la is unquestionably a potent monocyte/macrophage chemoattractant 
(Standiford et al 1993b), but in addition it is also involved in regulating the effects of 
many other immune cell types. Macrophages are not only a predominant source of 
MIP-la expression, they are also themselves targets for the action of MIP-la. Fahey 
et al (1992) reported that native MIP-1 purified from LPS stimulated macrophages 
(containing both MIP-la and MIP-1 P), was able to enhance the antibody independent 
macrophage cytotoxicity for tumour cells and stimulate the proliferation of mature 
tissue macrophages. In addition MIP-la, but not MIP-lp, was able to induce 
secretion of TNF, IL-la and IL-6. An excess of MIP-lp was in fact able to suppress 
the MIP-la induced production of TNF.
It is clear, that whilst MIP-la and MIP-1 p appear to be co-expressed from 
many cell types and show many similar functions, they do also exert some distinct 
ones too. This is most apparent in their abilities to regulate stem cell proliferation (see 
below), but also in their effects on different lymphocyte populations. Taub et al (1993) 
showed that human MIP-la preferentially attracted activated CD4+ T cells, whilst 
human MIP-lp was preferential for activated CD8+ T cells. This differential attraction
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was confirmed by Schall et al (1993), who also demonstrated that MIP-la was a more 
potent B cell chemoattractant than MIP-lp. Although proteoglycan binding appears 
dispensable for the function of MIP-la in stem cell assays, a report by Tanaka et al
(1993) suggests that proteoglycan binding may be important for inflammatory 
function. MIP-lp was shown to be present on lymph node endothelium and this 
proteoglycan bound MIP-1 p induced the binding of T cell to VCAM-1 in vitro. This 
supports the notion that proteoglycans are involved in the localisation of chemokines 
to endothelial and other cell surfaces, where they act to recruit immune cells from the 
periphery to sites of inflammation.
In addition to actions on monocytes, T cells and neutrophils, MIP-la has also 
been reported to activate basophils (Alam et al 1992), chemoattract (but not 
degranulate) IgE plus antigen activated mast cells (Taub et al 1995b) and induce the 
migration and activation of eosinophils (Rot et al 1992). MIP-la has also been 
reported to enhance IgE and IgG4 production from human B cells (Kimata et al 1996) 
and to up-regulate synthesis of the latent metalloproteinase, pro-metalloproteinase-9 
(proMMP-9) from lymphocytes (Johnatty et al 1997). Taken together, these reports 
demonstrate an important role for MIP-la in the recruitment of specific immune cell- 
types into various tissues during inflammation. In addition MIP-la appears to play a 
modulatory role on a variety of functions exerted by these recruited cells. MIP-la also 
plays a key role in the inflammatory cascade, through its ability to induce production 
of other cytokines such as TNF and IL-1, that may in turn induce additional MIP-la 
production and thus further amplify the local inflammatory response.
The most conclusive evidence verifying the in vivo importance of MIP-la has 
come from the recent generation of MIP-la “knockout” or “null” mice (MIP-la7'), in 
which the MIP-la gene was disrupted (Cook et al 1995). These mice had no overt 
haemopoietic abnormalities, suggesting that either MIP-la is dispensable for normal 
haemopoiesis or is functionally redundant and its actions are replaced by another 
factor in these MIP-la7' mice. In contrast however, MIP-la was required for 
generation of an inflammatory response to viral infection. Homozygous null mice 
were resistant to coxsackievirus-induced myocarditis compared with infected wild 
type mice, which did develop myocarditis. A reduced pneumonitis and delayed viral 
clearance was also observed in influenza virus infected MIP-la7' mice compared with
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infected wild type mice. Thus, MIP-la is involved in the inflammation associated 
with viral infection in vivo.
3.6.5 The Role of MIP-la as a Haemopoietic Regulator
The first report on the ability of MIP-la to function as a regulator of 
haemopoietic stem cell proliferation, was by Broxmeyer et al (1989). They used 
purified MIP-1, containing both MIP-la and MIP-lp, and observed that addition of 
MIP-1 led to enhanced proliferation of M-CSF or GM-CSF stimulated committed 
progenitors (GM-CFC). MIP-1 had no effect on G-CSF stimulated colony formation. 
Subsequently, Graham et al (1990) purified the previously identified stem cell 
inhibitor (SCI) or NBME-IV activity (Lord et al 1976) and discovered that it was 
identical to MIP-la. They were able to demonstrate that SCI/MIP-la inhibited colony 
formation from CFU-A type stem cells and its in vivo correlate, CFU-S, but not that of 
more committed GM-CFC progenitors. Neutralising polyclonal serum raised against 
MIP-1 was also able to block the inhibitory activity of both SCI and recombinant 
MIP-la. MIP-lp however, was unable to inhibit stem cell proliferation, at the 
concentrations used in these studies. Broxmeyer et al (1990) subsequently confirmed 
the inhibitory action of MIP-la and the inability of MIP-1 P to function as an inhibitor. 
This group also reported that MIP-lp was in fact able to block the suppressive effects 
of MIP-la on BFU-E, CFU-GEMM and CFU-GM colony formation (Broxmeyer et al
1991). However, this block only occurred when MIP-lp was added in an excess to 
MIP-la, as a 1:1 ratio did not result in a block of MIP-la inhibition (explaining why 
MIP-1, composed of a 1:1 ratio of MIP-la and p, was active as an inhibitor in the 
earlier study by Broxmeyer et al 1990).
The ability of MIP-la to function in vivo as an inhibitor of stem cell 
proliferation has also been addressed in several studies. Dunlop et al (1992) 
demonstrated that human MIP-la was active in a dose-dependent manner in vitro on 
dl2 CFU-S cells, and to a lesser extent on more mature d8 CFU-S cells. In the same 
study, the authors reported that administration of multiple doses of MIP-la was 
sufficient to protect the CFU-A / S compartment, following treatment with the 
cytotoxic drug cytosine arabinoside (Ara-C). Lord et al (1992) have reported that 
MIP-la will also protect CFU-S cells against the cytotoxic effects of hydroxyurea
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(HU). However, a later study by Quesniaux et al (1993), showed that more primitive 
stem cells were not protected by human MIP-la. In this model, a primary injection of 
5-FU was used to eliminate late progenitors and cause the more primitive, and 
normally quiescent, LTR stem cells (see section 1.3) to enter the cell cycle and 
therefore become sensitive to administration of a second dose of 5-FU. MIP-la did 
not prevent the depletion of LTR stem cells following the second 5-FU injection, 
suggesting that it did not prevent cycling of the LTR stem cells. MIP-la was however, 
able to inhibit the formation of more mature haemopoietic progenitors (GM-CFC, 
BFU-E, CFC-muiti, and pre-CFCmuiti). It should be noted that cytotoxic drugs (such as 
Ara-C, HU, and 5-FU) that target specific stages of the cell cycle, are not the only 
drugs utilised in chemotherapy. They are often used in combination with non-S phase 
drugs, such as cyclophosphamide. Studies such as those recently reported by Marshall 
et al (1997), are currently being undertaken to address whether or not MIP-la is a 
potentially useful myeloprotective agent against therapeutic regimes that are more 
applicable to current clinical settings.
The therapeutic value of MIP-la against leukaemic cells has also been 
investigated. Eaves et al (1993) have demonstrated that MIP-la does not inhibit the 
cycling of primitive chronic myeloid leukaemia (CML) cells supported in long-term 
cultures (LTC). MIP-la did however, inhibit the activation of normal primitive 
progenitors (but not more mature ones) in similar LTCs. This provides hope that MIP- 
l a  could prove useful in a therapeutic role, by providing protection of normal 
primitive stem cells against any cytotoxic agents, such as those used in chemotherapy, 
whilst simultaneously leaving CML cells susceptible. Chasty et al (1995) also reported 
that CML cells were relatively refractory to inhibition by MIP-la. Moreover, the 
authors demonstrated that these CML cells expressed similar levels of MIP-la 
receptors as did normal CD34+ cells. This suggests the inability of MIP-la to inhibit 
CML cells may lie in a downstream signalling event. Interestingly, Ferrajoli et al
(1994) reported that MIP-la could inhibit the proliferation of subsets of acute 
myelogenous leukaemia (AML) progenitors. However, subsequently Owen-Lynch et 
al (1996) have shown that sub-sets of AML cells are not inhibited by MIP-la. In this 
study, autonomous AML blast cells were refractory to MIP-la inhibition, whilst 
cytokine responsive AML cells were inhibited by MIP-la in the presence of either
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GM-CSF or SCF. However, when GM-CSF and SCF were used in combination, only 
a small number were inhibited by MIP-la with the remainder remaining refractory. 
Interestingly, in the earlier study reported by Ferrajoli et al (1994) only single cytokine 
additions were used. In contrast, the later study of Owen-Lynch et al (1996) used 
either single cytokine additions (in which the CML cells were inhibitable), or a 
combination of cytokines (in which most samples were refractory to MIP-la 
inhibition), or no cytokine treatment to allow autonomous growth. The use of multiple 
cytokines is more likely to be representative of the environment in vivo, and therefore 
this study suggests that in addition to CML cells, autonomous AML cells and some 
subsets of cytokine responsive AML cells may be potential targets for therapeutic 
regimes, in conjunction with MIP-la as a protective agent.
In addition to the inhibition of bone marrow haemopoiesis, MIP-la also 
functions in vitro as a potent, reversible inhibitor of both human and murine epidermal 
keratinocyte proliferation (Parkinson et al 1993). MIP-la mRNA was previously 
shown to be produced by epidermal langerhans cells (Heufler et al 1992) and it has 
been proposed, that within the skin, epidermal stem cells are held quiescent by MIP- 
l a  derived from langerhans cells located within the same epidermal proliferative unit 
(Graham and Pragnell 1992b).
Inhibition by MIP-la, seems to occur on a relatively restricted subset of 
haemopoietic stem cells, represented by the CFU-A / S compartment. MIP-la will not 
inhibit the most primitive stem cells, nor more mature ones. In fact it appears to 
function as a stimulator of more mature progenitors. In this respect, MIP-la shares 
many similarities with TGF-p. Indeed Keller et al (1994) have shown that MIP-la and 
TGF-P show overlapping, as well as distinct functions on haemopoietic stem cells. 
MIP-la and MIP-lp have extensive homology to each other, but MIP-la is more 
effective as an inhibitor and MIP-P may play a role in blocking this inhibition. It is 
also becoming evident that many other chemokines may function as inhibitors of 
haemopoiesis. A number of these novel chemokines have been reported to act as 
haemopoietic inhibitors including Exodus (or MIP-3a or LARC) (Hromas et al 
1997b), Exodus-2 (also known as 6C-Kine or SLC) (Hromas et al 1997a), myeloid 
progenitor inhibitory factor-2 (MPIF-2) (Patel et al 1997) and MIP related protein-2 
(MRP-2) also known as MPIF-1 or CCF18 (Youn et al 1995). With the exception of
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MPIF-2, all these reports of actions as putative inhibitory factors have come from the 
Broxmeyer laboratory. Broxmeyer et al (1993) have also previously suggested that in 
addition to MIP-la, MCP-1 (and some CXC chemokines) can also function as an 
inhibitor of haemopoietic progenitor cell proliferation. This observation is in 
contradiction to a previous report from our laboratory (Graham et al 1993), in which 
only MIP-la, and MIP-lp to a lesser extent, are active as inhibitors. Exactly why 
these contradictions exist is uncertain, but they may reflect differences resulting from 
the different types of assay used by each group. Nevertheless it remains a possibility 
that other future reports will confirm that many of these novel CC chemokines also 
function as haemopoietic inhibitors.
3.7 Chemokine Receptors
A great deal of research has been directed at trying to understand how various 
chemokines interact with their cognate receptors. It is now evident that the chemokine 
receptors belong to the superfamily of seven transmembrane spanning G protein- 
coupled receptors (7TMsGPCR) and a multitude of chemokine receptors have now 
been cloned. Recently, the fields of chemokine biology and virology have surprisingly 
merged. This has arisen through many outstanding contributions and resulted in the 
identification of an essential role for chemokines and chemokine receptors in the 
pathogenesis of HIV infection. A brief overview of the various known chemokines, 
together with their significance to viral pathogenesis is presented in the following 
sections.
3.7.1 Early characterisation of receptors
The first chemokine receptors to be identified were those for IL-8, and were 
named IL-8RA (Holmes et al 1991) and IL-8Rb (Murphy and Tiffany). IL-8 binds to 
both with high affinity, but IL-8RA is specific for IL-8, whereas IL-8RB binds other 
CXC chemokines (see table 3.2). With the cloning of these receptors it became 
possible to design degenerate oligonucleotide PCR primers, based on conserved 
sequences within the IL-8 receptors and other 7TMsGPCRs. Neote et al (1993a) and 
Gao et al (1993), subsequently cloned a receptor, CC-CKR1, from U937 cells and 
PMA differentiated HL60 cells, which bound MIP-la, MIP-lp, RANTES and MCP-1
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Table 3.2 : The Human Chemokine Receptor Family and their Ligands
Receptor Ligands that Bind
CCR1 MIP-la, RANTES , MIP-lp, MCP-3, MCP-2
CCR2 MCP-1, MCP-2, MCP-3, MCP-5
CCR3 Eotaxin, RANTES, Eotaxin 2, MCP-2 ?, MCP-4 ?
CCR4 TARC, MDC (MIP-la, RANTES, MIP-ip, MCP-1)
CCR5 RANTES, MIP-la, MIP-lp
CCR6 MIP-3a
CCR7 MIP-3P
CCR8 1-309
D6 MIP-la, MIP-lp, MCP-1,2,3 and 4, Eotaxin, HCC- 
RANTES
CXCR1 IL-8
CXCR2 IL-8, Gro-a, Gro-P, Gro-y, NAP-2, ENA-78, GCP-2
CXCR3 IP-10, Mig
CXCR4 SDF-1
CX3CRI Fractalkine
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with various affinities and this became the first CC chemokine receptor. Many human 
and murine receptors have been cloned since and the nomenclature was changed in 
1996, to accommodate these. Receptors are now prefixed with CXC or CC, depending 
on whether they bind CC or CXC chemokines. Thus, IL-8Ra and IL-8Rb became 
CXCR1 and CXCR2 respectively, whilst CC-CKR1 became CCR1. It is now evident 
that many CC and CXC receptors bind multiple ligands, with varying affinities. To date 
no CC chemokine has been reported to bind to a CXC receptor and vice versa, with 
the exception of the Dufly antigen receptor (discussed in section 3.8) and certain 
virally encpded proteins. The assignation of ligands is therefore complex and made 
further so by differences between species. To simplify this, the known human CC and 
CXC chemokine receptors and their known ligands have been summarised in table 3.2.
3.7.2 The 7TMsGPCR superfamily
The chemokine receptors identified to date are all members of the 7TMsGPCR 
superfamily that also includes receptors for other proinflammatory mediators such as 
C5a, as well as the best characterised member, the (52-adrenergic receptor. The 
proposed structure of one such chemokine receptor, CCR1, is shown in figure 3.1. 
Binding of the cognate ligand results in activation of heterotrimeric G protein 
complexes, followed by dissociation of the a  subunit from the py subunit which leads 
to activation of phospholipase C (PLC) pi and p2. PLC activation then results in the 
generation of the second messengers diacylglycerol (DAG) and inositol (1,4,5)- 
triphosphate (IP3). These secondary messengers then trigger a signalling cascade, in 
which DAG activates protein kinase C, whilst IP3 mobilises calcium from intracellular 
stores in the cytoplasm and ultimately gives rise to responses such as chemotaxis, 
degranulation and the respiratory burst. Many different forms of G protein subunit 
exist and fall into two classes, the Gq class includes Gotq, G all, G al4, G al5 and 
Gal6 (Simon et al 1991) and the Gi class that includes G2 and Gi3. The Gq class are 
all sensitive to pertussis-toxin (PTX), whilst the Gi proteins are PTX-insensitive and 
appear to directly activate PLCp2 through the G-GPy-PLCP2 pathway via release of 
GPy. In general chemokine receptors are PTX-sensitive, though there are exceptions 
such as the IL-8 receptors which can function in a PTX-insensitive manner
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(Wu et al 1993). Research is currently ongoing to further understand the interaction 
between chemokines, their receptors and the different G proteins. Recent work by 
Kuang et al (1996), suggests that the CC receptors show different specificities in 
coupling Got class proteins (unlike the CXC receptors) and implies that they may have 
distinct functions in vivo, a notion supported by the fact that there is obvious 
differential expression of Got proteins.
3.7.3 Receptors for the CC chemokines
3.7.3.1 CCR1
As can be seen from table 3.2 CCR1 is a receptor for multiple chemokines. In 
general it appears to be a receptor for M IP-la and RANTES (Neote et al 1993a), 
although MCP-2 and MCP-3 are functional ligands too (Ben-Baruch et al 1995). 
CCR1 appears to be expressed on a wide variety of cell types, including primary 
monocytes/macrophages and cell lines, neutrophils, B and T lymphocytes, eosinophils 
and astrocytes (Neote et al 1993a, Post et al 1995, Tanabe et al 1997). A couple of 
studies have attempted to address the in vivo function of CCR1, through generation of 
CCR1 homozygous null mice. In the first of these, by Gao et al (1997), the mice were 
phenotypically normal. There was evidence however, for disordered steady state, in 
vitro induced trafficking and proliferation of myeloid progenitors in CCR1'' mice. 
Furtherpiore, mature neutrophils from CCR1" mice failed to under chemotaxis in vitro 
in response to MIP-la. These results suggest that CCR1 has a role in haemopoiesis 
and inflammation in vivo. The haemopoietic abnormalities are surprising in the light of 
the normal haemopoiesis shown by M IP-la^ mice (Cook et al 1995) and studies from 
our laboratory that suggest CCR1 is not the receptor through which M IP-la inhibits 
stem cell proliferation (Graham et al 1996). One reason for these apparent 
discrepancies is that the study by Gao et al used an in vitro stimulus (LPS) to assess 
the trafficking and proliferation of myeloid progenitor cells. Therefore this does not 
prove that CCR1 is critical for in vivo control of myeloid progenitor cell trafficking and 
proliferation. In another study, performed by Gerard and collegues using CCR1 
deficient mice, CCR1 was shown to be important for progression of inflammation 
(Gerard et al 1997). The authors reported that deletion of CCR1 was associated with
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protection from Pancreatitis-associated lung injury and moreover that this was 
associated with decreased levels of TNF-a.
3.7.3.2 CCR2
The CCR2 receptor was first cloned by Charo et al (1994) from the 
MonoMac6 cell line. The receptor appears to exist in two forms, CCR2A and CCR2B, 
generated by alternative splicing of a single gene. They appear to differ only in their 
C-terminal tails, although CCR2A is not as well expressed on the cell surface. CCR2B 
appears to be an MCP-specific receptor and does not bind either MIP-la, MIP-lp, or 
. RANTES (Myers et al 1995). Through the use of truncation mutants and site-directed 
.^.mutagenesis, the Charo group has been very productive in determining regions 
: ‘ involved in interactions between CCR2 and in particular, MCP-1 (Monteclaro and 
Charo 1996, Monteclaro and Charo 1997, Wong et al 1997, Arai et al 1997). Most 
recently, a non-redundant role for CCR2 in macrophage recruitment and host defence 
against bacterial pathogens was reported (Kurihara et al 1997, Kuziel et al 1997)
3.7.3.3 CCR3
CCR3 is a receptor with a more restricted expression pattern. It appears highly 
expressed on eosinophils (Kitaura et al 1996) and basophils (Uguccioni et al 1997).
i
I Limited expression has also been reported on elicited macrophages and neutrophils 
(Gao et al 1996), although the functional relevance of this is questionable. Human 
CCR3 is very specific in binding only eotaxin, MCP-3, MCP-4, and RANTES, all of 
which are eosinophil chemoattractants. This further reinforces the notion of CCR3 
being an eosinophil/basophil specific receptor. However, a very recent study suggests 
a wider role in the allergic response, in that CCR3 appears to be expressed on Th2 
cells and moreover, that eotaxin was able to stimulate increases in intracellular 
calcium and chemotaxis of CCR3+ T cells (Sallusto et al 1997). This finding is 
particularly interesting, because it suggests that eotaxin can attract eosinophils, 
basophils and Th2 cells, three of the most important cells for development of an 
inflammatory allergic response.
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3.7.3.4 CCR4
Human CCR4 was originally cloned from a human immature basophilic cell 
line (Power et al 1995) and was found to be expressed strongly in the thymus, as well 
as in T and B lymphocytes, peripheral blood monocytes and in IL-5 stimulated 
basophils. Originally, human CCR4 was reported to be a functional receptor for MIP- 
la , RANTES and MCP-1, however it is now uncertain whether this is indeed true. 
The murine homologue was subsequently cloned (Hoogewerf et al 1996) and shown 
to have similar binding characteristics and tissue expression as its human homologue. 
Imai and collegues have demonstrated that the T cell directed CC chemokine TARC, 
was a specific ligand for CCR4 and did not bind to any other known receptors (Imai et 
al (1997). More recently this group reported that macrophage-derived chemokine 
(MDC) was also a functional ligand for CCR4 Imai et al (1998).
3.73.5 CCR5
CCR5 was first cloned by Samson et al (1996a) and subsequently by Raport et 
al (1996) and Combadiere et al (1996). CCR5 is abundantly expressed on 
macrophages and T cells and appears to be a relatively specific receptor, binding only 
MIP-la, MIP-1 p and RANTES (Raport et al 1996). Recently, Samson et al (1997) 
demonstrated that a region within the second extracellular loop of CCR5 was critical 
for high affinity binding of these ligands and subsequent functional response. CCR5 
is now the focus of intense study, as a result of its recent identification as a'co-factor 
for HIV entry and this is discussed further in section 3.9.
3.7.3.6 Other CC Receptors
CCRs 1-5 are the most studied CC chemokine receptors to date, but several 
other receptors have recently been identified. CCR6 appears to show relatively 
restricted expression in B and T lymphocytes and was strongly expressed in CD34+- 
derived dendritic cells, but not on monocyte-derived ones, nor on monocytes, 
granulocytes or NK cells (Baba et al 1997, Greaves et al 1997). CCR7 was recently 
reported as a receptor for the novel chemokine MIP-3P or ELC (Yoshida et al 1997) 
and is strongly expressed in B and T lymphocytes (Birkenbach et al 1993). The 
receptor for 1-309, a human CC chemokine was recently identified and named CCR8 
(Tiffany et al 1997, Stuber Roos et al 1997). D6 is a recently characterised receptor,
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cloned in our laboratory (Nibbs et al 1997). It is unusual in having an altered 
DRYLAIV motif in the second intracellular loop, which is normally highly conserved 
and which appears critical for signalling. Murine D6 is the highest affinity receptor for 
MIP-la identified to date. The human homologue of this was recently cloned (Nibbs 
et al 1998) and is also a high affinity receptor for MIP-la, and also binds MIP-lp, 
MCPs 1-4, eotaxin and HCC-1. Unusually however, D6 does not appear to flux 
calcium in HEK293 cells. The functional significance of this and the other unusual 
characteristics of D6 are unclear at present.
3.7.4 Receptors for the CXC Chemokines
As indicated in section 3.7.1, CXCR1 is a receptor specific for IL-8, whilst 
CXCR2 is also a receptor for IL-8, as well as for other CXC chemokines. Recently, 
expression of CXCR2 was demonstrated on subsets of neurons within the CNS 
(Horuk et al 1997). Loetscher et al (1996) cloned the receptor (CXCR3) for IP-10 and 
Mig, that appears to be mainly expressed in activated T cells and which does not bind 
to any of the other known CXC chemokines. Murine CXCR4, cloned by Nagasawa et 
al (1996b) was shown to be the receptor for SDF-1 and the murine homologue of the 
human fusin HIV entry cofactor identified by Feng et al (1996). The role of CXCR4 in 
HIV entry will be discussed in section 3.9. CXCR4, like CCR2, appears to be 
expressed in two forms (CXCR4A and B) derived from a single gene by alternative 
splicing (Heesen et al 1996).
3.8 The Duffy Antigen for Chemokines (DARC)
One of the most unusual identified chemokine receptors is DARC. The Duffy 
antigen is an erythrocyte cell surface receptor for the malarial parasite, plasmodium 
vivax (reviewed by Hadley and Peiper 1997). Surprisingly, a promiscuous chemokine 
receptor that bound both CXC and CC chemokines (with the exception of MIP-la) 
was also identified on erythrocytes (Neote et al 1993b) and subsequently shown to be 
identical to the Duffy antigen (Horuk et al 1993). DARC as it was named, is also 
expressed on the endothelial cell lining some postcapillary venules and on Purkinje 
cells in the cerebellum of the brain (Horuk et al 1996). The precise function of DARC 
in vivo is still unclear, as it does not appear to present chemokines in an active form to 
receptors, nor does it appear to signal. It may instead function to soak up excess
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chemokines from the circulation. Its strong conservation between species and the 
observation that Duffy blood group negative individuals (who are malaria resistant) do 
still express Duffy on endothelial cells of postcapillary venules, suggests that it does 
serve a critical role in vivo. Very recently, it was reported by Rot and his colleagues, 
that IL-8 is actually internalised by venular endothelial cells (EC) and transcytosed to 
the luminal surface where it is presented to adherent leukocytes on the membrane of 
EC (Middleton et al 1997). It is possible that DARC plays a role in this chemokine 
transcytosis and presentation.
3.9 Chemokines, their Receptors and Significance to HIV Pathogenesis
Beginning in late 1995, the fields of chemokine and AIDS research have 
rapidly merged, in what has already become one of the most significant breakthroughs 
in AIDS research over the last 15 years. The review by D’ Souza and Harden (1996) 
provides an excellent summary of this. The following section briefly overviews some 
of the reports that led to the discovery of the critical role of chemokines and their 
receptors in HIV pathogenesis.
One of the great elusive mysteries of AIDS research has been the missing 
cofactor / receptor required for entry of HIV-1 into cells in addition to the previously 
identified CD4 molecule (Dalgleish et al 1984). Cocchi et al (1995) demonstrated that 
MIP-la, MIP-lp, RANTES were three soluble factors released by CD8+ T cells, that 
suppressed the entry of primary strains of HIV-1 and provided the first clues to 
solving this puzzle. In 1996, Feng et al made a seminal discovery and identified the 
second receptor necessary for HIV-1 entry into T cell lines, so called T-tropic viruses. 
They named this protein fusin, because it aided HIV fusion (Feng et al 1996). Fusin is 
identical to CXCR4, the receptor for SDF-1 (Bleul et al 1996b), and was only 
permissive for entry of T-tropic strains and not for macrophage-tropic (M-tropic) 
viruses. Subsequently, five groups simultaneously reported that the cofactor for M- 
tropic viruses was the CCR5 receptor and that CCR2b and CCR3 also functioned as 
cofactors, though less effectively (Dragic et al 1996, Deng et al 1996, Alkhatib et al 
1996, Doranz et al 1996, Choe et al 1996). It is now clear that during infection some 
viruses evolve to become dual-tropic and can utilise both CC and CXC receptors 
(Doranz et al 1996), whilst some strains of HTV-2 can use CXCR4 in a CD4 
independent fashion (Endres et al 1996). Intense study is now directed at determining
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critical interactions between different regions of CD4, HIV and various receptors. It 
now appears that the gpl20 protein of HIV induces a complex between CD4, gpl20 
and CXCR4 (Lapham et al 1996). Others have shown similar interactions for CCR5, 
in which gpl20 interacts directly with CCR5, whilst CD4 appears to promote these 
interactions (Wu et al 1996). The V3 domain of HIV gpl20 appears critical for this 
interaction (Cocchi et al 1996).
It has been demonstrated that receptor signalling and internalisation are not 
required for CCR5 to function as an HIV-1 entry co-factor (Gosling et al 1997, Farzan 
et al 1997a, Aramori et al 1997). Interestingly, Weissman et al (1997) have suggested 
that recombinant M-tropic HIV and SIV envelope proteins can induce a signal through 
CCR5 on CD4+ T cells, which mediates T cell chemotaxis. Davis et al (1997) recently 
reported that chemokines and HIV-1 envelope glycoproteins induced tyrosine 
phosphorylation of the protein tyrosine kinase, Pyk2 (Davis et al 1997). This response 
required CXCR4 and CCR5 to be accessible at the cell surface. The significance of 
these intracellular signalling events are unclear at present.
Several reports have established a genetic correlation of protection. Paxton et 
al (1996) reported that the CD8+ T cells of individuals who remained uninfected, 
despite multiple high-risk exposures, had greater antiviral activity than those of 
unexposed controls. Their CD4+ T Cells also appeared less susceptible to M-tropic 
viral infection. This protection appeared to relate to the activity of the suppressive 
factors MIP-la, MIP-1 p, and RANTES. Several groups subsequently demonstrated a 
genetic basis for protection of multiply-exposed high-risk individuals against HIV-1 
infection. Some exposed, uninfected individuals were shown to have a homozygous 
defect in their CCR5 gene. This was the result of a 32 bp deletion in the CCR5 allele, 
resulting in expression of a truncated CCR5 protein, that is not expressed on the cell 
surface (Samson et al 1996b, Liu et al 1996). A heterozygous allelic defect may or 
may not provide a limited protective effect (Dean et al 1996, Huang et al 1996). It is 
clear however, that the protective role of the CCR5 deletion allele is not absolute. 
Although rare, individuals who are homozygous for this defect can be infected (Biti et 
al 1997), perhaps if the original infecting virus evolves to utilise CXCR4 (Michael et 
al 1997a). Reports have also identified allelic variants of CCR2, though the existence 
of any protective role is unclear (Michael et al 1997b, Smith et al 1997).
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As well as genetic variants in cofactor receptors, the role of endogenous 
suppressive chemokines in protection against HIV is crucial. Unfortunately 
determination of their roles is not so simple, whilst it is clear that SDF-1 can suppress 
T-tropic infection via CXCR4 (Bleul et al 1996b) and the CC chemokines MIP-la, 
MIP-lp and RANTES suppress M-tropic infection (Cocchi et al 1996), it is unlikely 
that these are the only suppressive chemokines (Moriuchi et al 1997). Indeed Pal et al 
(1997) recently identified another CC chemokine, macrophage derived chemokine 
(MDC), as being suppressive. Most recently a rare genetic variant of SDF-1 was 
identified (Winkler et al 1998). This polymorphism (SDF-1 3’A) was in the 3’ 
untranslated region of SDF-1 and the homozygous variant provided a protective effect 
against the onset of AIDS, whilst the recessive variant was also protective, particularly 
during the later stages of disease progression. This protective effect was even more 
effective than those conferred by the CCR5 (CCR5 del32) and CCR2 (CCR2-641) 
receptor variants discussed previously in this section. It was speculated that this 
protective effect may be due to an enhanced level of SDF-1 production, though this 
remains to be proven.
Although CCR5 and CXCR4 appear to be the primary cofactors along with 
CCR2b, and CCR3 in the CNS (He et al 1997), other HTV entry co-receptors will no 
doubt be identified. Indeed, several orphan receptors have already been identified 
(Farzan et al 1997b), along with an unusual chemokine-like receptor, STRL33 that 
appears to function as a fusion-cofactor for both M and T-tropic HIV-1 (Liao et al 
1997).
Clearly the field of HIV-related chemokine biology is in its infancy, but 
already chemokine antagonists and other strategies are being developed in attempts to 
produce therapeutic solutions for intervention and perhaps ultimately a cure for HIV 
infection.
3.10 Virally Encoded Chemokine and Chemokine Receptor Homologues
As a result of the recent interest in chemokines and viral pathogenesis, it has 
now emerged that many viruses encode homologues of chemokine and chemokine 
receptor-like genes. The first evidence for this was reported in 1994, with the 
identification of a chemokine receptor-like gene in the US28 open reading frame of 
the human cytomegalovirus (CMV). The US28 gene encodes a receptor that was
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functional in response to MIP-la, RANTES and MCP-1 (Gao and Murphy 1994). A 
viral homologue of the CXCR2 receptor is encoded by the ECRF3 gene of herpesvirus 
saimiri (Ahuja and Murphy 1993).
More recently, human herpesvirus 8 (HHV8) or Kaposi’s sarcoma-associated 
herpesvirus (KSHV) has been shown to encode several viral homologues. vMIP-I and 
vMIP-II have homology to MIP-la, whilst the virus also encodes a viral form of IL-6, 
vIL-6 (Moore et al 1996). Arvanitakis et al (1997) have recently identified a KSHV 
encoded G protein-coupled receptor-like gene, with homology to the IL-8 receptors 
and ECRF3 gene. This receptor-like protein appears to bind both CC and CXC 
chemokines. Unusually, this homologue appears to be constitutively active and 
stimulated cell proliferation, suggesting it could be a potential viral oncogene. This 
oncogenic potential was recently confirmed, by Bais et al (1998), who demonstrated 
that signalling via this G-protein-coupled KSHV encoded receptor resulted in cell 
transformation, tumourigenicity and a switch to an angiogenic phenotype mediated by 
vascular endothelial growth factor (VEGF). vMIP-II was recently shown to function as 
a broad spectrum antagonist and inhibited HIV-1 entry via CCR3, CCR5 and CXCR4 
(Kledal et al 1997), as well as being a chemoattractant for CCR3+ eosinophils 
(Bosshoff et al 1997).
Molluscum contagiosum virus (MSV) types I and II were recently shown to 
encode a chemokine-like gene. The products were able to block the chemotactic 
responses of monocytes to MIP-la, but were not chemotactic themselves. These 
proteins were also active as inhibitors of human progenitor cell proliferation, with 
even greater potency than human MIP-la (Krathwohl et al 1997).
Lalani et al (1997) purified a gamma interferon receptor homologue, M-T7, 
encoded by myxoma virus and demonstrated that it interacted with the heparin binding 
domains of both CC and CXC chemokines. M-T7 has no homology with any known 
chemokine receptors and the significance of it’s apparent abilities are unclear at 
present.
Clearly many viruses have evolved or acquired chemokine-like and chemokine 
receptor-like genes. In general, viruses do not have the spare coding capacity to 
encode such genes without good reason, but at present the role that these play in viral 
pathogenesis is unknown. Further study of the virally encoded homologues may well
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enable further understanding of the role of chemokines and their receptors in the 
immuno-haemopoietic system.
3.11 In Summary
It should be evident by now, that the control of the immuno-haemopoietic 
system is enormously complex. Central to its regulation, are a multitude of growth 
factors and cytokines, together with their cognate receptors. These form an interacting 
network, that ultimately functions at every level from early development, through to 
the control of constitutive and inducible haemopoiesis. Within this network, the 
chemokine MIP-la, is a particularly important mediator. It functions as a regulator of 
both stem cell proliferation and inflammation. Recent studies have highlighted the 
importance of MIP-la and other chemokines to viral pathogenesis and enabled great 
advances in our understanding of MIP-la, particularly concerning interactions with 
its various receptors. However, little is known regarding the mechanisms that operate 
to regulate the expression of MIP-la and its receptors. This is particularly true in the 
context of haemopoiesis and the interaction of MIP-la with other growth factors 
within the bone marrow microenvironment. This therefore presents an exciting area 
for further research.
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AIMS OF THESIS
In order to fully understand the complex process of haemopoiesis, it is 
necessary to understand the role that haemopoietic growth factors and cytokines play 
in regulating this process. It is now evident that a large interacting network of such 
regulatory cytokines exists and these have been implicated in various aspects of 
haemopoietic control, within the haemopoietic stem cell compartment. It is also 
apparent that both stimulatory and inhibitory molecules function within this network. 
Our group has a particular interest in one such inhibitor of haemopoietic stem cell 
proliferation, namely macrophage inflammatory protein-1 alpha (MIP-la). Current 
evidence suggests that MIP-la is member of this network and therefore in order to 
fully understand the role of MIP-la in haemopoietic stem cell inhibition, it is also 
necessary to further understand how its expression within the bone marrow is 
regulated. Recently our laboratory identified an endogenous, reciprocal relationship in 
bone marrow-derived macrophages between MIP-la and transforming growth factor- 
beta (TGF-p), in which it appears that TGF-P acts to suppress MIP-la expression. 
Whilst the level of MIP-la expression within the bone marrow is very low, it is 
detectable and this implies that stimulatory mechanisms may exist to overcome this 
TGF-p mediated suppressive block. The aim of this study therefore, was to investigate 
the potential effects of haemopoietic growth factors on the regulation of MIP-la 
expression. It was believed probable that within the bone marrow microenvironment, 
positively acting factors were also functional in the regulatory control of MIP-la 
expression. Investigation of the effects of such positively acting factors and any 
relationship between them, MIP-la and TGF-p, might enable further understanding of 
the circumstances under which MIP-la expression might be altered, and thus provide 
further insight into its function within the haemopoietic stem cell or inflammatory cell 
compartments.
PART II: MATERIALS AND METHODS
CHAPTER 4: MATERIALS
Table 4.1: Plasmids for Generation of Probe Fragments
Plasmid name Identity o f  Insert Insert size Excision sites Source
pSK.p-Actin Murine 1200 bp Pst I D. Jarmin
P-Actin cDNA
pSK.LD78 Human ~300 bp Pst I S. Wylie
M IP -la  cDNA
pM TX-M IP-la Murine -3 0 0  bp E c o R I/X h o I  S. Wylie
M IP -la  cDNA
pMTX-MIP-ip Murine
M IP-ip cDNA
pSK.mCCRl Full murine
C C R 1cD N A
pSK.mCCR3 Full murine
CCR3 cDNA
pSK.mCCR4 Full murine
CCR4 cDNA
pSK.mCCR5 Full murine
CCR5 cDNA
pSK.mD6 Full murine
D6 cDNA
pMARC Full murine MCP-3 776 bp BamH I / Xho I Dr. T. Baumruker
(MARC) cDNA
pcJE-1 FullJE 578 bp EcoRI Dr. B. Rollins
cDNA
-3 0 0  bp EcoR I /  Xho I S. Wylie
1346 bp BamH I /  Not I Dr. R. Nibbs
1392 bp BamH I /N o t  I Dr. R. Nibbs
1364 bp BamH I /N o t  I Dr. R. Nibbs
1095 bp BamH I /  Not I Dr. R. Nibbs
1621 bp BamH I / Not I Dr. R. Nibbs
Address
Beatson Institute 
Beatson Institute 
Beatson Institute
Beatson Institute
Beatson Institute
Beatson Institute
Beatson Institute
Beatson Institute
Beatson Institute
Novartis F.I. 
(Vienna, Austria)
(Dana-Farber 
Cancer Institute 
MA, USA)
pcDNA-3
hCCRl
Full human 
CCR1 cDNA
1065 bp Hind DI /  Not I Dr. T. Schall MMRI
(Palo-Alto, CA, 
USA)
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Table 4.2: Plasmids for Use in RT-PCR Analysis
Plasmid name Identity of Insert Source
pCDM8.mIL-5Ra Full murine Dr. G. Plaetnick
IL-5R-a chain cDNA
pCRII.rGAPDH Rat glyceraldehyde-3- M. Walker
phosphate dehydrogenase 
(GAPDH) cDNA (containing 
sequences between bp 300 - 1020)
pSK.mCCRl
pSK.mCCR3
pSK.mCCR4 Details as per Table 4.1
pSK.mCCR5
pSK.mD6
Address
Roche Research 
(Gent, Belgium)
Beatson Institute
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Table 4.3: PCR Primers- Identity
Name Orientation Amplifies Comments
DJ03 5’ Murine IL-5Ra Amplifies both membrane bound and
DJ04 3’ soluble IL-5Ra chain fragments
DJ09 5’ Murine MIP-la Crosses 1st Intron/exon boundary
DJ10 3 ’ (247 bp mRNA, ~ 1 kb genomic)
DJ11 5’ Murine GAPDH
DJ12 3’
DJ17 5’ Human MIP-la
DJ18 3’
DJ23 5’ Murine D6
DJ24 3’
DJ25 5’ Murine CCR1
DJ26 3’
DJ27 5’ Murine CCR3
DJ28 3’
DJ29 5’ Murine CCR4
DJ30 3’
DJ31 5’ Murine CCR5
DJ32 3’
DJ33 5’ Murine CCR2
DJ34 3’
RNPCR.PA5 5’ Murine and human Mouse mRNA= 247 bp
RNPCR.pA3 3’ P-Actin
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Table 4.4: PCR Primers- Sequences
3’
3’
3’ 
3’
3’ 
3’
3’ 
3’
3’
DJ24 5’ GGAAGAGACAGTAATGAGTAAGGC 3’
DJ25 5’ CTTCTATTCTTCCTCCTCTGGAC 3’
DJ26 5’ GAGCTCATGTTCTCCTGTGGA 3’
DJ27 5’ CTTGCAGGACTGGCAGCATTG 3 ’
DJ28 5’ CAAAAATAAGACGGATGGCCTTG 3’
DJ29 5’ GAATGAGAAGAAGAACAGAG 3’
DJ30 5’ CTGGACATGTCAGCCGAGTAGAC 3’
DJ31 5’ CTTTACCAGATCTCAGAAAGAAGG 3’
DJ32 5’ GAGTCTCTGTTCCTGCATGG 3’
DJ33 5’ CAAAGGAAATGGAAGACAATA 3’
DJ34 5’ GAAATGTTGGGTTGGCTC 3’
DJ03 5’ GCCATTGACCAAGTGAATCC
DJ04 5’ GTGGAATTTCCCATGACTTC
DJ09 5’ ATGAAGGTCTCCACCACTGCC
DJ10 5’ TCAGGCATTCAGTTCCAGGTC'
DJ11 5’ TGAGTATGTCGTGGAGTCTAC
DJ12 5’ GGCCATGTAGGCCATGAGGTC
DJ17 5’ CACTTGCTGCTGACACG
DJ18 5’ CAACCAGTCCATAGAAGAGG
DJ23 5’ GTTTTCTTCATGCTGTGGTTCC
RNPCR.pA5 5’ TCCATCATGAAGTGTGACGT 3’
RNPCR.PA3 5’ TACTCCTGCTTGCTGATCCAC 3’
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4.5 Tissue Culture Supplies
Supplier Address
Beatson Institute 
Central Services
(Glasgow, UK) Sterile phosphate buffered saline (PBS) 
Sterile glassware and pipettes
R2, Beatson Institute (Glasgow, UK) L929 CM
Becton Dickinson, UK Ltd. (Plymouth, UK) Falcon tubes (15 ml and 50 ml)
Costar (Cambridge, MA 
USA)
6 and 24 well culture plates 
Cell scrapers
Gelman Sciences (Northampton, UK) Sterile acrodisc syringe filters 
(0.2 pm and 0.45 pm)
Gibco Life Technologies (Paisley, UK) MEM alpha stock
L-glutamine (200 mM)
Sodium pyruvate (100 mM)
Sodium bicarbonate (7.5 %)
MEM Non essential amino acids (lOOx) 
Hepes (1 M)
Trypsin (2.5 %)
Greiner Labortechnik (Stonehouse, UK) Endotoxin-free plugged pipetteman tips
Nalge Nunc International (Roskilde, Denmark) Tissue Culture Flasks
Cryotubes
Sigma Chemical Co. (Poole, UK) Endotoxin-free Dulbecco’s PBS (10 x)
2-Mercaptoethanol (2mM stock in PBS) 
Donor Horse Serum
Bovine Serum Albumin, FractionV, 7.5% 
RPMI-1640 Medium 
Dulbecco’s MEM
TCS Biologicals Ltd. (Buckingham, UK) Foetal Calf Serum
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4.6 Cytokines and Antibodies
The murine MIP-la PM2 deletion mutant was the form of MIP-la used in these studies and was as 
described in Graham et al (1994).
Supplier Address
R&D Systems Europe (Abingdon, UK) Recombinant anti-murine MIP-la
antibody 
Recombinant human TGF-P 1 
Recombinant murine GM-CSF 
Recombinant human GM-CSF 
Recombinant murine IL-3 
Recombinant murine IL-5 
Recombinant murine G-CSF 
Recombinant murine IL-6
Sigma Immunochemicals (Poole, UK) Anti-goat IgG (HRP-conjugated)
Dr. N. Hole (University of 
Durham, UK)
COS-cell derived murine LIF
4.7 Kits
Supplier Address
Amersham International (Amersham, UK) ECL Western blotting detection kit
Invitrogen BY (Leek, The Netherlands) Micro-FastTrack mRNA isolation kit
Perkin Elmer (Foster City, CA, USA) GeneAmp® RNA PCR core kit
Pharmacia Biotech (St Albans, UK) Ready-To-Go DNA labelling kit
Qiagen Inc. (Chatsworth, CA, USA) QIAGEN plasmid preparation kits 
QLAquick gel extraction kit
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4.8 Membranes, Paper and X-ray Film
Supplier Address
Amersham International (Amersham, UK) Hybond N nylon membranes
Genetics Research, Ltd (Felstead Dumnow, UK) Saranwrap
Millipore Corp. (Bedford, USA) Immobilon-P transfer membranes
Vemon-Carus, Ltd. (Preston, UK) Gauze swabs
Whatman International Ltd. (Maidstone, UK) 3MM blotting paper
Kodak Scientific Imaging (Cambridge, UK) X-OMAT AR X-ray film
Sytems Ltd.
Technical Photo Systems (Cumbernauld, UK ) Fuji RX Medical X-ray film
4.9 Nucleotides
Supplier Address
Amersham International (Amersham, UK) [cc-32P]-dCTP: 3000 Ci/mmol
Dupont NEN (Stevenage, UK) 125Iodine: lOOmCi/ml
4.10 Protein and DNA Markers
Supplier Address
Amersham International (Amersham, UK) Rainbow coloured protein molecular 
weight markers:
(Highm.w.: 14,300-220,000 Da) 
(Low m.w.: 2,300-46,000 Da)
Gibco BRL (Paisley, UK) RNA ladder (0.24-9.5 kb)
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Low DNA mass ladder 
123 bp DNA ladder 
1 Kb DNA ladder
4.11 Enzymes, Enzyme Buffers and Enzyme Inhibitors
Supplier Address
Gibco BRL
Boehringer Mannheim
(Paisley, UK) All Restriction enzymes and buffers 
(unless stated otherwise) 
T4 DNA ligase (1 U/pl)
5x ligation buffer
(Mannheim, Germany) RNase free DNase I (10 U/pl)
Invitrogen BY (Leek, The Netherlands) RNaseZap (RNase inhibitor)
Pharmacia Biotech (St Albans, UK) One-phor-all plus™ restriction 
enzyme buffer
4.12 Columns
Supplier Address
Pharmacia Biotech (St Albans, UK) NICK columns
4.13 Chemicals
Supplier Address
Boehringer Mannheim (Mannheim, Germany) MOPS
DIFCO Laboratories (Michigan, USA) Bactoagar
Fisons Scientific Equipment (Loughborough, UK) Formaldehyde (38 %  w/v)
Glycerol
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GIBCO BRL
James Burroughs Ltd. 
Pierce and Warriner 
Severn Biotech Ltd.
Sigma chemical Co.
Thornton and Ross 
Fisher Scientific UK Ltd.
4.14 Bacterial Culture
4.14.1 Solutions 
Supplier
(Paisley, UK) Agarose
TRIzol reagent
Phenol/Chloroform/Isoamyl alcohol 
(25:24:1, v/v) (pH 8.0)
(Witham, UK) Ethanol
(Chester, UK) Iodogen reagent
(Kidderminster, UK) Design-a-gel 30 % (w/v) Acrylamide,
0.8 % (w/v) bis-Acrylamide solution
(Poole, UK) Ampicillin
Bromophenol blue 
Diethylpyrocarbonate (DEPC) 
Dithriothreitol (DTT)
Ethidium bromide
DNA samples (lOmg/ml) 
RNA samples (1 mg/ml, in 
DEPC treated water) 
Fura-2-AM 
TEMED 
Tween 20
(Huddersfield, UK) Liquid Paraffin
(Loughborough, UK) All other chemicals not listed above
Address
Beatson Institute 
Central Services
(Glasgow, UK) Luria-Broth
87
4.14.2 Host strains
Supplier Address
GIBCO BRL (Paisley, UK) DH5a competent cells
4.15 Solutions
DEPC-water
4.15.1 Agarose gel electrophoresis 
lx TE (pH 8.0)
50x TAE
DNA sample loading buffer
4.15.2 DNase I digestion
DNase I restriction buffer (lOx)
4.15.3 Northern blotting and hybridisation
lOx MOPS buffer (pH 7.0)
0.1% DEPC in sterile distilled water, 
shaken and left overnight at room temperature. 
Autoclaved and allowed to cool.
10 mM Tris.HCl (pH 8.0)
1 mM EDTA
2 M Tris-acetate
5 mM EDTA (pH 8.0)
50 % Glycerol (v/v) 
lx TAE
Bromophenol blue to colour
50 mM Sodium acetate (pH 5.2) 
1 M Magnesium chloride 
made up in DEPC-water
0.4 M MOPS (pH 7.0) 
0.1 M Sodium acetate 
10 mM EDTA
RNA sample loading buffer 50 %  Glycerol (v/v) 
lx MOPS
Bromophenol blue to colour 
made up in DEPC-water
20x SSC 3 M Sodium chloride 
0.3 M Sodium citrate
(Pre-)hybridisation buffer 0.25 M Sodium phosphate (pH 7.0) 
7 % SDS (w/v)
4.15.3 SDS-Polyacrylamide Gel Electrophoresis (SDS/PAGE) and Western blotting
17.5 % Polyacrylamide gel (resolving) 17.5 %  Acrylamide mix (w/v)
375 mM Tris.HCl (pH 8.8)
0.1 % SDS (v/v)
0.1% Ammonium persulphate (w/v) 
0.04 % TEMED (v/v)
5 % Polyacrylamide gel (stacking) 5 % Acrylamide mix (w/v)
125 mM Tris.HCl (pH 6.8)
0.1 % SDS (w/v)
0.1 % Ammonium persulphate (w/v) 
0.01 % TEMED (v/v)
Protein sample loading buffer 5 pi 10 % SDS / DTT (sample buffer) 
7 pi 50 % glycerol (with Bromophenol 
blue to colour)
SDS / PAGE running buffer 200 mM Glycine 
25 mM Tris-acetate 
0.1 % SDS (w/v)
Transfer buffer 40 mM Glycine 
50 mM Tris.HCl 
0.04 % SDS (w/v)
20 %  Methanol (v/v)
4.15.4 Binding studies 
Binding buffer
4.15.5 Calcium mobilisation studies
HACM buffer
lx MEM alpha medium:
[20 % MEM alpha stock (v/v),
1 mM L-Glutamine,
0.1 % Sodium bicarbonate (v/v), 
25 % DHS (v/v),
20 % L-929 CM (v/v)].
25mM HEPES (pH 7.4)
0.2 % Sodium azide (w/v)
125 mM Sodium chloride 
5 mM Potassium chloride 
0.025 % BSA, fraction V (w/v) 
1 mM Magnesium chloride 
20 mM HEPES (pH 7.4)
0.5 mM D-Glucose
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CHAPTER 5: METHODS
5.1 Mice
Female B6D2F1 mice, aged between 4-6 weeks at arrival, were used for all 
experimental procedures. Mice were purchased from Harlan UK, Ltd. (Oxon, UK) and 
housed within the animal facility at the Beatson Institute.
5.2 Cell Lines
Cell lines were obtained from the sources indicated in table 5.1. All cell lines 
were maintained at 37°C in a dry atmosphere of 5% CO2 in air.
5.2.1 THP-1
The human pro-monocytic cell line THP-1, derived from a patient with acute 
monocytic leukaemia (Tsuchiya et al 1980), was maintained in RPMI 1640 + 2 mM 
glutamine / 0.02 mM p-mercaptoethanol / 10 % FCS in Nunc 75 cm2 tissue culture 
flasks. THP-1 cells grow in suspension and were subcultured every 2-3 days, by 
resuspension in fresh medium at a concentration of 2-9 x 105 cells/ml.
5.2.2 BCL1 (clone 13.20-3B3)
The murine chronic B-cell leukaemia cell line BCL1 clone 13.20-3B3, derived 
from the BCL1 tumour cell line (Gronowicz et al 1980) was maintained in RPMI 
1640 + 10 mM HEPES / 2 mM glutamine / 0.1 mM non-essential amino acids /1  mM 
Sodium pyruvate / 0.05 mM P-mercaptoethanol / 10 % FCS in Nunc 75 cm2 tissue 
culture flasks. BCL1 cells are a loosely adherent cell line and were subcultured upon 
reaching 75-90 % confluence (approximately every 2-3 days), by sharply tapping the 
flask against the palm of the hand 3-4 times. The detached cells were then 
resuspended in fresh medium at a subcultivation ratio of 1:3 to 1:5.
5.2.3 HEK 293-hCCR5 stable transfectants
Human embryonic kidney (HEK) 293 cells stably transfected with human 
CCR5 were maintained in DMEM + 4 mM glutamine / 10 % FCS in Nunc 175 cm2 
tissue culture flasks. Cells were subcultured every 2-3 days, upon reaching 75-90 %
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Table 5.1: Tissue Culture Cell Lines
Supplier Address Cell line Type of Cell line
European Collection of Animal (Salisbury,
Cell cultures (ECACC) UK)
THP-1 Human Monocytic 
leukaemia
American Type Culture 
Collection (ATCC)
(Rockville, 
MD, USA)
BCL1 (clone Murine B-cell
13.20-3B3) leukaemia
Dr. R. J. Nibbs (Beatson Institute) HEK hCCR5 Human Embryonic 
kidney cells, stably 
transfected with 
hCCR5
Table 5.2: Analysis of Bone Marrow-Derived Macrophage Population
Day Percentage of non-specific
Esterase Positive Cells
4 82 %
5 96 %
6 98.5 %
7 99 %
8 100%
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confluence, by detaching with trypsin and resuspending in fresh medium at a 
concentration of 5 x 105 to 1 x 106 cells/ml.
5.3 Bone Marrow-Derived Macrophages
5.3.1 Harvesting of bone marrow
4-6 wk old female B6D2F1 mice were used throughout for the harvesting of 
bone marrow. Mice were killed by cervical dislocation. The femora were excised 
using surgical scissors and excess muscle removed from the bone shaft and ends using 
a tissue soaked in ethanol. Both ends of the femora were then cut off with scissors and 
the bone marrow cells expelled by flushing through a 21 gauge needle with 2.5 ml per 
femur of a-modified MEM supplemented with 25 % DHS. Approximately 6-9 x 106 
bone marrow cells were routinely obtained from each femur using this method.
5.3.2 Derivation of bone marrow-derived macrophages
Bone marrow cells were obtained (as above) and resuspended at 5 xlO^ /ml in 
a-modified MEM supplemented with 25 % DHS and 20 % L929 CM as source of M- 
CSF. Following incubation for 7 days at 37°C in a dry atmosphere of 5 % CO2, the
remaining adherent cells consisted of a homogeneous (>99 %) population of bone 
marrow-derived macrophages (BMM), as determined by staining of cytocentrifuge 
preparations with the macrophage-specific enzyme alpha-napthyl acetate esterase (see
table 5.2). These BMM cells were proliferating as assessed by incorporation 
analysis. Day 7 was selected as the optimal day for usage and unless stated otherwise, 
all procedures using BMM were performed using this time point.
5.4 Stimulation of Cell lines and Bone Marrow-Derived Macrophages
All reasonable precautions were taken to ensure that contamination of 
experiments with endotoxin / lipopolysaccharide (LPS) did not occur. These included 
purchase of endotoxin-free recombinant cytokines and antibodies, as well as the usage 
of sterile plastic tissue culture pipettes and aerosol resistant plugged pipetteman tips. 
All recombinant cytokines and antibodies were reconstituted according to the 
manufacturers guidelines in entoxin free PBS / 0.1 % BSA (v/v). Cells were
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stimulated as indicated in the figure legends accompanying each figure, with either 
recombinant cytokines/antibodies or with PBS / 0.1 % BSA (v/v) for negative 
controls.
5.5 DNA Methodology
5.5.1 Transformation of bacterial host cells with plasmid DNA
Plasmid constructs were obtained from the sources indicated in tables 4.1 and 
4.2, and commercially available DH5a competent cells were transformed with the 
appropriate plasmid construct. Briefly, DH5a cells were removed from -70 °C and 
ih. thawed on ice. 50 pi aliquots of thawed cells were dispensed into pre-chilled Falcon 
2059 tubes, 1 pi of plasmid construct DNA (10-50 ng/pl) added and the mixture very 
gently swirled, before incubating on ice for 30 minutes. The cells were then heat 
shocked at 42 °C for exactly 45 seconds, returned to ice for 2 minutes and then 90 pi 
of Luria broth added. This mixture was then shaken at 225 rpm for 45 minutes at 37 
°C, to permit sufficient time for the ampicillin resistance gene to be expressed. 100 pi 
| and 50 pi of transformed cells were then spread onto prewarmed LB-Amp plates (6.5 
g of Bactoagar in 400 ml Luria Broth, mixed and autoclaved, allowed to cool to ~37
i
°C. The agar mix was then supplemented with 100 pg/ml ampicillin and 10-20 ml 
poured into 10 cm petri dishes. Plates were then allowed to set completely). The 
spread plates were allowed to stand for 5-10 minutes at room temperature, then 
inverted and incubated overnight at 37 °C.
5.5.2 Growth of plasmids
A 25 ml sterile universal container containing 5 ml of Luria Broth plus 
ampicillin (100 pg/ml) was innoculated with a single colony of cells (from LB-AMP 
plates prepared in section 5.5.1) using a sterile innoculating loop. This was then 
incubated for 8 hours at 37 °C with shaking at 225 rpm. This starter culture was then 
added to 100 ml of Luria Broth containing ampicillin (100 pg/ml) in a 1 litre conical 
flask and incubated overnight at 37 °C with shaking at 225 rpm.
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5.5.3 Plasmid preparation
Plasmids were prepared using the commercially available QIAGEN midi or 
maxi plasmid kits, according to the manufacturer’s instructions; -briefly as follows. 
Bacterial suspensions (derived as in section 5.5.2) were transferred to 250 ml 
centrifuge bottles (Sorvall instruments) and spun at 3000 rpm for 5 minutes in a GS-3 
rotor, using a Sorvall RC-5B superspeed centrifuge. The supernatants were discarded 
and any residual liquid drained off briefly by inversion. The bacterial pellets were then 
resuspended in either 4 ml (midi) or 10 ml (maxi) of PI resuspension buffer (50 mM 
Tris.HCl, 10 mM EDTA pH 8.0, 100 pg/ml RNase A). Once the pellet was suspended 
in PI, the bottles were gently rocked on an orbital shaker to allow complete 
resuspension of the bacterial pellet. The suspension was then transferred to 50 ml 
centrifuge tubes (Sorvall instruments) and either 4 ml (midi) or 10 ml (maxi) of P2 
lysis buffer (200 mM NaOH, 1 % SDS) added. Tubes were immediately capped, 
gently inverted 4-6 times to mix and incubated at room temperature for 5 min. 4 ml 
(midi) or 10 ml (maxi) of pre-chilled P3 neutralisation buffer (3 M KAc, pH 5.5) was 
then added, mixed gently by inverting 5-6 times and incubated on ice for 15 minutes 
(midi) or 20 minutes (maxi). The tubes were then spun for 30 minutes in an SS-34 
rotor at 10000 rpm. The supernatant was then carefully decanted, through a double 
layered surgical gauze swab to remove particulate material and prevent subsequent 
blocking of QIAGEN columns. During the above spin, QIAGEN columns were 
equilibrated with buffer QBT (750 mM NaCl, 50 mM MOPS, 15 % ethanol, pH 7.0, 
0.15 % Triton X-100)- 4 ml QBT for tip 100 (midi) or 10 ml QBT for tip 500 (maxi). 
The filtered supernatant was then applied to the column and allowed to drain through 
by gravity flow. The column was then washed with 2 x 10 ml (midi) or 2 x 30 ml 
(maxi) of QC wash buffer (1 M NaCl, 50 mM Tris.HCl, 15 % ethanol, pH 7.0). The 
DNA was eluted from the column with either 5 ml (midi) or 15 ml (maxi) of QF 
buffer (1.25 M NaCl, 50 mM Tris.HCl, 15 % ethanol, pH 8.5). The DNA was then 
precipitated with 0.7 volumes of isopropanol and centrifuged at 10000 rpm at 4 °C for 
30 minutes as described above. The supernatant was carefully discarded and the pellet 
resuspended in 300 pi of distilled water. This was transferred to a 1.5 ml microfuge 
tube and the DNA re-precipitated with 0.1 volume of 3 M Sodium acetate (pH 5.2) 
and 2.5 volumes of ethanol and spun at 13500 rpm in a MSE bench-top microfuge, at 
room temperature for 15 minutes. The pellet was washed carefully with 500 pi of 70
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% ethanol and respun at 13500 rpm for 5 minutes. The supematent was discarded and 
the pellet was then air-dried for 10 minutes and resuspended in a suitable quantity of 
sterile distilled water. The amount of DNA present was then quantified as follows. 
495 pi of distilled water was mixed with 5 pi of plasmid DNA and the optical density 
measured at 260 nm and 280 nm, using a Beckman spectrophotometer. A single OD 
unit at 260 nm (OD260 = 1) is equivalent to 50 ug/ml of double stranded DNA, thus 
allowing the concentration of DNA present in samples to be determined with 
accuracy. Plasmid DNA was stored at -20 °C before usage.
5.5.4 Digestion of plasmid DNA with restriction enzymes
i h. . 20-50 pg of plasmid DNA was digested in a total reaction volume of less than
: 100 pi, as follows. The appropriate amount of DNA to be digested was added to a 1.5
ml screw cap microfuge tube. 0.1 volume (of the total reaction volume) of the 
appropriate 10 x React™ buffer was then added. Dependent upon which restriction 
enzyme(s) were selected, the React™ buffer was chosen to give the optimal conditions 
' for the selected enzyme. Where two different restriction enzymes were used, a
compromise was reached and a buffer chosen that enabled the highest possible
r
efficiency for both enzymes. If this was not possible, then the One-Phor-all plus™ 
buffer (Pharmacia, UK) was used instead. The restriction enzyme(s) was then added, 
making sure the volume did not exceed 0.1 volume of the final reaction volume in 
order to prevent inhibition of the reaction by glycerol in the enzymes. The reaction 
mix was then made up to the final desired reaction volume with distilled water and 
incubated at 37 °C for 60 minutes. Reactions were then either used immediately for 
downstream applications or were stored at -20 °C until use.
5.5.5 Agarose gel electrophoresis of DNA
The following protocol was used for the routine analysis of DNA derived from 
plasmid preparations, restriction enzyme digestion of plasmid DNA, quantification of 
DNA probe fragments and visualisation of products generated by polymerase chain 
reaction (PCR);- as follows. DNA samples were resolved on a non-denaturing agarose 
gel. 1-2 % agarose w/v was added to a conical flask and made up to a final volume of 
either 75 ml for small casting trays or 150 ml for large ones, with distilled water. The
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agarose was melted for 2-3 minutes in a standard 750 W microwave, 50 x TAE buffer 
was then added to give a final working concentration of 1 x TAE and 2.5 pi or 5 pi 
(small and large gels respectively) of ethidium bromide (10 mg/ml) added. The 
agarose was then allowed to cool to the point at which it could be safely hand held, 
before pouring into casting trays. Gels were allowed to set for 30-60 minutes before 
use). DNA samples were added to 2.5 pi of DNA gel loading buffer (see section 
4.15.1) and the volume made up to 10 pi with distilled water (for larger loading 
volumes the quantities were adjusted accordingly). The DNA was separated by 
running the gels at a constant 90 volts. The gels were then checked after 1-2 hours by 
visualisation of the ethidium bromide stained DNA bands on a UV transilluminator 
(X=312 nm). The gel image was then recorded using an Appligene imager (Appligene 
Oncor, UK). For derivation of probe fragments the appropriate band(s) was excised 
using a sterile scalpel at this point. For Southern blotting of DNA (see section 5.7), the 
gel was image was recorded alongside a fluorescent ruler and then excess agarose 
trimmed off prior to blotting.
5.5.6 Isolation of probe fragments for generating radiolabelled probes
Plasmid DNA encoding the selected DNA probe was digested with the 
appropriate restriction enzymes (see section 5.5.4), resolved by agarose gel 
electrophoresis and the appropriately sized band of DNA excised from the gel with a 
sterile scalpel (see section 5.5.5). The gel fragment was collected in a 1.5 ml screw 
cap tube and the weight of agarose measured. The agarose was removed and the DNA 
eluted, using the QIAquick gel extraction kit (Qiagen). Briefly, 3 volumes (0.1 g of 
agarose = approximately 100 pi = 1 volume) of extraction buffer were added to the 
excised band. This was heated at 55 °C for 10 minutes and the tube inverted every 2 
minutes to ensure complete dissolution. This solution was loaded onto a QIAquick 
spin column and spun at 13500 rpm for 1 min. The flow-through was discarded and 
the column washed with 750 pi of wash buffer by spinning at 13500 rpm for 1 min. 
The column was then spun again for an additional minute to remove traces of wash 
buffer. The DNA was eluted from the column by placing in a clean 1.5 ml eppendorf 
and adding 30 pi of TE, pH 8.0 to the centre of the spin column. This was left for 1 
minute, before the column was spun for 1 minute at 13500 rpm and the DNA
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collected. The eluted DNA was visualised and quantified by agarose gel 
electrophoresis of 2 pi of DNA on a 1 % non-denaturing agarose gel (see section 
5.5.5) and comparison against a known quantity of low DNA mass ladder run on the 
same gel.
5.6 RNA Methodology
5.6.1 RNase free environment
In order to maintain the integrity of RNA samples during isolation, storage and 
subsequent downstream handling, stringent precautions were taken to prevent 
degradation by RNases. Disposable sterile plastic pipettes, plugged sterile nuclease- 
free aerosol resistant pipetteman tips and disposable sterile plastic tubes were used for 
handling of RNA samples. All such plasticware, as well as chemical reagents were 
designated exclusively for use with RNA. Bench top surfaces and non-disposable 
equipment were wiped with RNase-Zap (Invitrogen, Netherlands), a commercially 
available solution for inhibiting RNases. DEPC treated sterile distilled water was used 
for making up RNA sample loading buffer, ethidium bromide and for resuspension of 
RNA samples.
5.6.2 Isolation of total RNA
Cells were stimulated with appropriate growth factors (or PBS / 0.1 BSA 
(v/v)) and total RNA was then isolated using TRIzol™ (Gibco Life Technologies, 
UK), a commercially available acid guanidinium thiocyanate-phenol-chloroform 
based extraction mixture (Chomcyznski et al 1987), according to the manufacturer’s 
instructions. Briefly as follows. For RNA isolation from adherent cells in 75 cm 
flasks, growth medium was removed and 10 ml of Trizol™ added. For isolation of 
RNA from cells grown in suspension, the cells were spun down at 1000 rpm, the 
growth medium removed and 10 mis of TRIzol™ added. RNA from adherently and 
suspension grown cells was isolated in an identical way from this point. The flask was 
swirled (or the tube gently mixed) to ensure complete coverage of the full cell surface 
area with TRIzol™ and then left for 5 minutes at room temperature, with occasional 
swirling of flasks (or mixing of tubes) every 2 minutes. The solution was then pipetted
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several times, using an automatic pipette aid, to ensure complete cell lysis. The 
solution was then transferred to a 15 ml “snap cap” Falcon 2059 tube and 2 ml of 
chloroform added. Tubes were shaken vigorously for 15 seconds, allowed to stand at 
room temperature for 2-3 minutes and then spun in a Sorvall RC-5B supercentrifuge at 
3000 rpm for 15 minutes using HB4 or HB6 swing-out rotors. The resulting aqueous 
layer was then promptly removed to a fresh 15 ml tube and 5 ml of isopropanol added. 
The solution was mixed by inversion and left to stand at room temperature for 10 
minutes, after which it was spun at 3000 rpm for 10 minutes. The isopropanol 
supernatant was discarded and the pellet resuspended in 10 ml of 70 % ethanol, to 
wash the RNA. Tubes were spun at 3000 rpm for 5 minutes, the ethanol wash 
discarded and the tubes inverted on the bench for 10 minutes to drain off excess 
ethanol, before air drying the pellets to remove all remaining ethanol. The RNA was 
resuspended in 50-200 pi of DEPC treated water, and transferred to sterile 1.5 ml 
screw cap tubes. The RNA was then quantified by adding 5 pi of RNA to 495 pi of 
distilled water and measuring the OD260 nm (as in section 5.5.3, except that an OD260 
of 1 is equivalent to 40 pg/ml for RNA). RNA samples were stored at -20 °C until use.
5.6.3 Isolation of PolyA+ mRNA
PolyA+ mRNA was isolated from snap-frozen eye and leg muscle tissue 
samples or from frozen cell suspensions of peritoneal cavity cells and bone marrow 
cells derived from either wild type or GM-CSF transgenic mice, using the 
commercially available Micro-FastTrack™ kit (Invitrogen). Briefly as follows, a 
mortar and pestle was cleaned with RNase-Zap, placed on dry ice and a piece of snap- 
frozen tissue was placed in the mortar. The tissue was then ground in liquid nitrogen, 
before transferring to a clean RNase-free tube. The tissue was then resuspended in 1 
ml of lysis buffer, preheated to 45 °C. For frozen cell suspensions the cell pellet was 
resuspended in 5 ml of lysis buffer and incubated at 45 °C until thawed, before 
dispersing into 5 x 1 ml aliquots. The cell suspension was then homogenised by 
passing through a syringe fitted with an 18-21 gauge needle. This was repeated until 
the entire suspension could be drawn up into the syringe. The mRNA isolation 
protocol was then followed according to the manufacturer’s instructions. The PolyA+ 
mRNA was eluted in a final volume of 10 pi of elution buffer. 5 pi of mRNA was
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then Northern blotted and the membrane hybridised, as described in sections 5.6.4, 5.7 
and 5.8.
5.6.4 Agarose gel electrophoresis of RNA
Total RNA was separated and visualised in a similar fashion to that used for 
DNA samples, the main difference being the usage of denaturing conditions. Total 
RNA was isolated and quantified (see section 5.6.2.) and 20 pg of RNA was added to 
sterile 1.5 ml screw cap tubes and freeze-dried in a speedivac. The pellet was then 
resuspended in 20 pi of RNA sample loading buffer (see section 4.15.2), denatured in 
a boiling water bath for 5 minutes and samples placed on ice for 2 minutes to prevent 
renaturation of RNA strands. Tubes were briefly spun in a microfuge and 1 pi of 
ethidium bromide added (10 mg/ml stock). Samples were loaded and resolved on a 
denaturing agarose gel (1.4 % w/v agarose, 1 x MOPS buffer, 2.2 M formaldehyde 
and made up to 150 ml with sterile distilled water). Gels were run at a constant 90 
volts, until the Bromophenol blue band had migrated almost 2/3 of the distance of the 
gel (approximately 3 hours). At this time the integrity of the RNA was checked under 
UV transillumination and the gel image recorded alongside a fluorescent ruler to allow 
subsequent sizing of RNA species (as described in section 5.5.5). Gels were then 
trimmed of excess agarose and Northern blotted (see section 5.7).
5.7 Southern and Northern Blotting of DNA and RNA
DNA and RNA resolved by agarose gel electrophoresis can be transferred to 
nitrocellulose membranes by capillary transfer. For both Southern and Northern 
blotting the procedure is essentially the same (except for the use of RNase free 
solutions). Briefly, a glass tank was partially filled with 500 ml of 10 x SSC and a 
rectangular piece of glass was raised above the tank, to form a platform. A larger 
rectangular piece of Whatman 3MM blotting paper was then soaked in 10 x SSC and 
placed on the glass platform, with the ends of the paper in the tank of SSC thus 
forming a wick. A second piece of SSC soaked 3MM paper, the same size as the glass, 
was then placed on top. The agarose gel was then placed with the open wells face 
down on the platform. A sheet of Hybond-N membrane (Amersham, UK) cut to the 
same size as the gel was soaked briefly in sterile distilled water, followed by 10 x SSC 
(RNase free for RNA gels) and then layered over the gel. Clean, redundant strips of
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autoradiographic film were then used to cover the exposed platform area around the 
gel, to prevent bypass of the paper wick by subsequent layers. The membrane was then 
layered with 2 membrane sized pieces of 3MM paper soaked in SSC and any air 
excluded from the layers by gently rolling with a 1/2 size plastic pipette. 3-4 layers of 
paper towelling, each layer 6 towels thick and arranged in a perpendicular direction to 
the previous layer, were then placed on top. Finally a sheet of glass was used as a 
platform for the addition of a moderately heavy weight and the gels blotted overnight. 
Following blotting the membranes were briefly soaked in nuclease-free 10 x SSC to 
remove any pieces of agarose. The RNA was then fixed on to the membranes by UV 
crosslinking, using a UV Stratalinker 1800 (Stratagene). Membranes were wrapped in 
Saranwrap and stored at 4 °C prior to use.
5.8 Probing of Blots with Radiolabelled Probes
Essentially the same procedures were used for probing of both Southern and 
Northern blots.
5.8.1 Preparation of radiolabelled probes
Probe fragments generated by restriction enzyme digestion were isolated (see 
section 5.5.6) and radiolabelled using a commercially available random priming kit, 
Ready-to-Go (Pharmacia, UK), according to the manufacturer’s instructions. Briefly, 
25-50 ng denatured DNA probe fragment was added to a rehydrated Ready-to-Go 
tube. 5 pi of [a-32P]-dCTP (3000 Ci/mmol) was added and the reaction incubated at 
37 °C for 15 minutes. Unincorporated 32P-labelled nucleotides were separated from 
the radiolabelled probe by passing the reaction through a NICK column (Pharmacia), 
according to the manufacturer’s instructions. The radiolabelled probe was then 
denatured by heating in a boiling water bath for 2-3 minutes and placed on ice for 2 
minutes prior to use.
5.8.2 Pre-hybridisation and hybridisation conditions for Northern and Southern 
blots.
Pre-hybridisation and hybridisation of membranes (see section 5.7 for 
generation) were both carried out at 65 °C, using 0.25 M Na2HPC>4 / 7 % SDS, pH 7.0 
as both pre-hybridisation and hybridisation buffers. These steps were performed using
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hybridisation bottles and carried out in a rotary hybridisation oven (Hybaid, UK). 
Briefly, membranes were layered on top of hybridisation mesh (Hybaid) and then 
rolled up and placed in the bottles, with up to 4 blots per bottle. 10-20 ml of pre­
hybridisation fluid was then added and the blots incubated at 65 °C for at least 1 hour. 
Following pre-hybridisation the denatured radiolabelled probe was added and 
hybridisation continued overnight at 65 °C.
5.8.3 Washing of blots and exposure to X-ray film
Membranes were washed once in 2 x SSC / 0.1 % SDS for 30 min at room 
temperature, followed by 20 min at 65 °C with fresh solution and then with 0.5 x SSC 
■ «- / 0.1 % SDS for 30 min at 65 °C. The membranes were then monitored and additional
washing performed if required (20 min at 65°C with 1 x SSC / 0.1% SDS and finally 
if necessary, once for 10 min with 0.01 x SSC / 0.1 % SDS at 65 °C). After washing 
the membranes were wrapped in Saranwrap and transferred to an exposure cassette 
incorporating an intensifying screen. Membranes were exposed to Kodak X-ray film 
(X OMAT-AR) at -70 °C for 4 hours initially (1 hour for Southerns), then for longer 
periods (overnight if needed or for up to 7 days as appropriate).
5.8.4 Stripping of blots
Blots were stripped to remove bound radiolabelled probes, by boiling the 
membranes in 300-500 ml of 0.1 % SDS for 10 min. Membranes could then be used 
in further experimentation.
5.8.5 Scanning densitometric analysis of blots
Northern and Southern blots were scanned using a flat bed laser densitometer 
and analysed using the Quantity One software program (both purchased from Protein 
Databases Inc., NY, USA).
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5.9 Protein Detection
5.9.1 Preparation of cell conditioned medium
Bone marrow-derived macrophages were grown for 7 days in 15 ml of a- 
MEM conditioned medium supplemented with 25 % DHS and 20 % L929 CM, as 
described in section 5.3. Cells were then either treated with recombinant murine GM- 
CSF at a concentration of 10 ng/ml, or with PBS / 0.1 % BSA (v/v) for controls. 
Medium was collected after 12, 24,48 and 72 hours of treatment.
5.9.2 Purification of MIP-la from bone marrow-derived macrophage cell 
conditioned medium
Bone marrow-derived macrophages were grown and treated as described in 
section 5.9.1. Cell conditioned medium was removed after 12, 24, 48 and 72 hours. 10 
ml of each sample of cell conditioned medium was then purified using a combination 
of heparin and blue sepharose affinity chromatography, followed by reverse phase 
high performance liquid chromatography (HPLC). This purification of MIP-la protein 
was performed by Dr. J. deBono, whom also performed the Western blot shown in 
figure 6.3.6. His assistance with this purification is very gratefully acknowledged.
5.9.3 SDS polyacrylamide gel electrophoresis
SDS Polyacrylamide gel electrophoresis was performed using a minigel 
system. 17.5 % polyacrylamide gels were prepared using a commercially available 
acrylamide / bis-acrylamide stock solution (30 % w/v acrylamide / 0.8 % w/v bis- 
acrylamide) (Severn Biotech Ltd.), as detailed in section 4.15.3. This solution was 
then poured between two mini-gel glass plates. The surface of this was then layered 
with water saturated isobutanol, to create a smooth interface between stacking and 
resolving gels (as well as preventing oxidisation of the acrylamide mixture and thus 
speeding up setting). The gel was left to set at room temperature. A 5 % stacking gel 
was then prepared in a similar way as previously for the resolving gel (see section
4.15.3), except that a smaller quantity was prepared. The water saturated iso-butanol 
was poured off and the top of the resolving gel washed 3 x with distilled water. 
Residual water was removed with a small piece of 3 MM paper. The 5 % stacking gel 
was then poured between the glass plates, on top of the resolving gel and a comb of
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the appropriate size inserted to create the loading wells. This was allowed to set at 
room temperature (approximately 30-60 minutes) and the comb carefully removed. 
Protein samples were prepared for electrophoresis in 1.5 ml screw cap tubes, by 
adding 20 pi of sample to 15 pi of SDS/DTT sample loading buffer (see section
4.15.3) and samples reduced and denatured in a boiling water bath for 5 minutes. 
Samples were immediately loaded onto the gel, along with molecular weight rainbow 
markers (Amersham) to enable subsequent sizing of bands and to verify transfer of 
proteins during Western blotting. Electrophoresis of gels was carried out at room 
temperature in SDS/PAGE running buffer (see section 4.15.3) at 150 V, until the blue 
dye front was at 4 cm from the bottom of the resolving gel.
5.9.4 Western blotting
Western blotting was then used to analyse the purified MIP-la content of cell 
conditioned medium derived from bone marrow-derived macrophages. Proteins 
separated by SDS/PAGE (see section 5.9.5, above) were transferred to Immobilon-P 
membrane by the process of semi-dry blotting using an electroblotter (Biogel 
Electophoresis Systems, UK). Gels were blotted for 60 minutes at a constant current 
of 8 mA/cm gel area, and was performed as follows. Pieces of Whatman 3MM 
blotting paper were cut to the same size as the gel to be blotted. Four pieces of paper 
were soaked in transfer buffer (see section 4.15.3) and placed on the base plate of the 
electroblotter. A piece of Immobilon-P, also cut to the dimensions of the 
polyacrylamide gel, was pre-soaked briefly in methanol followed by brief washing in 
distilled water and was soaked in transfer buffer for 2 minutes before layering on top 
of the blotting paper. The polyacrylamide gel was then placed on top of the 
Immobilon-P, followed by 3 pieces of blotting paper soaked in transfer buffer. Any air 
bubbles trapped in the layers were removed by gentle rolling of the top layer with a 
plastic pipette. The top plate of the electroblotter was moistened with transfer buffer 
and the apparatus assembled. The electroblotter was then switched on and run at the 
conditions mentioned above. After blotting the apparatus was disassembled and the 
membrane incubated overnight in BLOTTO solution (5 % dried milk in PBS, 0.1 % 
NP40) at 4 °C, to block non-specific binding sites. The membrane was then washed 
for 1 hour at room temperature in several changes of fresh BLOTTO. The membrane 
was then exposed to the primary polyclonal antibody, for 1 hour, at the appropriate
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dilution (for goat anti-MIP-la (R&D systems) usually 1:1000 in 10 ml of BLOTTO). 
The membrane was washed for 45 minutes in at least 3 changes of BLOTTO, before 
incubation for 40 - 60 minutes with the secondary anti-goat IgG antibody conjugated 
to horse radish peroxidase (Sigma), in 10-50 ml BLOTTO. The membrane was then 
washed in several changes of PBS / 0.1 % tween 20 for 1 hour. Binding of antibody to 
membranes was visualised using the enhanced chemiluminescence (ECL) kit 
(Amersham). Briefly, the membrane was removed from the final wash step, excess 
solution drained off and the membrane was then agitated in combined ECL solutions 
for 60 seconds. Excess solution was drained off from one comer of the membrane, 
using a paper towel before the membrane was wrapped in Saranwrap and placed in an 
exposure cassette. An initial exposure was carried out for 2 minutes, using Fuji RX 
Medical X-ray film, additional exposures were then carried as appropriate to enable 
protein bands to be visualised.
5.10 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Methodology
5.10.1 DNase I digestion of total RNA
Total RNA samples were treated with DNase I in order to eliminate the 
potential for residual DNA contaminating total RNA samples, to act as a template for 
PCR amplification. Briefly, 40 pg of total RNA was digested with 2 pi of DNase I (10 
U/pl stock) in the presence of 50 mM sodium acetate (pH 5.2) and 1 M magnesium 
chloride and made up to 200 pi with DEPC-water. The reaction was incubated at room 
temperature for 15 minutes, before heating at 95 °C for 5 minutes and then placing on 
ice for 10 minutes. The reaction was then extracted twice with phenol / chloroform / 
isoamyl-alcohol (25:24:1), pH 8.0. The RNA was precipitated with 0.1 volume of 3M 
NaAC and 2.5 volumes of 100 % ethanol for 60 minutes at -70 °C, before spinning 
down at 13500 rpm for 15 minutes. The pellet was washed with 500 pi of 70 % 
ethanol and spun down at 13500 rpm for 10 minutes. After brief air drying the pellet 
was resuspended in 30 pi of DEPC-water (approximately 1 pg/pl).
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5.10.2 RT-PCR methodology I (amplification from total RNA)
The commercially available Gene Amp® RNA PCR Core kit (Perkin Elmer, 
CA, USA) was used to detect the expression of RNA transcripts from total RNA 
samples. Total RNA was DNase I digested as described in section 5.10.1. The 
manufacturer’s instructions were followed with minor adjustments. Briefly as follows, 
reverse transcription reactions were set up as 20 pi reactions from a master mix (5 
mM MgCb, 1 x PCR buffer II, 1 U/ml RNase inhibitor, 2.5 pM Oligo d(T)i6, 1.75 pM 
random hexamers). 1 pi of DNase I digested RNA (~1 pg/pl) was added to 10 pi of 
master mix, mixed by pipetting and then incubated at 70 °C for 5 minutes. Then 8 pi 
of dNTP mix (1 mM each of dGTP, dATP, dCTP and dTTP) was added, followed by 
1 pi of MuLV reverse transcriptase (2.5 U/pl) or 1 pi of DEPC-water. The reaction 
was then incubated for 10 minutes at room temperature to allow the Oligo d(T)i6to be 
extended by the reverse transcriptase. The reaction tubes were then transferred to a 
Perkin Elmer Thermal Cycler 480, and incubated at 42 °C for 20 minutes, followed by 
5 minutes at 99 °C and 15 minutes at 5 °C. A PCR master mix was then prepared (0.5 
mM MgCb, 1 x PCR buffer II, AmpliTaq® DNA polymerase (2.5 U/100 pi)) and 74 
pi added to 20 pi of reverse transcription reaction from above. 3 pi each of 5’ and 3’ 
primers (200 ng/pl) were then added (see tables 4.3 and 4.4 for identity and 
sequences). The whole reaction mix was mixed by pipetting and then overlaid with 
100 pi of liquid paraffin. Tubes were incubated in a Thermal Cycler for 1 minute at 94 
°C and then for 30-35 cycles at the following conditions. A) For amplification of MIP- 
la  sequences: 1 minute at 94 °C, 2 minutes at 60 °C, 2 minutes at 72 °C, followed by 
soaking at 4 °C. B) For amplification of CC chemokine receptor sequences: 1 minute 
at 94 °C, 1 minute at 55 °C, 1 minute 30 seconds at 72 °C, followed by soaking at 4 
°C. C) For amplification of IL-5Ra chain fragments: 1 minute at 94 °C, 2 minutes at 
56 °C, 3 minutes at 72 °C, followed by soaking at 4 °C. Samples were stored at 4 °C 
prior to visualisation of 20 pi of amplified DNA product, by agarose gel 
electrophoresis on a 1 % agarose gel.
5.10.3 RT-PCR methodology II (amplification from polyA+ mRNA)
The Gene Amp® RNA PCR Core kit was again used, this time for the 
detection of RNA transcripts from polyA+ mRNA. PolyA+ mRNA was derived (as
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described in section 5.6.3) and 0.5 pi (eye and leg muscle) or 2 pi (bone marrow or 
peritoneal cells) of this used as a template for the generation of cDNA, prior to PCR 
amplification. The basic RT-PCR methodology was exactly as described for total 
RNA, with the following modifications: 1) the reactions were performed in 10 pi 
reaction volumes for the reverse transcriptase step and 50 pi for the PCR step, 2) the 
use of random hexamers was omitted, 3) A single master mix was prepared for the 
reverse transcriptase step, and then split into 2 tubes prior to the addition of either 
Wild type or GM-CSF transgenic polyA+ mRNA. The reverse transcriptase step was 
then carried out as before. 4) The 2 reverse transcriptase reactions were then split into 
2 again and a PCR master mix added to each of the 4 tubes. 5) 5’ and 3’ primers for 
► the detection of either MIP-la or p-Actin were then added to each reaction as
appropriate. 6) Each of the 4 reactions (wildtype or GM-CSF with either MIP-la or p- 
Actin primers) was then split into 5 tubes. Tubes were then incubated in a Thermal
r
Cycler for 1 minute at 94 °C and then at the following conditions 1 minute at 94 °C, 2 
minutes at 60 °C, 2 minutes at 72 °C. Tubes were removed after 15, 20, 25, 30 and 35 
| cycles respectively and stored at 4 °C prior to analysis on a 2 % agarose gel.
5.11 Receptor Binding Studies
5.11.1125I labelling of MIP-la protein
Labelling of MIP-la protein with Na125I (Dupont NEN) using Iodo-gen, a 
commercially available iodination reagent, was performed by Dr. RJ.B. Nibbs as 
described previously (Graham et al 1993). The assistance of Dr. Nibbs in this labelling 
and during other aspects of these studies is very gratefully acknowledged.
5.11.2 MIP-la receptor binding studies on bone marrow-derived macrophages
BMM were grown as described in section 5.3. At day 5 of growth, cells were 
scraped free and replated at 2 x 105 cells in 24 well plates and then incubated at 37 °C
for a further 24 h to allow cell re-adherence. After this time the cells were stimulated 
with 10 ng/ml recombinant murine GM-CSF or with PBS / 0.1 % BSA (v/v) for 16 h. 
Treatment of plates was staggered at 30 minute intervals, to allow sufficient time to 
process each plate. After 16 h treatment the plates were washed with PBS and the cells
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incubated with 250 pi of binding buffer (a-modified MEM supplemented with 25 % 
DHS, 20 % L929 CM, 0.2 % sodium azide and 25 mM Hepes (pH 7.4)) containing 4
125nM I labelled MIP-la and variable concentrations of unlabelled MIP-la competitor 
or PBS, up to a final volume of 260 pi. Cells were then washed 3 times with 2 ml of 
ice-cold PBS. The amount of bound radioactivity was determined by lysing the 
washed cells in 0.5 ml 1 % SDS and counting the lysate in a gamma counter 
(Beckman Gamma 5500B). Each point was assayed in triplicate and experiments 
performed at least twice. Analysis of binding results was then performed using the 
LIGAND software program (Munson and Robard 1980).
5.12 Calcium Flux Studies
5.12.1 Calcium flux studies in bone marrow-derived macrophages
BMM were grown as described in section 5.3. Cells were either stimulated on 
day 7 with 10 ng/ml recombinant murine GM-CSF or with PBS for 16 h. Cells were 
then washed once with PBS and scraped free into HACM buffer (see section 4.15.5) 
and spun down at 1000 rpm for 5 minutes. Cells were resuspended at 1 x 106 cells/ml 
and washed twice in HACM buffer. The tubes containing the cell suspensions were 
then covered in aluminium foil and the light sensitive fluorescent dye Fura-2 AM 
added to the cell suspension, at a concentration of 2.5 pM. The cell suspension was 
then incubated at 37 °C for 1 hour. The tubes were gently inverted to mix the 
suspension after 20 and 40 minutes of incubation. The cells were spun down at 1000 
rpm for 5 minutes and washed twice with warmed HACM buffer. Cells were then 
resuspended at 2 x 106 /ml in warmed HACM buffer. Cells were kept at 37 °C and 
used immediately for fluxing studies, briefly as follows. A spectrophotometer cuvette, 
containing a magnetic stirrer bar was placed in a Perkin Elmer luminescence 
spectrophotometer LS50 and 2 ml of cell suspension was aliquoted directly into the 
cuvette. After 15 seconds 20 pi of CaCl2 (100 mM stock) was added and the cuvette 
incubated at 37 °C for 2 minutes, with a high level of stirring. The time drive was then 
started on the spectrophotometer and after 15 seconds, MIP-la (final concentration 
100 ng/ml) was added directly to the cell suspension in the cuvette. Overall changes in
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the intensity of FURA-2 AM were then assessed, thus enabling any changes in 
intracellular calcium mobilisation to be determined.
5.12.2 Calcium flux studies in THP-1 cells
THP-1 cells were grown in RPMI 1640 / 10 % FCS to a concentration of 5 x 
10s /ml, as described in section 5.2.1. Cells were then stimulated with either 10 ng/ml 
recombinant human GM-CSF or PBS / 0.1 % BSA (v/v), for 16 h. Cells were spun 
down and washed once in PBS and then resuspended at 1 x 106 cells/ml and washed 
twice in HACM buffer. Calcium flux studies were then performed exactly as 
described in section 5.12.1 above.
PART III: RESULTS AND DISCUSSION
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CHAPTER 6: RESULTS
6.1 Overview
In order to investigate the potential of haemopoietic growth factors to regulate 
the expression of MIP-la, it was first necessary to find a cell type that provided a 
system suitable for such investigation. As described in section 1.4.1, the macrophage 
is one of the primary cell types within the stromal microenvironment. It is therefore 
likely to be an important source of MIP-la within the bone marrow and in peripheral 
tissues. Murine ‘bone marrow-derived macrophages’ (BMM) provide a homogeneous 
population, previously used by others as a model system for marrow macrophages 
(Temeles et al 1993) and which are suitable for investigations on bone marrow- 
derived MIP-la. These cells have also previously been successfully used by our 
laboratory, in other studies on MIP-la regulation (Maltman et al 1993, 1996). BMM 
were therefore selected as a model cell system, with which to investigate the 
regulation of MIP-la expression by haemopoietic growth factors.
It is widely recognised that a large interacting network functions within the 
bone marrow to regulate the processes of constitutive and inducible haemopoiesis (see 
introduction) and current evidence suggests that MIP-la is a member of this network. 
At present, little is known about the regulatory factors controlling MIP-la expression 
within the bone marrow. Initially therefore, known haemopoietic growth factors with 
previously identified effects on macrophage functions, were investigated for their 
ability to modulate MIP-la expression in BMM.
6.2 Effect of G-CSF, LIF and IL-6 on the Expression of MIP-la in BMM
G-CSF, LIF and IL-6 are all important regulators of various facets of 
haemopoiesis (see introduction). LIF receptors are known to be expressed on both 
normal and leukaemic macrophages (Hilton et al 1988), whilst G-CSF receptors have 
been reported to be expressed on macrophages (Shieh et al 1991), as have receptors 
for IL-6 (Lotem and Sachs 1987, Shabo et al 1988). Their effect on the expression of 
MIP-la mRNA in day 7 BMM was therefore investigated. This was performed by 
Northern blot analysis of total RNA isolated from BMM after 4 h treatment with 
various concentrations of G-CSF, LIF or IL-6. As shown in Figure 6.1,
Figure 6.1: Northern blot analysis of the effect of G-CSF, IL-6 and LIF on 
the expression of M IP-la mRNA in BMM.
A) Effect of G-CSF. 1) control; 2) 4 h 1 ng/ml; 3) 4 h 10 ng/ml; 4) 4 h 50 ng/ml.
B) Effect of IL-6. 1) control; 2) 4 h 1 ng/ml; 3) 4 h 10 ng/ml; 4) 4 h 50 ng/ml.
C) Effect of LIF. 1) control; 2) 4 h 10 U/ml; 3) 4 h 100 U/ml. Top blot in each 
panel shows a blot hybridised with a probe for MIP-la, whilst the bottom blot in 
each panel shows the same blot, stripped and reprobed for p-Actin. This figure 
represents a single experiment. The numbers in the table below show the relative 
levels of M IP-la mRNA for this experiment, as assessed by scanning densitometric 
analysis and normalisation against the level of P-Actin mRNA.
Control 1 ng/ml 10 ng/ml 50 ng/ml
G-CSF 1 1.32 1.42 1.28
IL-6 1 0.36 0.53 0.68
Control 10 U/ml 100 U/ml
LIF 1 0.48 0.56
1 1 0
M IP-la
p-Actin
B
M IP-la
p-Actin
M IP-la
1 2  3 4
1 2  3 4
1 2  3
p-Actin
I l l
a low basal level of MIP-la expression was detectable in unstimulated BMM. 
Addition of G-CSF, LIF or IL-6 had no apparent effect on this level of expression, 
compared with control cells, as determined by densitometric analysis of Northern 
blots and normalisation for RNA loading using the house-keeping gene p-Actin. This 
demonstrated that G-CSF, IL-6 and LIF do not appear to modulate MIP-la expression 
in BMM.
6.3. Effect of GM-CSF on the Expression of MIP-la mRNA in BMM
6.3.1 GM-CSF induces MIP-a expression
The cytokine GM-CSF has been widely studied for its effects on various 
haemopoietic cell types, particularly those of the granulocyte / macrophage lineages. It 
was therefore considered a potential candidate for regulation of macrophage-derived 
MIP-la expression within the bone marrow. The effects of GM-CSF on MIP-la 
mRNA expression in BMM were investigated by Northern blot analysis and as 
previously, a low level of basal MIP-la expression was observed. However, following 
treatment of BMM with recombinant murine GM-CSF (10 ng/ml) for 4 h, this 
expression appeared to be elevated by approximately 10-fold, as indicated in figure 
6.2. Ethidium bromide staining confirmed that loading of RNA in each lane was equal 
(data not shown). In all future Northern blot analysis, blots were stripped and re­
probed with p-Actin to allow normalisation for any loading differences between lanes. 
The striking level of induction observed in GM-CSF treated BMM, compared to that 
of control cells, suggested that GM-CSF functions as a modulator of MIP-la 
expression and therefore warranted further investigation.
6.3.2 Induction of MIP-a expression by GM-CSF is rapid, but transient
To further assess the effect of GM-CSF on MIP-la expression, BMM were 
treated with GM-CSF for various lengths of time and then the levels of MIP-la 
mRNA were analysed as previously, by Northern blotting and densitometric analysis. 
Figure 6.3 shows one such experiment. MIP-la expression was rapidly induced, by 
approximately 3-fold compared to control cells, within 1 h following GM-CSF 
addition (compare lanes 1 and 2). In fact, in some other experiments increased
1 2
Figure 6.2: Northern blot analysis of the effect of GM-CSF on the 
expression of M IP-la mRNA in BMM.
1 )  c o n t r o l ;  2 )  4  h  1 0  n g / m l  G M - C S F .  L o a d i n g  l e v e l s  w e r e  c o n f i r m e d  
b y  e t h i d i u m  b r o m i d e  s t a i n i n g .  T h i s  f i g u r e  r e p r e s e n t s  a  s i n g l e  e x p e r i m e n t .  
S c a n n i n g  d e n s i t o m e t r i c  a n a l y s i s  r e v e a l e d  t h a t  t h e  l e v e l  o f  M I P - l a  m R N A  
i n  G M - C S F  t r e a t e d  c e l l s  ( l a n e  2 )  w a s  i n c r e a s e d  b y  a p p r o x i m a t e l y  9 . 6 3 - f o l d  
r e l a t i v e  t o  t h a t  o f  c o n t r o l  t r e a t e d  c e l l s  ( l a n e  1 ) .
Figure 6.3:
This figure represents data for a single experiment. The numbers in the table 
below show the relative levels of M IP-la mRNA for this experiment, as assessed 
by scanning densitometric analysis and normalisation against the level of P-Actin 
mRNA in 1 h control treated cells. * = data shown in the figure opposite.
lh  GM-CSF 2 h- GM-CSF 4 h GM-CSF 6 h GM-CSF
*1.00 *3.34 *3.50 *13.7 *17.4
1.00 3.64 5.00 22.9 9.03
Average 1.00 3.49 4.25 18.3 13.2
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Figure 6.3: Northern blot analysis of the effect of GM-CSF on a time course of 
M IP-la expression in BMM.
1 )  1 h  c o n t r o l ;  2 )  1 h  G M - C S F  ( 1 0  n g / m l )  ; 3 )  2  h  c o n t r o l ;  4 )  2  h  G M - C S F ;  5 )  4  h  
c o n t r o l  6 )  4  h  G M - C S F ;  7 )  6  h  c o n t r o l ;  8 )  6  h  G M - C S F .  T o p  p a n e l  s h o w s  a  b l o t  
h y b r i d i s e d  w i t h  a  p r o b e  f o r  M I P - l a ,  t h e  b o t t o m  p a n e l  s h o w s  t h e  s a m e  b l o t ,  s t r i p p e d  
a n d  r e p r o b e d  f o r  p - A c t i n .
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expression was visible within 30 minutes of GM-CSF stimulation (data not shown). 
The level of MIP-la mRNA increased between 1 and 4 h following GM-CSF 
stimulation, with up to a 20-fold increase relative to control cells (compare lanes 5 and
6). Comparison of lanes 7 and 8 shows that MIP-la expression was still elevated 
after 6 h, though not more so than at 4 h. In most experiments however, this peak was 
reached 4 h after stimulation with GM-CSF and subsequently declined within 6 h 
(data not shown). Treatment of BMM with GM-CSF for 4 h gave the most consistent 
increase in MIP-la expression.
6.3.3 Induction of MIP-a mRNA expression in response to a titration of GM-CSF 
concentration
In order to assess the potency of the inductive effect of GM-CSF on MIP-la 
mRNA expression, BMM were stimulated with a titration of GM-CSF (1 pg/ml to 10 
ng/ml) and the level of MIP-la mRNA assessed by Northern blot analysis 4 h after 
addition of GM-CSF. Figure 6.4 shows MIP-la mRNA expression to be induced in a 
dose dependent manner, and densitometric analysis demonstrated that as little as 0.1 
ng/ml of GM-CSF resulted in approximately a 3-fold increase in the level of MIP-la 
mRNA compared to control values (compare lanes 1 and 4). The increase in MIP-la 
mRNA appeared to plateau with between 5 and 10 ng/ml GM-CSF, resulting in 
approximately a 10-fold increase in this experiment (compare lane 1, with lanes 7 and 
8). However, it should be noted that the MIP-la blot is overexposed and the increase 
in MIP-la is perhaps therefore likely to be greater than that suggested by the scanning 
densitometric analysis. As 10 ng/ml appeared to be just beyond the “shoulder” of this 
plateau and therefore likely to give a full induction, all future experiments were 
performed using 10 ng/ml GM-CSF for 4h (unless stated otherwise).
6.3.4 Induction of MIP-a mRNA expression is not dependent on factors present 
in serum or L929 conditioned medium
BMM are grown in the presence of high levels of both serum and M-CSF (in 
the form of L929 conditioned medium). These cells will enter a quiescent state if 
deprived of serum for 16 h and absolutely require the presence of a source of M-CSF 
for their differentiation, continued proliferation and survival (Becker et al 1987). In
Figure 6.4:
This figure represents data for a single experiment. The numbers in the table 
below show the relative levels of MIP-la mRNA for this experiment, as assessed 
by scanning densitometric analysis and normalisation against the level of p-Actin 
mRNA in control treated cells.
...............................................Concentration of GM-CSF added
Control 1 pg/ml 10 pg/ml 0.1 ng/ml 0.5 ng/ml 1 ng/ml 5 ng/ml 10 ng/ml
1.00 1.10 1.74 3.1 4.4 8.1 11 9.20
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Figure 6.4: Northern blot analysis of the effect of a titration of GM-CSF on 
M IP-la mRNA expression in BMM.
B M M  w e r e  t r e a t e d  f o r  4  h  w i t h  t h e  f o l l o w i n g  c o n c e n t r a t i o n s  o f  G M - C S F :
1 )  c o n t r o l ;  2 )  1 p g / m l ;  3 )  1 0  p g / m l ;  4 )  0 . 1  n g / m l ;  5 )  0 . 5  n g / m l ;  6 )  1 n g / m l ;
7 )  5  n g / m l ;  8 )  1 0  n g / m l .  T o p  p a n e l  s h o w s  a  b l o t  h y b r i d i s e d  w i t h  a  p r o b e  f o r  M I P -  l a ,  
t h e  b o t t o m  p a n e l  s h o w s  t h e  s a m e  b l o t ,  s t r i p p e d  a n d  r e p r o b e d  f o r  p - A c t i n .
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order to assess whether either serum or L929 conditioned medium (L-929 CM) played 
a co-operative part in the induction of M IP-la expression by GM-CSF, cells were 
stimulated for 4 h with GM-CSF in the presence or absence, of either serum or L-929 
CM.
Panel A of figure 6.5 shows that similar levels of M IP-la mRNA were induced 
in either the presence, or absence of serum. Densitometric analysis revealed that this 
induction was approximately 4-fold, in both the presence or absence of serum.
Panel B of figure 6.5 shows that the absence of L-929 CM did not result in the 
abolition of GM-CSF induced M IP-la expression. In fact, densitometric analysis 
revealed that in the absence of L-929 CM the induction of M IP-la mRNA appeared to 
increase by approximately 170 %, rising from 11-fold in the presence of L-929 CM to 
29-fold in the absence of L-929 CM. This suggests that M IP-la suppressive factors 
may be present in the conditioned medium of L-929 cells.
These results demonstrate that GM-CSF does not require the presence of 
factors present in either serum or L-929 CM, to induce MIP-la mRNA expression.
6.3.5 GM-CSF directly induces the expression of MIP-la mRNA
It has previously been demonstrated using neutrophils that LPS is able to 
synergise with GM-CSF to induce M IP-la expression, although GM-CSF was unable 
to induce M IP-la expression when used as a sole agent (Kasama et al 1993). In order 
to exclude the presence of LPS as far as possible and therefore rule out a role for LPS 
in the observed induction of M IP-la expression, BMM were stimulated under 
essentially LPS-free conditions. To demonstrate that GM-CSF was indispensable for 
this observed induction, the effects of GM-CSF on M IP-la expression were assessed 
in the presence of a GM-CSF specific neutralising antibody. Figure 6.6 shows that as 
previously, GM-CSF increased the level of M IP-la mRNA by approximately 10-fold 
relative to control values. However, in the presence of a GM-CSF neutralising 
antibody this induction was almost completely abrogated. Densitometric analysis of 
blots revealed that the basal level of MIP-la expression did not appear to be 
significantly different between the control and those cells treated with neutralising 
antibody. This suggests that there is no autocrine regulation of M IP-la expression in
Figure 6.5; Northern blot analysis of the effect of GM-CSF on M IP-la 
mRNA expression in BMM, in the absence or presence of either serum or 
L-929 CM.
A) Effect of serum. BMM were treated as follows: 1) control plus serum; 2) 4 h 
GM-CSF (10 ng/ml) plus serum; 3) control (serum-free); 4) 4 h GM-CSF (serum- 
free). B) Effect of L-929 CM. 1) control plus L-929 CM; 2) 4 h GM-CSF (10 
ng/ml) plus L-929 CM; 3) control (L-929 CM-free); 4) 4 h GM-CSF (L-929 CM- 
free). Top blot in each panel shows a blot hybridised with a probe for MIP-la, 
whilst the lower blot in each panel shows the same blot stripped and reprobed for 
P-Actin. This figure represents single experiments. Tables A and B below, show 
the relative levels of MIP-la mRNA for the experiments shown in panels A and B 
(opposite), as assessed by scanning densitometric analysis and normalisation 
against the level of P-Actin mRNA.
A
Plus Serum Serum Free
Control GM-CSF -Control GM-CSF
1 4.0 1 3.2
B
Plus 1/-929 CM Minus L-929 CM
Control GM-CSF Control GM-CSF
1 10.7 1 28.7
+ Serum Serum Free
I----------------------------1 I---------------------------- 1
1 2  3 4
M IP-la
p-Actin
•  A
•  •  •  •
+ L929 CM 
I----------------------------1
- L929 CM 
I---------------------------- 1
Figure 6.6;
The numbers in the table below show the relative levels of M IP-la mRNA for 
these 2 experiments, as assessed by scanning densitometric analysis and 
normalisation against the level of J3-Actin mRNA in control treated cells.
* = data shown in the figure opposite
Control GM-CSF GM-CSF7 Nab Nab
*4.00 *23.4) *-4.23 *3:41
1.00 34.0 2.60 0.86
Average 1.00 J28.5 3-40 2,14
1 1 8
M IP-la
p-Actin
Figure 6.6: Northern blot analysis of the effect of a neutralising GM-CSF 
antibody on GM-CSF induced M IP-la mRNA expression in BMM, under 
LPS-free conditions.
B M M  w e r e  t r e a t e d  a s  f o l l o w s :  1 )  c o n t r o l ;  2 )  4  h  1 0  n g / m l  G M - C S F ;  3 )  1 0  n g / m l  
G M - C S F  p l u s  n e u t r a l i s i n g  a n t i b o d y  ( 5  p g / m l ) ;  4 )  n e u t r a l i s i n g  a n t i b o d y .  T o p  
p a n e l  s h o w s  a  b l o t  h y b r i d i s e d  w i t h  a  p r o b e  f o r  M I P - l a ,  t h e  b o t t o m  p a n e l  s h o w s  
t h e  s a m e  b l o t ,  s t r i p p e d  a n d  r e p r o b e d  f o r  p - A c t i n .  T h i s  f i g u r e  i s  r e p r e s e n t a t i v e  o f  
2 .  s e p a r a t e  e x p e r i m e n t s .
119
macrophages, by GM-CSF.
These results suggest that GM-CSF directly induces the expression of MIP-la 
mRNA and because these experiments were performed using conditions and reagents 
known to be essentially LPS-free, it is highly unlikely that GM-CSF is acting in 
synergy with LPS.
6.3.6 GM-CSF induces MIP-la protein expression in BMM
To assess whether increases in MIP-la expression at mRNA level were also 
reflected by increases in MIP-la protein expression, BMM were either treated with 
GM-CSF (10 ng/ml) or PBS / 0.1 % BSA (v/v), and conditioned medium collected 
after various lengths of time. The samples were collected later than for total RNA, to 
allow sufficient time for MIP-la mRNA to be translated to protein and to allow time 
for the levels of protein to accumulate in the macrophage growth medium to a level at 
which they could be detected. The content of MIP-la protein in these BMM 
supernatants was then measured by Western blot analysis. In initial experiments, no 
MIP-la protein could be detected in supernatants from either control or GM-CSF 
treated BMM, although a recombinant MIP-la control was detectable. These 
observations suggested either that the level of MIP-la protein in these cells was too 
low to detect by Western blot analysis, or that GM-CSF stimulation does not result in 
an increase in MIP-la protein expression.
It has previously been demonstrated that the level of MIP-la protein in 
unstimulated BMM is extremely low and often undetectable by Western blot analysis 
(Maltman et al 1993). Therefore, in order to assess whether MIP-la protein 
expression was induced in BMM by GM-CSF, MIP-la present in supernatants from 
control and GM-CSF stimulated BMM was purified by a combination of heparin and 
blue sepharose affinity chromatography, followed by reverse phase HPLC. This 
purification simultaneously also resulted in approximately a 100-fold concentration of 
protein. The level of purified MIP-la protein in these supernatants was then assessed 
by Western blotting analysis. Figure 6.7 shows that MIP-la protein was undetectable 
in unstimulated BMM over the time course of the experiment, but that treatment with 
GM-CSF (10 ng/ml) resulted in an increased level of MIP-la protein expression. This 
increase was just visible 24 h after addition of GM-CSF and increased steadily with
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Figure 6.7: Western blot analysis of the effect of GM-CSF on M IP-la 
protein expression in BMM.
B M M  c e l l  c o n d i t i o n e d  m e d i u m  w a s  c o l l e c t e d  a f t e r  t h e  a p p r o p r i a t e  t i m e  
a s  d e n o t e d  a t  t h e  t o p  o f  e a c h  l a n e .  B M M  w e r e  t r e a t e d  a s  f o l l o w s :
P B S  / 0 . 1 %  B S A  c o n t r o l  ( l e f t  h a n d  4  l a n e s )  o r  G M - C S F  ( 1 0  n g / m l )
( r i g h t  h a n d  4  l a n e s ) .  P r o t e i n s  w e r e  r e s o l v e d  b y  S D S / P A G E  o n  a  1 7 . 5  %  
g e l .  M I P - l a  p r o t e i n  w a s  d e t e c t e d  u s i n g  a  m u r i n e  a n t i - M I P - l a  a n t i b o d y  
a n d  E C L  r e a g e n t s ,  a s  d e t a i l e d  i n  t h e  M a t e r i a l s  a n d  M e t h o d s .
T h i s  f i g u r e  r e p r e s e n t s  d a t a  f o r  a  s i n g l e  e x p e r i m e n t  a n d  b o t h  t h e  p r o t e i n  p u r i f i c a t i o n  
a n d  t h e  W e s t e r n  b l o t  a n a l y s i s  w e r e  p e r f o r m e d  b y  D r .  J o h a n n  d e  B o n o ,  a s  d e t a i l e d  i n  
t h e  m a t e r i a l s  a n d  m e t h o d s .  T h e  r e p r o d u c t i o n  o f  h i s  w o r k  h e r e ,  i s  v e r y  g r a t e f u l l y  
a c k n o w l e d g e d .
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time up to 72 h. This data suggests that whilst the level of MIP-la protein in BMM is 
very low, a finding in accordance with previous reports from our laboratory (Maltman 
et al 1993), the level of MIP-la protein does increase following GM-CSF treatment. 
This demonstrates that induction of MIP-la expression observed at an mRNA level, is 
also reflected at the level of MIP-la protein expression and suggests that the induction 
of MIP-la by GM-CSF may be physiologically important.
6.4 Effect of IL-3 on MIP-la mRNA Expression in BMM
GM-CSF is a member of a cytokine family and exhibits some functional 
overlap with IL-3. It is speculated that this is the result of the shared usage of a 
receptor component, the common p subunit (or Pc), found as a component of both 
GM-CSF and IL-3 heterodimeric receptors (see introduction). Moreover, IL-3 has 
previously been reported, along with GM-CSF, to affect bone marrow-derived 
macrophage functions (Takamatsu et al 1996). It was therefore speculated that IL-3 
might also exert an inductive effect on MIP-la expression in BMM, in a similar 
fashion to that of GM-CSF.
6.4.1 Titration of the inductive effect of IL-3 on MIP-la mRNA expression
To assess the ability of IL-3 to regulate MIP-la mRNA expression, BMM 
were treated with a titration of IL-3 (1 pg/ml to 10 ng/ml) for 4 h. Panel A of figure
6.8 shows MIP-la mRNA expression to be increased in a dose dependent manner, and 
densitometric analysis revealed that concentrations as low as 0.1 to 1 ng/ml of IL-3 
were sufficient to induce substantial expression of MIP-la mRNA. As with GM-CSF, 
the expression of MIP-la plateaued with between 5 ng/ml and 10 ng/ml of IL-3, 
resulting in approximately a 20 to 25-fold increase in the levels of MIP-la mRNA 
relative to control values. A time course of MIP-la expression in response to IL-3 (10 
ng/ml), also revealed a similar time course to that seen GM-CSF (data not shown). As 
a dose of 10 ng/ml appeared to be just beyond the shoulder of this plateau, all future 
stimulations using IL-3 were performed using a dose of 10 ng/ml for 4 h. These results 
indicate that in addition to GM-CSF, IL-3 is also an inducer of MIP-la expression.
Panel B of figure 6.8 shows that treatment of BMM with IL-3 increased the 
level of MIP-la mRNA by approximately 23-fold relative to control values, but that
Figure 6.8: Northern blot analysis of the effect of IL-3 on M IP-la mRNA 
expression in BMM.
A) Effect of a titration of IL-3 on M IP-la mRNA expression. BMM were treated 
for 4 h with the following concentrations of IL-3: 1) control; 2) 1 pg/ml; 3) 10 
pg/ml; 4) 0.1 ng/ml; 5) 0.5 ng/ml; 6) 1 ng/ml; 7) 5 ng/ml; 8) 10 ng/ml. B) Effect of 
a neutralising EL-3 antibody on EL-3 induced M IP-la mRNA expression. BMM 
were treated for 4 h as follows: 1) control; 2) 10 ng/ml IL-3; 3) 10 ng/ml IL-3 plus 
neutralising antibody (5 pg/ml); 4) neutralising antibody. Top blot in each panel 
shows a blot hybridised with a probe for MIP-la, the bottom blot in each panel 
shows the same blot, stripped and reprobed for (3-Actin. This figure is 
representative of a single, and 2 separate experiments respectively. Table A below 
shows the relative levels of mRNA for M IP-la (as shown in panel A, opposite) 
and calculated from the data obtained by scanning densitometric analysis and 
normalisation against the calculated level of (3-Actin mRNA. Table B shows the 
relative levels of mRNA for MIP-la, calculated from 2 separate experiments (* = 
data for experiment shown in panel B, opposite).
A
Concentration of IL-: \
Control 1 pg/ml 10 pg/ml 0.1 ng/ml 0.5 ng/ml 1 ng/ml 5ng/ml lOng/ml
1.00 1.20 1.00 2.80 10.0 25.0 18.0 24.0
B
Control IL-3 IL-3/NAb NAb
*1.00 *23.2 *0.55 *0.53
1.00 24.8 6.40 3.16
Average 1.00 24.0 3.48 3.69
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M IP-la I  § I
p-Actin
B
1 2  3 4
M IP-la
p-Actin
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in the presence of an IL-3 neutralising antibody this induction was reduced to the same 
level as that of the control cells. As with GM-CSF, densitometric analysis o f blots 
showed that the basal level of MIP-la expression appeared to be similar in both 
control and IL-3 neutralising antibody treated cells, suggesting that there is no 
involvement of autocrine IL-3 in regulating the overall expression of M IP-la in 
macrophages. In summary, these data suggest that, like GM-CSF, IL-3 directly 
induces the expression of MIP-la mRNA. This experiment was performed using 
conditions and reagents known to be essentially LPS-ffee and IL-3 is therefore 
unlikely to be acting in synergy with LPS.
6.5 Effect of IL-5 on MIP-la mRNA Expression
IL-5 is also a member of the same small subfamily of cytokines, comprised of 
GM-CSF and IL-3, and in addition shares the Pc component in its receptor. The 
ability of IL-5 to regulate MIP-la expression was therefore investigated.
6.5.1 IL-5 does not induce expression of MIP-la mRNA in BMM
BMM were treated with a titration of IL-5 (1 pg/ml to 10 ng/ml) and the level 
of MIP-la mRNA analysed after 4 h. Figure 6.9 shows a Northern blot of one such 
experiment. Densitometric analysis revealed that the level of MIP-la expression was 
not altered following treatment of BMM with IL-5, at any of the concentrations tested. 
This data suggests either that IL-5 has no effects on the expression of MIP-la, at the 
concentrations tested, or that BMM do not have the capacity to respond to IL-5. The 
observation that no increase in MIPa expression occurred in the presence of IL-5, also 
suggests that LPS was not present in these experiments and confirms that this system 
is very clean with respect to the potential presence of LPS.
6.5.2 BMM do not express mRNA for the IL-5Ra chain
To attempt to explain the inability of BMM to respond to IL-5, expression of 
the IL-5 specific a  chain receptor subunit (IL-5Ra) was examined in BMM by 
Northern blot analysis and RT-PCR analysis. No expression of IL-5Ra chain was 
detectable in BMM by Northern blot analysis (data not shown). Figure 6.10 shows that 
IL-5Ra chain expression was also undetectable in BMM by RT-PCR analysis (lane 3).
Figure 6.9:
The numbers in the table below show the relative levels of M IP-la mRNA 
for these 3 experiments, as assessed by scanning densitometric analysis and 
normalisation against the level of P-Actin mRNA in control treated cells.
* = data shown in the figure opposite
Control 1 pg/ml 10 pg/ml 0.1 ng/ml 0.5ng/ml 1 ng/ml 5 ng/ml 10 ng/ml
*1.0 *1.41 *1.10 *1.44 *0.60 *0.98 *0.90 *2.10
1.0 1.54 0.77 1.09 1.37 2.20 0.90 1.50
1.0 0.60 1.10 1.20 1.90 2.20 4.40 1.60
Average 1.0 1.18 0.99 1.24 1.29 1.79 1.93 1.73
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Figure 6.9: Northern blot analysis of the effect of a titration of IL-5 on 
M IP-la mRNA expression in BMM.
B M M  w e r e  t r e a t e d  f o r  4  h  w i t h  t h e  f o l l o w i n g  c o n c e n t r a t i o n s  o f  I L - 5 :
1 )  c o n t r o l ;  2 )  1 p g / m l ;  3 )  1 0  p g / m l ;  4 )  0 . 1  n g / m l ;  5 )  0 . 5  n g / m l ; 6 )  1 n g / m l ;
7 )  5  n g / m l ;  8 )  1 0  n g / m l .  T o p  p a n e l  s h o w s  a  b l o t  h y b r i d i s e d  w i t h  a  p r o b e  f o r  
M I P - l a ,  t h e  b o t t o m  p a n e l  s h o w s  t h e  s a m e  b l o t  s t r i p p e d  a n d  r e p r o b e d  f o r  
( 3 - A c t i n .  T h i s  f i g u r e  i s  r e p r e s e n t a t i v e  o f  a t  l e a s t  3  s e p a r a t e  e x p e r i m e n t s .
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Figure 6.10: RT-PCR analysis of the expression of the IL-5Ra chain in BMM.
T o t a l  R N A  w a s  i s o l a t e d  a n d  a n a l y s e d  f o r  t h e  e x p r e s s i o n  o f  e i t h e r  G A P D H  o r  I L - 5 R a  
c h a i n  a s  f o l l o w s :  L a n e s  1 - 3  s h o w  r e a c t i o n s  p e r f o r m e d  u s i n g  B M M  R N A ,  w h i l s t  l a n e s  
4 - 6  s h o w  r e a c t i o n s  p e r f o r m e d  u s i n g  B C L - 1  R N A  ( a  p o s i t i v e  c o n t r o l  c e l l  l i n e  f o r  
m I L - 5 R a  c h a i n  e x p r e s s i o n ) .  R e a c t i o n s  w e r e  p e r f o r m e d  u s i n g  e i t h e r  G A P D H  p r i m e r s  
( l a n e s  1 - 3 )  o r  w i t h  p r i m e r s  s p e c i f i c  f o r  m I L - 5 R a  c h a i n  ( l a n e s  4 - 7 ) .  L a n e s  2  a n d  5  
a r e  n e g a t i v e  c o n t r o l  r e a c t i o n s  p e r f o r m e d  w i t h o u t  t h e  a d d i t i o n  o f  r e v e r s e  t r a n s c r i p t a s e .  
T h e  r e a c t i o n  s h o w n  i n  l a n e  7  i s  a  p o s i t i v e  c o n t r o l ,  p e r f o r m e d  u s i n g  m l L - 5 R a  c h a i n  
c D N A .  T h e  I L - 5 R a  c h a i n  p r i m e r s  u s e d  f o r  t h e  P C R  r e a c t i o n  d e f i n e  f r a g m e n t s  o f  t h e  
f o l l o w i n g  s i z e :  a r r o w  a )  5 4 8  b p ;  a r r o w  b )  4 5 2  b p ;  a r r o w  c )  3 6 9 ;  a r r o w  d )  a  p o s s i b l e  
a l t e r n a t i v e l y  s p l i c e d  v a r i a n t .  T h i s  f i g u r e  r e p r e s e n t s  d a t a  f r o m  a  s i n g l e  e x p e r i m e n t .
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Also included was a positive control cell line, BCL-1 (lane 6), previously shown to 
express the DL-5Ra chain. Four bands were observed in this and they corresponded 
exactly to those previous identified by Takaki et al (1990) as follows. Arrow a) 
membrane bound form; arrows b) and c) soluble IL-5R; arrow d) probably corresponds 
to an alternatively spliced mRNA variant. Also shown is an internal control for the 
housekeeping gene GAPDH (lanes 1 and 4). This data strongly suggests that BMM are 
unable to respond to IL-5, due to the absence of IL-5Ra chain and therefore a 
functional EL-5 receptor. It does not however preclude the possibility of EL-5 
regulating the expression of M IP-la in other cell types, that do express functional EL-5 
receptors.
6.5.3 EL-5 does not induce expression of MIP-la mRNA in bone marrow cells
The bone marrow consists of a heterogeneous population of cells which 
includes cells other than macrophages, some of which are known to be IL-5 
responsive. As M IP-la expression was undetectable in unfractionated murine bone 
marrow cells by Northern blot analysis, the expression of MEP-la mRNA was 
examined by RT-PCR analysis in order to determine whether cells within the bone 
marrow could alter their expression of MIP-la in response to EL-5. Figure 6.11 shows 
that M IP-la is readily detectable in untreated bone marrow cells, but that this level of 
expression does not appear to be significantly altered following treatment with EL-5. 
This suggests that cells within the bone marrow do not readily increase their expression 
of M IP-la mRNA, in response to IL-5. It is possible however, that cells may respond 
but that the number of responsive cells is too low to result in a significant change in the 
overall level of M IP-la mRNA expression.
6.6 Effect of GM-CSF on the Expression of mRNA for other CC chemokines
M IP-la is a member of a large superfamily of cytokines known as the 
chemokines which are divided into several subfamilies, with MIP-la being a member 
of the CC subfamily (see introduction). It had been previously demonstrated that IL-8, 
a member of the CXC chemokine subfamily, was inducible in monocytes by GM-CSF 
and EL-3 stimulation (Takahashi et al 1993). Therefore, the effect of GM-CSF and
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Figure 6.11: RT-PCR analysis of the effect of IL-5 on the expression 
of M IP-la mRNA in murine bone marrow cells.
B o n e  m a r r o w  c e l l s  h a r v e s t e d  f r o m  m u r i n e  f e m o r a  w e r e  t r e a t e d  f o r  4  h  a s  
f o l l o w s :  L a n e  1 )  C o n t r o l  t r e a t e d  c e l l s ;  l a n e  2 )  I L - 5  t r e a t e d  ( 1 0  n g / m l ) .  
R T - P C R  a n a l y s i s  w a s  t h e n  u s e d  t o  e x a m i n e  t h e  e x p r e s s i o n  o f  M I P - l a .
T h e  r e a c t i o n s  s h o w n  i n  l a n e s  3  a n d  4  a r e  p o s i t i v e  P C R  c o n t r o l s  p e r f o r m e d  
u s i n g  g e n o m i c  D N A  a n d  M I P - l a  c D N A ,  r e s p e c t i v e l y .  T o p  p a n e l  s h o w s  
p r o d u c t s  o f  r e a c t i o n s  p e r f o r m e d  w i t h  M I P - l a  p r i m e r s ,  w h i l s t  b o t t o m  p a n e l  
s h o w s  t h o s e  p e r f o r m e d  w i t h  p - A c t i n  p r i m e r s .  T h i s  f i g u r e  r e p r e s e n t s  d a t a  f r o m  
a  s i n g l e  e x p e r i m e n t .
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IL-3 on the expression of other murine members of the CC subfamily was 
investigated in BMM, to examine if GM-CSF induction was specific to MIP-la.
6.6.1 GM-CSF induces expression of MIP-lp mRNA
MIP-lp is very similar to MIP-la, both in its expression and in many of its 
functions. BMM were therefore treated with either GM-CSF or IL-3 (both at 10 
ng/ml) for 4 h and then the level of murine MIP-ip mRNA analysed by Northern blot 
analysis, using a MIP-ip-specific probe. Figure 6.12 shows that MIP-ip mRNA is 
induced by GM-CSF and IL-3 and densitometric analysis revealed this induction to be 
approximately 15 to 20-fold, a similar magnitude to that observed for MIP-la.
6.6.2 GM-CSF and IL-3 induce expression of JE and MARC mRNA
MARC and JE are two other murine CC chemokines known to be expressed 
by monocytes and macrophages (see introduction). The expression of JE and MARC 
mRNA was examined using an identical protocol to that used for MIP-lp expression. 
Figures 6.13 A and 6.13 B show that both JE and MARC mRNA are substantially 
induced by both GM-CSF and IL-3.
These results suggest that expression of at least 3 other chemokines, in 
addition to MIP-la, can be regulated by GM-CSF and implies that additional 
chemokines not investigated here may also be regulated in a similar fashion.
6.7. Effect of TGF-pl on the GM-CSF and IL-3 Induced Expression of CC 
Chemokines
Previous work in our laboratory has documented the existence of an 
endogenous reciprocal relationship in BMM, between MIP-la and TGF-pl (Maltman 
et al 1993, 1996). It is proposed that TGF-pl may function to suppress the expression 
of MIP-la in the bone marrow, and yet MIP-la expression is detectable (Cluitmans 
et al 1995), suggesting that other endogenous factors may act to oppose this block. In 
the light of the observations documented here, that GM-CSF and IL-3 are both strong 
inducers of MIP-la expression in BMM, the potential relationship between TGF-pl, 
GM-CSF, IL-3 and MIP-la expression was investigated.
Figure 6.12:
The numbers in the table below show the relative levels of MUM P mRNA for 
these 2 experiments, as assessed by scanning densitometric analysis and 
normalisation against the level of P-Actin mRNA in control treated cells.
* = data shown in the figure opposite
Control GM-CSF Control IL-3
*1.00 *14.7 *1.00 *18.0
1.00 14.5 1.00 22.0
Average 1.00 14.6 1.00 20.0
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Figure 6.12: Northern blot analysis of the effect of GM-CSF and IL-3 on the 
expression of MIP-lp mRNA in BMM.
A)  E f f e c t  o f  G M - C S F  o n  M I P - l p  e x p r e s s i o n .  B M M  w e r e  t r e a t e d  f o r  4  h  a s  f o l l o w s :
1 )  c o n t r o l ;  2 )  G M - C S F  ( 1 0  n g / m l ) .  B) E f f e c t  o f  I L - 3  o n  M I P - l p  e x p r e s s i o n .  B M M  
w e r e  t r e a t e d  a s  f o l l o w s :  1 )  c o n t r o l ;  2 )  I L - 3  ( 1 0  n g / m l ) .  T h e  t o p  b l o t  o f  e a c h  p a n e l  
s h o w s  a  b l o t  h y b r i d i s e d  w i t h  a  p r o b e  f o r  M I P - l p ,  t h e  b o t t o m  b l o t  o f  e a c h  p a n e l  
s h o w s  t h e  s a m e  b l o t ,  s t r i p p e d  a n d  r e p r o b e d  f o r  p - A c t i n .  T h i s  f i g u r e  i s  r e p r e s e n t a t i v e  
o f  2  s e p a r a t e  e x p e r i m e n t s .
Figure 6.13: Northern blot analysis of the effect of GM-CSF and EL-3 on the 
expression of JE and MARC mRNA in BMM.
A) Effect of GM-CSF and IL-3 on JE expression. BMM were treated as follows: 
1) control; 2) 4 h GM-CSF (10 ng/ml); 3) 4 h IL-3 (10 ng/ml). B) Effect of GM- 
CSF and EL-3 on MARC expression. BMM were treated as in A above. Top blot 
of each panel shows a blot hybridised with a probe for either JE or MARC, the 
bottom blot in each panel shows the same blot stripped and reprobed for b-Actin. 
This figure is representative of 3 separate experiments. The table below shows the 
relative levels of mRNA for JE and MARC for 3 separate experiments (*= data for 
those experiments shown opposite in panels A and B, respectively), as assessed by 
scanning densitometric analysis and normalisation against the calculated level of (3- 
Actin mRNA.
JE
Control GM-CSF IL-3
*1.00 *33.0 *52.0
1.00 25.0 62.0
. . . . 1.00
Average 1.00 39.0 49.0
MARC
1.00 9.78 10.4
1.00 10.4 7.00
*1.00 *16.0 *25.0
Average 1.00 12.1 14.1
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6.7.1 TGF-pl can suppress the induction of MIP-la mRNA expression induced 
by GM-CSF and IL-3
The ability of TGF-pl to suppress MIP-la expression in the presence of GM- 
CSF or IL-3 was assessed. BMM were stimulated with GM-CSF or IL-3 as described 
above, either in the presence or absence of TGF-pi (20 ng/ml). A previous study in 
our laboratory had shown suppression of MIP-la expression, with around 1 pM TGF- 
pi (Maltman et al 1993). A dose of 20 ng/ml was selected for the experiments 
reported herein, as this was in excess of the doses used in the previous studies and 
therefore likely to result in suppression of MIP-la expression, despite the presence the 
strong inducing stimulus of GM-CSF. Figure 6.14 shows one such experiment. As 
previously, densitometric analysis revealed that GM-CSF and IL-3 potently induced 
MIP-la mRNA expression, approximately 20-fold, relative to control values 
(compare lane 1 with lanes 2 and 4). However, in the presence of TGF-pl, this 
induction was reduced by approximately 55-85 % (compare lane 2 with 3, and lane 4 
with 5). As previously reported, TGF-pl alone was able to suppress the level of MIP- 
la  expression below the basal level normally seen in unstimulated cells (compare lane 
1 with 6). These data indicate that TGF-pi is indeed able to suppress the induction of 
MIP-la mRNA expression induced by GM-CSF and IL-3. However, this suppression 
does not appear complete despite the very high level of TGF-pi used, suggesting that 
GM-CSF and IL-3 are indeed strong inducers of MIP-la expression and may therefore 
be able to overcome TGF-pl suppression of MIP-la expression in vivo. These results 
indicate that the opposing regulatory stimuli exerted by GM-CSF and TGF-P on MIP- 
la  expression are probably not exclusive of each other and are also unlikely to be an 
“all or nothing effect”. The interactions occuring in vivo are therefore likely to be 
dynamic and dependent upon the relative levels of GM-CSF, IL-3 and TGF-p present 
within the bone marrow microenvironment at any given time.
6.7.2 The suppression of GM-CSF induced MIP-la expression by TGF-pl is 
dose-dependent
In order to further examine the relationship between TGF-pl, GM-CSF and 
MIP-la, BMM were treated with GM-CSF in the presence of a titration of TGF-P 1. 
Figure 6.15 shows that as above, TGF-P 1 suppressed the induction of MIP-la mRNA
Figure 6.14:
The numbers in the table below show the relative levels of MIP-la mRNA for this 
experiment, as assessed by scanning densitometric analysis and normalisation 
against the level of (3-Actin mRNA in control treated cells. * = data shown in the 
figure opposite.
Control GM-CSF GM-CSF + 
TGF-pl
IL-3 IL-3 + 
TGF-P 1
TGF-p 1
*1.0 *21.0 *3.30 *22.8 *10.4 N/M
1.0 6.0 1.90 7.40 3.22 N/M
Average 1.0 13.5 2.60 15.1 6.81 N/M
N/M = not measurable
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Figure 6.14: Northern blot analysis of the effect of TGF-(3l on the induction of 
M IP-la mRNA expression by GM-CSF and IL-3.
B M M  w e r e  s t i m u l a t e d  f o r  4  h  w i t h  t h e  f o l l o w i n g  a d d i t i o n s :  1 )  c o n t r o l ;  2 )  G M - C S F  
( 1 0  n g / m l  ) ;  3 )  G M - C S F  p l u s  T G F - p l  ( 2 0  n g / m l ) ;  4 )  I L - 3  ( 1 0  n g / m l ) ;  5 )  I L - 3  p l u s  
T G F - ( 3 l ;  6 )  T G F - ( 3 l .  T o p  p a n e l  s h o w s  a  b l o t  h y b r i d i s e d  w i t h  a  p r o b e  f o r  M I P - l a ,  
w h i l s t  t h e  b o t t o m  p a n e l  s h o w s  t h e  s a m e  b l o t  s t r i p p e d  a n d  r e p r o b e d  f o r  p - A c t i n .  T h i s  
f i g u r e  i s  r e p r e s e n t a t i v e  o f  2 .  s e p a r a t e  e x p e r i m e n t s .
Figure 6.15:
This figure represents data from a single experiment. The numbers in the table 
below show the relative levels of MIP-la mRNA for this experiment, as assessed 
by scanning densitometric analysis and normalisation against the level of (3-Actin 
mRNA in control treated cells.
Control GM-CSF GM + 20ng/ml 
TGF-P 1
GM+2ng/ml
TGF-pl
GM+200pg 
/ml TGF-P 1
GM+20pg/ 
ml TGF-pl
1.00 11.9 2.49 3.70 10.8 5.70
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Figure 6.15: Northern blot analysis of the effect of a titration of TGF-pl on 
the induction of M IP-la mRNA expression by GM-CSF
B M M  w e r e  s t i m u l a t e d  f o r  4  h  w i t h  t h e  f o l l o w i n g  a d d i t i o n s :  1 )  c o n t r o l ;  2 )  G M - C S F  
( 1 0  n g / m l  ) ;  3 )  G M - C S F  p l u s  T G F - P  1 ( 2 0  n g / m l ) ;  4 ) ;  G M - C S F  p l u s  T G F - p l  
( 2  n g / m l ) ;  5 )  G M - C S F  p l u s  T G F - P  1 ( 2 0 0  p g / m l ) ;  6 )  G M - C S F  p l u s  T G F - p  ( 2 0  p g / m l ) .  
T o p  p a n e l  s h o w s  a  b l o t  p r o b e d  w i t h  M I P - l a ,  w h i l s t  t h e  l o w e r  p a n e l  s h o w s  t h e  s a m e  
b l o t  s t r i p p e d  a n d  r e p r o b e d  w i t h  a  p r o b e  f o r  p - A c t i n .
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by GM-CSF, by approximately 80 % (compare lane 1 with lanes 2 and 3). As the 
amount of TGF-pl was decreased, so the level of MIP-la expression rose (compare 
lanes 4, 5, and 6 with lane 3). The level of expression observed with the lowest dose 
of TGF-pl (0.02 ng/ml) was unexpectedly lower than that seen with a 10-fold higher 
dose of TGF-P 1 (lanes 6 and 5 respectively). The reason for this is unclear, but may 
be the result of a slightly unequal loading of RNA between lanes as indicated by the P- 
Actin blot. These results confirm the observations made in the previous experiment, 
that TGF-pl is a suppressor of MIP-la expression, but that GM-CSF may be 
sufficiently potent to at least partially overcome TGF-pl mediated suppression.
6.7.3 TGF-pl can also suppress the induction of JE and MARC mRNA 
expression induced by GM-CSF and IL-3
As described in section 6.6.2, GM-CSF and IL-3 can induce the expression of 
several chemokines in addition to that of MIP-la. This observation suggested that 
TGF-P might have the potential to suppress the induction of these additional 
chemokines. The expression of MARC and JE mRNA following GM-CSF or IL- 
3 treatment was therefore examined in the presence of TGF-p 1 (20 ng/ml). Figure 
6.16 shows that like MIP-la, the induction of both MARC and JE by GM-CSF or IL- 
3, can be suppressed in the presence of TGF-P 1 (by approximately 50-75 %). As 
before, this TGF-pl suppression was not absolute and some induction of both MARC 
and JE expression was still evident in the presence of GM-CSF or IL-3, relative to 
control values. As with MIP-la, in the absence of either GM-CSF or IL-3, the basal 
levels of both MARC and JE appeared to be suppressed by TGF-p. These results 
indicate that, as with MIP-la, the basal or the induced expression of other CC 
chemokines can be negatively regulated by TGF-pl.
6.8 Effect of GM-CSF, IL-3 and TGF-pi on the Expression of MIP-la Receptors
As outlined in the introduction, the last few years have seen a rapid growth in 
the understanding of the interactions between chemokines and their cognate receptors. 
Many chemokines, including MIP-la, are somewhat unusual in their ability to bind 
and functionally activate more than one receptor. In fact, as indicated in table 3.1, 
MIP-la has been reported to be a functional ligand for at least 4 receptors. To date,
Figure 6.16: Northern blot analysis of the effect of TGF-pi on the induction 
of MARC and JE mRNA expression by GM-CSF and IL-3.
A) Effect of TGF-pl on the induction of MARC mRNA by GM-CSF and IL-3. 
BMM were treated for 4 h under the following conditions 1) control; 2) GM-CSF 
(10 ng/ml); 3) GM-CSF plus TGF-pi (20 ng/ml); 4) IL-3 (10 ng/ml); 5) IL-3 plus 
TGF-pl; 6) TGF-pl. B) Effect of TGF-pl on the induction of JE mRNA by GM- 
CSF and IL-3. BMM were treated as A) above. Top blot in each panel shows a 
blot hybridised with a probe for either MARC or JE, whilst the bottom blot in each 
panel shows the same blot stripped and reprobed for P-Actin. This figure is 
representative of 2 separate experiments. The table below shows the relative levels 
of mRNA for MARC and JE for these 2 separate experiments (*= data for those 
experiments shown opposite in panels A and B, respectively), as assessed by 
scanning densitometric analysis and normalisation against the calculated level of P- 
Actin mRNA.
JE
Control GM-CSF GM-CSF/TGF-P IL-3 IL-3/TGF-3 TGF-P
1.00 122 70.3 121 51.4 N/M
*1.00 *62.3 *31.4 *92.0 *25.0 N/M
Average 1.00 92.1 50.9 49.0 38.2 N/M
MARC
*1.00 *119 *48.6 *120 *65 N/M
1.00 210 69.3 325 143 N/M
Average 1.00 165 58 223 104 N/M
MARC
p-Actin
• • t ■
• • 4 1 *
B
1 2 3 4 5
• I 4IE V
. . . . .p-Actin
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whilst some progress has been made in understanding the regulation of MIP-la 
expression, very little is known regarding the regulatory controls governing the 
expression of the various MIP-la receptors. Given the potent inductive effect of GM- 
CSF and IL-3 on MIP-la expression reported in the previous sections, it was decided 
to examine whether GM-CSF and IL-3 could also affect the expression of MIP-la 
receptors.
6.8.1 GM-CSF and IL-3 increase the expression of CCR1 in BMM, but not that 
of CCR5
As discussed in the introduction, the CC chemokine receptors CCR1 and 
CCR5 are known to be widely expressed on cells of the macrophage lineage. 
Therefore the expression of CCR1 and CCR5, together with that of CCR3, CCR4 and 
D6, was examined in BMM using northern blot analysis. No expression of CCR3, 
CCR4, and D6 was visible in BMM, as assessed by northern blot analysis. 
Densitometric analysis revealed that the expression of CCR1 mRNA was increased 
approximately 3-5 fold following GM-CSF or IL-3 stimulation of BMM, relative to 
control values (see figure 6.17 panel A, compare lanes 2 and 3 with lane 1). This was 
the typical level of expression observed following GM-CSF stimulation, although as 
much as a 10-fold increase in expression was observed in some experiments. In 
contrast however, no change in the level of CCR5 expression was observed following 
treatment with GM-CSF or IL-3 (see figure 6.17 panel B, compare lanes 2 and 3 with 
lane 1).
6.8.2 GM-CSF and IL-3 also regulate the expression of CCR1, but not that of 
CCR5, in splenic cells
Splenic cells were also used, in an crude attempt to examine the expression of 
CCR1 and CCR5 in other cell types. Figure 6.18 shows that a very similar pattern of 
expression for CCR1 and CCR5 is evident in splenic cells, as is observed in BMM. As 
in BMM, CCR1 expression is elevated following stimulation of splenic cells with 
GM-CSF or IL-3, but CCR5 expression remains unaltered. The normal murine spleen 
is comprised mainly of a mixture of B and T cells and erythrocytes. Given the few 
numbers of macrophages present in normal mouse spleen, it is highly unlikely that the 
observed increase in CCR1 expression observed by Northern blotting, was
Figure 6.17: Northern blot analysis of the effect of GM-CSF and EL-3 on the 
expression of CCR1 and CCR5 mRNA in BMM.
A) Effect of GM-CSF and IL-3 on CCR1 expression. 1) control; 2) 4 h GM-CSF 
(10 ng/ml); 3) 4 h IL-3 (10 ng/ml). B) Effect of GM-CSF and IL-3 on CCR5 
expression. BMM were treated as A) above. Top blot of each panel shows a blot 
hybridised with a probe for either CCR1 or CCR5, whilst the bottom blot in each 
panel shows the same blot, stripped and reprobed for P-Actin. This figure is 
representative of 3 separate experiments. The table below shows the relative levels 
of mRNA for CCR1 and CCR5 for these 3 separate experiments (*= data for 
those experiments shown opposite in panels A and B, respectively), as assessed by 
scanning densitometric analysis and normalisation against the calculated level of p- 
Actin mRNA.
CCR1
Control GM-CSF IL-3
*1.00 *3.10 *4.60
1.00 4.76 6.80
9.06 8.96
Average 1.00 5.64 6.79
CCR5
*1.00 *1.00 *0.85
1.00 1.16 0.91
1.00 1.43 1.24
Average 1.00 1.20 1.00
CCR1
p-Actin
CCR5
p-Actin
Figure 6.18: Northern blot analysis of the effect of GM-CSF and IL-3 on the 
expression of CCR1 and CCR5 mRNA in splenic cells.
A) Effect of GM-CSF and IL-3 on CCR1 expression. Splenic cells were treated as 
follows 1) control; 2) 4 h GM-CSF (10 ng/ml); 3) 4 h IL-3 (10 ng/ml). B) Effect of 
GM-CSF and IL-3 on CCR5 expression. Splenic cells were treated as A) above. 
Top blot of each panel shows a blot hybridised with a probe for either CCR1 or 
CCR5, whilst the bottom blot in each panel shows the same blot, stripped and 
reprobed for P-Actin. This figure is representative of 2 separate experiments. The 
table below shows the relative levels of mRNA for CCR1 and CCR5 for these 2 
separate experiments (*= data for those experiments shown opposite in panels A 
and B, respectively), as assessed by scanning densitometric analysis and 
normalisation against the calculated level of p-Actin mRNA.
CCR1
Control GM-CSF IL-3
*1.00 *4.98 *3.20
Average 1.00 3.73 2.36
CCR5
*1.00 *1.44 *1.43
1.00 1.82 0.93
Average 1.00 1.63 1.18
CCR1
p-Actin
CCR5
p-Actin
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macrophage derived. This data therefore suggests that increased CCR1 expression 
may also occur outwith the bone marrow in non-macrophage cell types, in response to 
GM-CSF and IL-3.
6.8.3 GM-CSF and IL-3 do not affect the expression of other MIP-la receptors in 
BMM
As indicated above, northern blot analysis of BMM failed to reveal detectable 
expression of mRNA for other MIP-la receptors, namely CCR4 and D6. Nor was 
expression of murine CCR3 detected, a receptor which may, or may not, be a 
functional MIP-la receptor and which was previously reported to be expressed in 
monocytes (Graham et al 1996) (data not shown). The highly sensitive technique of 
RT-PCR was therefore used to examine the expression of these receptors in BMM and 
splenic cells. Panel A of figure 6.19 shows that no expression of either CCR3 or 
CCR4 was detected in BMM, either in the presence, or absence of GM-CSF or IL-3. 
Included were positive controls for CCR3 (lane 8) and CCR4 (lane 12), as well as 
those for the housekeeping gene GAPDH (lanes 1-4), to show that the RT-PCR had 
indeed worked successfully and allow some inferences to be made concerning the 
loading between lanes. A similar observation was made in splenic cells (data not 
shown).
Panel B of figure 6.19 shows that expression of CCR2, which does not bind 
MIP-la, was detectable in BMM but its expression was not altered by the addition of 
GM-CSF (compare lane 4 with lane 5). As before, a positive control for CCR2 (lane 
6) and internal controls for P-Actin (lanes 1-3) were included.
Panel C of figure 6.19 shows that expression of D6 was also undetectable in 
BMM, either in the presence or absence of GM-CSF (compare lane 4 with lane 5). 
Also included was a positive control for D6 (lane 6) and internal controls for p-Actin 
(lanes 1-3).
6.8.4 TGF-pi does not markedly alter the expression of CCR1 and CCR5 in 
BMM
As outlined in previous sections, TGF-pl appears to be a potent suppressor of 
GM-CSF and IL-3 induced MIP-la expression. With the knowledge that GM-CSF
Figure 6.19: RT-PCR analysis of the expression of CCR3, CCR4, D6 and 
CCR2 following stimulation with GM-CSF or IL-3.
BMM were treated for 4 h with GM-CSF and IL-3, total RNA isolated and RT- 
PCR analysis performed to determine the expression of various CC chemokine 
receptors as follows:
A) CCR3 and CCR4 expression. Lanes 1, 5 and 9 show reactions performed with 
control RNA; lanes 2, 6 and 10 show reactions performed with RNA derived from 
cells treated for 4 h with GM-CSF (10 ng/ml); lanes 3, 7 and 11 show reactions 
performed with RNA derived from cells treated for 4 h with IL-3 (10 ng/ml); lanes 
4, 8 and 12 show positive control reactions performed with cDNAs for GAPDH, 
CCR3, and CCR4 respectively. Lanes 1-4 show reactions performed with GAPDH 
primers, whilst lanes 5-8 and 9-12 show reactions performed with primers for 
CCR3 and CCR4 respectively.
B) CCR2.expression. Lanes Land 4 show reactions performed, with.control RNA; 
lanes 2 and 5 show reactions performed with RNA derived from cells treated for 4 
h with GM-CSF (10 ng/ml); lanes 3 and 6 show positive control reactions 
performed with cDNAs for P-Actin and CCR2 respectively. Lanes 1-3 show 
reactions performed with primers for P-Actin, whilst lanes 4-6 show reactions 
performed with primers for CCR2.
C) D6 expression. Lane assignments as for B) above, except that reactions in lanes 
4-6 were performed with primers for D6.
This figure is representative of 3 separate experiments.
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and IL-3 also induce the expression of CCR1, but not CCR5, the effect of TGF-01 on 
CCR1 and CCR5 expression was also examined. Figure 6.20 shows that whilst TGF- 
pi does decrease the basal expression of both CCR1 and CCR5 following addition of 
GM-CSF or IL-3, the expression of CCR1 was induced as previously in the presence 
of GM-CSF (compare lanes 2 and 3, and lanes 4 and 5, with that of lane 1). This basal 
suppression of approximately 10-30 % was minimal in comparison to the 50-80 % 
suppression observed previously. TGF-pi appears to suppress only the basal level of 
expression of both CCR1 and CCR5. This basal suppression is most obvious when 
cells treated with TGF-pi are compared to control cells (compare lane 6 with the 
negative control, lane 1), an observation also previously noted for MIP-la. These data 
suggests that whilst TGF-pi may act to suppress basal expression of CCR1 and CCR5, 
it does not appear to markedly alter their expression following stimulation with GM- 
CSF or IL-3.
6.9 Effect of GM-CSF on MIP-la Receptor Levels on BMM
To assess whether the observed increase in CCR1 mRNA expression that 
occurred following GM-CSF stimulation was of functional relevance, the effect of 
GM-CSF on the BMM cell surface expression of M IP-la receptors was examined. 
BMM were either stimulated with GM-CSF (10 ng/ml) or with PBS / 0.1 % BSA (v/v) 
for 16 h and then radioligand displacement studies were performed in the presence of 4 
nM 125I labelled M IP-la and variable amounts of cold M IP-la competitor. Thp 
extended GM-CSF treatment time of 16 h, compared with the 4 h used for Northern 
blot analysis, was to allow sufficient time for CCR1 protein expression on the cell 
surface to reflect the mRNA levels. One such experiment is shown in figure 6.21 and 
shows a Scatchard analysis of displacement of radiolabelled M IP-la from control and 
GM-CSF treated BMM. This Scatchard analysis was performed using the Ligand 
software program, widely used for the analysis of receptor binding data. The plot 
indicates several things. Firstly, the binding of M IP-la to cell surface receptors 
appeared to occur with relatively similar affinities, with Kd’s (dissociation constant)of 
0.67 nM and 0.2 nM for control and GM-CSF treated BMM respectively (as indicated 
by the gradients of the slopes of the lines). Secondly, the number of M IP-la receptors 
increased following GM-CSF treatment, from over 20,000 to 46,000 receptors per
Figure 6.2Q:
The numbers in the table below show the relative levels of CCR1 and CCR5 
mRNA for these 3 experiments, as assessed by scanning densitometric analysis 
and normalisation against the level of Jl-Actin mRNA in control treated cells.
* = data sfiown in the figure opposite.
Control GM-CSF GM-CSF + 
TGF-pl
IL-3 IL-3 + 
JGF-01
JCF^pi
CCR1 *1.00 *3,10 *2.70 *4,60 *330 *0.09
130 2.33 130 139 Q.14
1.00 4,09 4.05 3.77 1.77 0.73
-
Average , 1,00 3.17 2,78 3.42 2.42 0.32
CCR5 *1.00 *1.43 *1.06 *1.11 *0.86 *0.47
1.00 1.10 038 0.91 0.35 0.30
/ 1:00 1.80 0.77 1.34 0.53 0.32
'
Average 1.00 1.44 0.80 1.12 069 036
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Figure 6.20: Northern blot analysis of the effect of TGF-pl on the expression of 
CCR1 and CCR5 mRNA, in the presence of GM-CSF and IL-3.
B M M  w e r e  t r e a t e d  f o r  4  h  w i t h  G M - C S F  o r  I L - 3 ,  i n  t h e  p r e s e n c e  o r  a b s e n c e  
o f  T G F - p l ,  a s  f o l l o w s :  A) C C R 1  e x p r e s s i o n .  1 )  c o n t r o l ;  2 )  G M - C S F  ( 1 0  n g / m l ) ;
3 )  G M - C S F  p l u s  T G F - p l  ( 2 0  n g / m l ) ;  4 )  I L - 3  ( 1 0  n g / m l ) ;  5 )  I L - 3  p l u s  T G F - P l  
( 2 0  n g / m l ) ;  6 )  T G F - p l .  B) C C R 5  e x p r e s s i o n .  A s  A )  a b o v e .  T o p  b l o t  o f  e a c h  p a n e l  
s h o w s  a  b l o t  h y b r i d i s e d  w i t h  a  p r o b e  f o r  e i t h e r  C C R 1 o r  C C R 5 ,  w h i l s t  t h e  b o t t o m  
b l o t  i n  e a c h  p a n e l  s h o w s  t h e  s a m e  b l o t  s t r i p p e d  a n d  r e p r o b e d  f o r  p - A c t i n .  T h i s  
f i g u r e  i s  r e p r e s e n t a t i v e  o f  3  s e p a r a t e  e x p e r i m e n t s .
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Figure 6.21 Scatchard analysis of the effect of GM-CSF on the binding of 
125I M IP-la to M IP-la receptors on BMM.
B M M  w e r e  t r e a t e d  f o r  1 6  h  w i t h  e i t h e r  a  P B S / 0 . 1 %  B S A  c o n t r o l  o r  w i t h  
G M - C S F  ( 1 0  n g / m l ) .  R a d i o l i g a n d  d i s p l a c e m e n t  s t u d i e s  w e r e  t h e n  p e r f o r m e d  
e i t h e r  w i t h  o r  w i t h o u t  t h e  a d d i t i o n  o f  v a r i a b l e  a m o u n t s  o f  c o l d  c o m p e t i t o r  
M I P - l a .  T o  e l i m i n a t e  s e l f - a g g r e g a t i o n ,  t h e  M I P - l a  u s e d  i n  t h i s  e x p e r i m e n t  
w a s  t h e  n o n - a g g r e g a t i n g  P M 2  m u t a n t  ( G r a h a m  et al  1 9 9 4 ) .  T h i s  a n a l y s i s  
r e p r e s e n t s  d a t a  d e r i v e d  f r o m  a  s i n g l e  e x p e r i m e n t .
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■  C O N T R O L  
□  G M - C S F
Figure 6.22 Plot of the effect of GM-CSF on BMM M IP-la receptor numbers.
D a t a  o b t a i n e d  f r o m  r a d i o l a b e l l e d  b i n d i n g  s t u d i e s  ( a s  s h o w n  i n  f i g u r e  6 . 9 . 1 ) ,  w a s  
a n a l y s e d  u s i n g  t h e  ‘ l i g a n d ’ s o f t w a r e  p a c k a g e ,  f r o m  w h i c h  t h e  n u m b e r  o f  c e l l  s u r f a c e  
M I P - l a  r e c e p t o r s  w a s  d e t e r m i n e d  ( a s  i n d i c a t e d  o n  t h e  Y  a x i s ) .
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cell, equating to approximately a 130 % increase (summarised in figure 6.22). It was 
not possible to determine exactly which MIP-a receptor was being elevated on BMM, 
following GM-CSF treatment, using the binding studies as performed herein. 
However, given the fact that BMM appear to express only CCR1 and CCR5, it is 
highly likely that the observed increase in MIP-la receptor numbers could only be 
attributable to expression of one of these two receptors. Further support for this is 
provided by the similarity of Kd values observed in this study, to those previously 
reported for murine CCR1 (Nibbs et al 1996). Given the fact that the Scatchard 
analysis suggested only a single class of MIP-la receptor, coupled with the previous 
failure to detect any increase in the expression of other known MIP-la receptors, it is 
most likely that an increase in the level of CCR1 was responsible for the observed 
increase in number of macrophage MIP-la cell surface receptors following GM-CSF 
treatment. It is also theoretically possible however, that this increase could have been 
due in part to an increase in an as yet unidentified MIP-la receptor present on BMM, 
though the apparent existence of only a single class of MIP-la receptor would suggest 
otherwise.
6.10 Effect of GM-CSF on the Ability of Cells Expressing MIP-la Receptors to 
Mobilise Calcium in Response to MIP-la
6.10.1 Effect of GM-CSF on the ability of BMM to mobilise calcium in response 
to MIP-la
The data obtained from the binding studies on BMM, as indicated in the above 
section, suggested that treatment of BMM with GM-CSF resulted in an increase in the 
total number of MIP-la receptors. This increase was in the region of 130 % and it is 
certainly feasible to speculate that an increase of this magnitude might be sufficient to 
result in an alteration in the functional response of GM-CSF stimulated BMM to MIP- 
la , relative to control BMM. One widely used standard for assessing the functional 
interaction between a chemokine and its receptor, is the ability of the activated 
receptor to mobilise calcium from intracellular stores within the cytoplasm. This can 
be measured in vitro, using the technique of ‘calcium fluxing’. Therefore, the effect of
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a 16 h GM-CSF stimulation on the ability of BMM to mobilise calcium was 
measured, according to previously detailed methods (see methods).
HEK-293 cells transfected with human CCR5, were included as a positive 
control and to verify the functional ability of the exogenously added recombinant 
MIP-la. Figure 6.23 shows one such experiment. The addition of MIP-la (100 
ng/ml), as indicated by an arrow, resulted in only a tiny flux peak in BMM and this 
was observed in both unstimulated and GM-CSF stimulated BMM (Panels B and C). 
This is more evident when the fluxes obtained with BMM were compared to those 
obtained with the control HEK-293 cells transfected with hCCR5 (panel A). Although 
the fluxes did appear to be extremely small, the results of the experiment shown in 
figure 6.23, suggest that GM-CSF may have a potential effect on the ability of BMM 
to mobilise calcium in response to MIP-la. BMM did flux, with a peak of 6 intensity 
units (see figure legend 6.23) in the presence of GM-CSF, compared to a peak of 2 
units observed for the control BMM. It should be noted however, that the experiment 
shown in figure 6.23 was the only one to show such an increase and this result was not 
reproducible. In fact, in most cases BMM failed to flux at all.
This data implies that whilst BMM may have the potential ability to flux 
calcium and that this may be enhanced by GM-CSF, this increase was small and 
inconclusive. BMM appear therefore, to be an inappropriate system in which to 
measure calcium mobilisation in response to MIP-la.
6.10.2 GM-CSF induces the expression of CCR1 mRNA in THP-1 cells
As discussed in the above section, BMM appear to be unsuitable cell choice 
for performing calcium flux studies in response to MIP-la. Therefore, in order to 
further analyse the observed effect of GM-CSF on the ability of 
macrophages/monocytes to mobilise calcium in response to MIP-la, another cell type 
was selected. The human pro-monocytic cell line THP-1 had been previously used 
with success for MIP-la calcium flux studies in our laboratory (R.J.B. Nibbs, 
personal communication) and was therefore considered as a suitable alternative. The 
effect of a 4 h addition of GM-CSF (10 ng/ml) on the expression of CCR1 mRNA in 
THP-1 cells was therefore measured by Northern blot analysis and one such 
experiment is shown in figure 6.24. Densitometric analysis showed that treatment of
Figure 6.23 Effect of GM-CSF stimulation on the ability of BMM to mobilise
calcium, in response to M fP-la.
BMM were treated with GM-CSF (10 ng/ml) as indicated below and after this time 
Ca 2+ studies were performed. A) shows HEK-293 cells transfected with human 
CCR5, as a positive control; B) control BMM; C) BMM plus 16 h GM-CSF. The 
point at which M IP-la was added is indicated by an arrow. The Y axis shows the 
intensity of Fura-2-AM emission at 500 nm. This figure is one^3 separate 
experiments.
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Figure 6.24: Northern blot analysis of the effect of human GM-CSF on the 
expression of human CCRl mRNA in THP-1 cells.
T H P - 1  c e l l s  w e r e  t r e a t e d  a s  f o l l o w s :  1 )  c o n t r o l  2 )  4  h  w i t h  h u m a n  G M - C S F  ( 1 0  n g / m l ) .  
T h e  t o p  b l o t  s h o w s  a  b l o t  h y b r i d i s e d  w i t h  a  p r o b e  f o r  h u m a n  C C R l ,  t h e  b o t t o m  p a n e l  
s h o w s  t h e  s a m e  b l o t ,  s t r i p p e d  a n d  r e p r o b e d  f o r  p - A c t i n .  T h i s  f i g u r e  i s  r e p r e s e n t a t i v e  o f  
3  s e p a r a t e  e x p e r i m e n t s .  T h e  n u m b e r s  i n  t h e  t a b l e  b e l o w  s h o w  t h e  r e l a t i v e  l e v e l s  o f  
C C R l  m R N A  f o r  t h e s e  2  e x p e r i m e n t s ,  a s  a s s e s s e d  b y  s c a n n i n g  d e n s i t o m e t r i c  a n a l y s i s  
a n d  n o r m a l i s a t i o n  a g a i n s t  t h e  l e v e l  o f  P - A c t i n  m R N A  i n  c o n t r o l  t r e a t e d  c e l l s .  *  =  d a t a  
s h o w n  i n  t h e  f i g u r e  o p p o s i t e
Control GM-CSF
hCCRl * 1 . 0 0 * 1 . 7 5
1 . 0 0 1 . 9 0
1 . 0 0 1 . 5 9
Average 1 . 0 0 1 . 7 5
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THP-1 cells with human GM-CSF resulted in approximately a 2-fold increase in the 
level of CCRl mRNA expression, which is of a slightly lower magnitude than that 
observed in BMM. This suggests that THP-1 cells are similar to BMM, in that they 
respond to GM-CSF by upregulating the expression of CCRl and therefore may be a 
more suitable choice of cell, in which to examine the effect of GM-CSF on calcium 
mobilisation.
6.10.3 GM-CSF Does Not Alter the Ability of THP-1 cells to Mobilise Calcium in 
Response to MIP-la
As previously described for BMM, the effect of a 16 h GM-CSF stimulation 
on the ability of THP-1 cells to mobilise calcium was measured. As before, HEK-293 
cells transfected with human CCR5 were included as a positive control (see figure 
6.25 panel A). Figure 6.25, shows that unlike BMM, unstimulated THP-1 cells 
respond well to addition of recombinant MIP-la. However, no increase in the ability 
of THP-1 cells to mobilise calcium was observed following GM-CSF stimulation. 
GM-CSF treated THP-1 cells responded to MIP-la with a peak flux of approximately 
20 units, compared to the peak of 23 units observed with control THP-1 cells 
(compare panel B with panel C). This data suggests that whilst GM-CSF does increase 
the expression of CCRl, this increased expression does not alter the ability of those 
cells to mobilise calcium and it is possible therefore that the 2-fold increase in CCRl 
expression is not functionally relevant. Although as discussed previously in section
6.10.1, a functional increase in BMM in response to MIP-la still remains a theoretical 
possibility, as the experiments shown in figure 6.25 were performed in THP-1 cells.
6.11 Analysis of MIP-la Expression in GM-CSF Transgenic Mouse Tissues
6.11.1 Overview: A potential link between MIP-la and the pathologies observed 
in GM-CSF transgenic mice
So far, the results presented in this study have indicated a role for GM-CSF in 
the regulation of MIP-la expression in vitro. Therefore, it was decided to examine the 
possibility that GM-CSF might be an important regulator of MIP-la function in vivo. 
As discussed in the introduction, derivation and analysis of GM-CSF transgenic mice 
has previously been reported (Lang et al 1987). These mice are characterised by
Figure 6.25 Effect of GM-CSF stimulation on the ability of THP-1 cells to
mobilise calcium, in response to MIP-la.
THP-1 cells were treated with human GM-CSF (10 ng/ml) as indicated below and 
after this time Ca 2+ studies were performed. A) shows HEK-293 cells transfected 
with human CCR5, as a positive control; B) control THP-1; C) THP-1 plus 16 h 
GM-CSF. The point at which MIP-la was added is indicated by an arrow. This 
figure is representative of 3 separate experiments. The Y axis shows the intensity 
of Fura-2-AM emission at 500 nm.
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several unusual phenotypic abnormalities, many of which involve the actions of 
macrophages. Perhaps the most striking of these, is the macrophage infiltration and 
defects associated with the abnormal development of the mouse eye in GM-CSF 
transgenic mice (Cuthbertson and Lang 1989). In GM-CSF transgenic mice, 
macrophages are autostimulated and produce elevated levels of IL-la, bFGF and TNF 
(Lang et al 1992). In addition to the ocular defects, GM-CSF transgenic mice also 
exhibit infiltration of inflammatory cells into the pleural and peritoneal cavities and 
within striated muscle. As discussed in the introduction, MIP-la is clearly an 
important mediator of both haemopoietic and inflammatory functions and is known to 
be expressed in many disease states, particularly within the lungs. Fahey et al (1992) 
also previously demonstrated that MIP-la was capable of increasing the expressing of 
proinflammatory cytokines, such as IL-1 and TNF. The finding that GM-CSF is a 
potent stimulator of MIP-la expression in macrophages, together with the importance 
of macrophages as a source of MIP-la and the predominant involvement of 
macrophages in the various pathologies observed in GM-CSF transgenic mice, 
suggests that MIP-la might be expressed at an elevated level in these GM-CSF 
transgenic mice and maybe involved in the migration of monocytes and macrophages 
in this animal model. It is therefore possible that MIP-la could be involved in the 
pathologies observed in these transgenic mice. The expression of MIP-la in selected 
tissues of wild type and GM-CSF transgenic mice was therefore examined, to 
determine if the expression of MIP-la was elevated in transgenic mice relative to wild 
type mice.
6.11.2 RT-PCR analysis of MIP-la expression in GM-CSF transgenic tissues
Using mRNA isolated from tissue samples frozen in liquid nitrogen 
immediately following excision, the highly sensitive technique of RT-PCR analysis 
was used to investigate the expression of MIP-la mRNA in eye, bone marrow, leg 
muscle and peritoneal cells derived from wild type and GM-CSF transgenic mice. The 
expression of the house keeping gene p-Actin was also examined in parallel, in an 
attempt to determine the relative amount of RNA input in each reaction. To allow any 
observed changes in expression to be more accurately assessed and observed during 
the log phase of amplification, samples were analysed after 15, 20, 25, 30 and 35
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cycles by agarose gel electrophoresis and subsequent Southern blotting of gels. 
Densitometric analysis was performed on the resulting autoradiographs and the level 
of MIP-la expression determined in GM-CSF transgenic samples, relative to wild 
type samples and to the level of p-Actin expression observed.
6.11.3 MIP-la expression appears elevated in the eyes of GM-CSF transgenic 
mice
Panel A of figure 6.26 shows the expression of MIP-la in wild type and 
transgenic mouse eye, as detected by RT-PCR analysis, whilst panel B below shows 
the expression of p-Actin. RT-PCR analysis revealed that expression of MIP-la was 
only barely visible in wild type eye after 35 cycles of PCR, although an additional 
band approximately 120 bp larger than expected appeared to be amplified in the wild 
type eye after 30-35 cycles (indicated by the arrows in figure 6.26, panel A; lanes 4 
and 5). Expression of bands of the expected size, but not of the larger size observed in 
the wild type eye, were however clearly visible in the GM-CSF transgenic eye after 30 
to 35 cycles (see figure 6.26, panel A; lanes 9 and 10; position indicated by lower 
arrow). Also included was a BMM RNA positive control for MIP-la (figure 6.26, 
panel A; lane 11). Figure 6.26, panel B; shows the expression of p-Actin to be very 
similar between the wild type and transgenic samples. The weak, but nevertheless 
detectable, expression of MIP-la observed in the wild type eye, was highly 
unexpected and the source of this expression remains unknown.
Figure 6.27 shows a subsequent Southern blot analysis of the gels shown in 
figure 6.26, with probes specific for MIP-la (panel A) and p-Actin (panel B). 
Analysis of these blots, in conjunction with the results shown in figure 6.26, revealed 
several things. Firstly, the MIP-la specific probe appeared only to hybridise to the 
band corresponding to the expected size of MIP-la and the larger band observed in 
the wild type eye by RT-PCR analysis was not detectable, even after prolonged 
exposure of the autoradiographs (see figure 6.27, panel A; lanes 4 and 5). Secondly, in 
support of the similar observation made in the RT-PCR analysis, the level of MIP-la 
expression appeared to be elevated in the GM-CSF transgenic eye when compared to 
that of the wild type (see figure 6.27, panel A; compare lanes 9 and 10 with those of 
lanes 4 and 5). Thirdly, some hybridisation was visible to bands corresponding to the
Figure 6.26: RT-PCR analysis of MIP-la expression in wild type and 
GM-CSF transgenic mouse eye.
Panel A, shows the results of an RT-PCR analysis for the detection of 
M IP-la mRNA, resolved by agarose gel electrophoresis. The arrow to the 
left of the gel indicates the position of the M IP-la mRNA product 
(expected size of ~267 bp), whilst the arrow above this, marked with a ?, 
indicates the relative position of a second unidentified band. Lanes 1-5 
show analysis of wild type mouse eye and 6-1 0 that of. GM-CSF transgenic 
eye. They represent PCR reactions performed for 15, 20, 25, 30 and 35 
cycles respectively. Lane 11 is a positive control for MIP-la, that shows a 
reaction performed with BMM RNA, whilst lane 12 shows a positive 
control for the PCR reaction performed using genomic DNA, Panel B, 
shows an identical analysis, performed in parallel, using primers specific for 
the detection of P-Actin, The lane assignments for lanes 1-10 are as 
indicated for A above. This figure represents a single experiment.
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Figure 6.27: Southern blot analysis of MIP-la and P-Actin expression 
detected by RT-PCR analysis, in wild type and GM-CSF transgenic mouse 
'eye...........................................................................................................................
Southern blot analyses were performed on the agarose gels shown in figure 6.26. 
Panel A, shows a blot hybridised with a probe for MIP-la. The lane assignments 
for lanes 1-11 are exactly as in the legend for figure 6.26. The lower arrow to the 
left of the blot indicates the position of the M IP-la band, the upper arrow (marked 
with GC) indicates the expected size of genomic DNA (~1 Kb). Panel B, shows a 
blot hybridised with a probe for P-Actin. The lane assignments for lanes 1-10 are 
as indicated in the legend for figure 6.26. The numbers in the table below represent 
an approximation of the relative levels of M IP-la product, as assessed by scanning 
densitometric analysis and normalisation to calculated p-Actin levels. They 
represent data from a single experiment.
Wild Type GM-CSF transgenic
30 Cycles 1.0 2.14
35 Cycles 1.0 5.50
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MIP-lcc
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expected size of genomic DNA, suggestive of contamination (see figure 6.27 panel A 
lanes 4 and 5). Indeed, very weak expression of bands corresponding to the expected 
size of genomic MIP-la were visible on the original gel, though these are not in fact 
visible in the image shown in figure 6.26. Figure 6.27; panel B, shows that expression 
of P-Actin was similar between wild type and GM-CSF samples, suggesting that the 
initial amount of RNA input to the RT-PCR reactions was very similar. However, it 
should be noted that the observed expression of p-Actin, as shown in figure 6.27, does 
not exactly reflect that observed in the gel analysis shown in figure 6.26. It is possible 
that this reduction may be the result of incomplete transfer of DNA from the gel, 
during the blotting process. Densitometric analysis showed that this increase in MIP- 
l a  expression was between approximately 2 and 6-fold. Attempts to sub-clone and 
sequence the larger sized band observed only in the wild type eye, proved 
unsuccessful and therefore the exact nature of this unidentified band remains 
unknown.
In summary, these results suggested that the expression of MIP-la mRNA 
may be elevated in the eyes of GM-CSF transgenic mice.
6.11.4 MIP-la expression may be elevated in the bone marrow of GM-CSF 
transgenic mice
Insufficient bone marrow material was available to allow, either the derivation 
of BMM, or the sorting of cell populations from total bone marrow. Therefore, the 
expression of MIP-la was examined by RT-PCR analysis using total bone marrow 
cells derived from wild type and GM-CSF transgenic mice, in a manner identical to 
the analysis performed in section 6.11.3. Products were resolved as before, by agarose 
gel electrophoresis and figure 6.28 shows the results of this analysis. Panel A shows 
the expression of MIP-la, whilst panel B shows that of p-Actin. Expression of MIP- 
la  was just visible in wild type bone marrow after 30 cycles of PCR and was clearly 
visible after a further 5 cycles (figure 6.28, panel A; lanes 4 and 5). In GM-CSF 
transgenic bone marrow this expression appeared to be very slightly elevated relative 
to the expression observed in wild type samples, with a small increase after 30 cycles 
and a more visibly evident increase after 35 cycles (see figure 6.28, panel A; compare 
lane 4 with lane 9, and lane 5 with lane 10). Also included was a genomic control
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( l a n e  1 1 )  a n d  a  p o s i t i v e  P C R  c o n t r o l  ( l a n e  1 2 ) .  I t  s h o u l d  a l s o  b e  n o t e d  t h a t  s o m e  
g e n o m i c  M I P - l a  e x p r e s s i o n  a p p e a r s  e v i d e n t  i n  w i l d  t y p e  b o n e  m a r r o w  s a m p l e s ,  
t h o u g h  t h i s  i s  n o t  e v i d e n t  f r o m  t h e  g e l  a s  r e p r o d u c e d  h e r e .  T h e  p r e s e n c e  o f  t h i s  m a y  
h a v e  r e s u l t e d  i n  s e q u e s t r a t i o n  o f  r e a c t i o n  c o m p o n e n t s  a n d  t h u s  a  r e d u c e d  
a m p l i f i c a t i o n  r e l a t i v e  t o  t h a t  o f  G M - C S F  t r a n s g e n i c  s a m p l e s .  P a n e l  B  o f  f i g u r e  6 . 2 8  
s h o w s  t h a t  t h e  e x p r e s s i o n  o f  P - A c t i n  w a s  n o t  t h e  s a m e  i n  w i l d  t y p e  a n d  G M - C S F  
t r a n s g e n i c  s a m p l e s  a n d  t h e  r e a s o n  f o r  t h i s  d i s c r e p a n c y  i s  u n c l e a r .  F i g u r e  6 . 2 9  s h o w s  a  
S o u t h e r n  b l o t  a n a l y s i s  o f  t h e  s a m e  g e l s  a s  s h o w n  i n  f i g u r e  6 . 2 8 .  U n e x p e c t e d l y ,  t h i s  
s h o w s  t h a t  t h e  g r e a t e s t  l e v e l  o f  M I P - l a  e x p r e s s i o n  a p p e a r e d  t o  o c c u r  a f t e r  3 0  c y c l e s ,  
a n d  w a s  a c t u a l l y  d e c r e a s e d  a f t e r  3 5  c y c l e s  ( s e e  f i g u r e  6 . 2 9 ,  p a n e l  B ;  l a n e s  4 - 5  a n d  9 -  
1 0 ) .  T h e  e x p r e s s i o n  a p p e a r e d  t o  b e  i n c r e a s e d  i n  G M - C S F  t r a n s g e n i c  b o n e  m a r r o w ,  
r e l a t i v e  t o  t h a t  o b s e r v e d  i n  t h e  w i l d  t y p e  ( c o m p a r e  l a n e s  4  a n d  9 ) .  L a n e  1 1  s h o w s  t h e  
p o s i t i v e  c o n t r o l  ( p r e v i o u s l y  l a n e  1 2  i n  f i g u r e  6 . 2 8 ) .  P a n e l  B  o f  f i g u r e  6 . 2 9  s h o w s  t h e  
e x p r e s s i o n  o f  p - A c t i n  a n d  c l e a r  d i f f e r e n c e s  i n  t h e  p a t t e r n  o f  p - A c t i n  e x p r e s s i o n  a r e  
e v i d e n t ,  c o m p a r e d  t o  t h a t  p r e v i o u s l y  o b s e r v e d  i n  p a n e l  B  o f  f i g u r e  6 . 2 8 .  T h e  r e a s o n s  
f o r  t h e  i n c o n s i s t e n c i e s  o b s e r v e d  i n  t h i s  e x p e r i m e n t  a r e  i n e x p l i c a b l e  a n d  i t  i s  t h e r e f o r e  
d i f f i c u l t  t o  d r a w  a n y  f i r m  c o n c l u s i o n s  f r o m  t h i s  d a t a . .  I t  s h o u l d  b e  b o m  i n  m i n d  
h o w e v e r ,  t h a t  t h i s  e x p e r i m e n t  c o u l d  o n l y  b e  p e r f o r m e d  o n c e  d u e  t o  t h e  l i m i t e d  a m o u n t  
o f  s a m p l e  m a t e r i a l  a v a i l a b l e  a n d  t h e s e  r e s u l t s  a r e  t h e r e f o r e  c l e a r l y  n o t  c o n c l u s i v e .  I t  i s  
p o s s i b l e  h o w e v e r ,  t h a t  t h e  r e s u l t s  o b t a i n e d  f r o m  t h e  R T - P C R  a n a l y s i s  a r e  i n d e e d  
c o r r e c t .  I f  t h i s  w e r e  t h e  c a s e ,  t h e n  t h i s  w o u l d  i n d i c a t e  t h a t  a n  e l e v a t e d  l e v e l  o f  M I P - l a  
e x p r e s s i o n  m a y  o c c u r  i n  t h e  b o n e  m a r r o w  o f  G M - C S F  t r a n s g e n i c  m i c e ,  c o m p a r e d  t o  
t h a t  o b s e r v e d  f o r  w i l d  t y p e .  I f  t r u e  t h i s  r e s u l t  w o u l d  b e  s u r p r i s i n g ,  i n  t h e  l i g h t  o f  t h e  
r e p o r t e d  o b s e r v a t i o n  t h a t  t h e  G M - C S F  t r a n s g e n e  w a s  n o t  d e t e c t a b l e  i n  t h e  b o n e  
m a r r o w  o f  G M - C S F  t r a n s g e n i c  m i c e  ( L a n g  et al  1 9 8 7 ) .  H o w e v e r ,  i t  s h o u l d  b e  n o t e d  
t h a t  e l e v a t e d  l e v e l s  o f  G M - C S F  w e r e  p r e v i o u s l y  r e p o r t e d  t o  b e  d e t e c t a b l e  i n  t h e  s e m m  
o f  G M - C S F  t r a n s g e n i c  m i c e  c o m p a r e d  t o  c o n t r o l  m i c e  ( L a n g  et al  1 9 8 7 )  a n d  t h i s  
c o u l d  p r o v i d e  a n  e x p l a n a t i o n  f o r  a n y  i n c r e a s e  i n  M I P - l a  e x p r e s s i o n  t h a t  m i g h t  
t h e o r e t i c a l l y  o c c u r .  D u e  t o  t h e  v e r y  l i m i t e d  a v a i l a b i l i t y  o f  s a m p l e  m a t e r i a l  a n d  t h e  
i n c o n c l u s i v e  r e s u l t s  o b t a i n e d ,  t h i s  e x p e r i m e n t  s h o u l d  c l e a r l y  b e  r e p e a t e d  w i t h  f r e s h  
m a t e r i a l .
Figure 6.28: RT-PCR analysis of MIP-la expression in wild type and 
GM-CSF transgenic mouse bone marrow.
Panel A, shows the results of an RT-PCR analysis for the detection of 
M IP-la mRNA, resolved by agarose gel electrophoresis. The arrow to the 
left of the gel indicates the position of the M IP-la mRNA product. Lanes 
1-5 show analysis of wild type mouse bone marrow and 6-10 that of GM- 
CSF transgenic bone marrow. They represent PCR reactions performed for 
15, 20, 25, 30 and 35 cycles respectively. Lane 11 shows a positive control 
for the PCR reaction performed using genomic DNA, whilst the reaction 
shown in lane 12 is a positive control for MIP-la performed using MIP-la 
cDNA. Panel B, shows an identical analysis, performed in parallel, using 
primers specific for the detection of P-Actin. The lane assignments for lanes 
1-10 are as indicated for A above. This figure represents a single 
experiment.
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Figure 6.29: Southern blot analysis of MIP-la and p-Actin expression 
detected by RT-PCR analysis, in wild type and GM-CSF transgenic bone 
marrow.
Southern blot analyses were performed on the agarose gels shown in figure 6.28 
Panel A, shows a blot hybridised with a probe for MIP-la. The lane assignments 
for lanes 1-10 are exactly as in the legend for figure 6.28, whilst lane 11 represents 
the positive control performed using MIP-la cDNA. The lower arrow to the left 
of the blot indicates the position of the MIP-la band, the upper arrow (marked 
with GC) indicates the expected size of genomic DNA. Panel B, shows a blot 
hybridised with a probe for P-Actin. The lane assignments for lanes 1-10 are as 
indicated in the legend for figure 6.28. The numbers in the table below represent an 
approximation of the relative levels of MIP-la product, as assessed by scanning 
densitometric analysis and normalisation to calculated p-Actin levels. They 
represent data from a single experiment.
Wild Type GM-CSF transgenic
30 Cycles 1.0 5.60
35 Cycles 1.0 0.60
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6.11.5 Expression of MIP-la does not appear elevated in striated muscle or 
peritoneal cells of GM-CSF transgenic mice
Results obtained from eye samples derived from GM-CSF transgenic mice 
indicated that MIP-la expression might be elevated in these mice, compared to wild 
type mice. Whilst these results were only preliminary and not conclusive, they did 
however suggest that examination of other tissues was warranted. The expression of 
MIP-la was therefore examined in samples of leg muscle and peritoneal cells, since 
macrophage infiltrates and dramatically increased numbers of cells have been 
observed in the striated muscle and peritoneal cavities of transgenic mice respectively.
Figure 6.30 shows an RT-PCR analysis of the expression of MIP-la (panel A) 
and p-Actin (panel B) in normal and GM-CSF transgenic leg muscle. A similar level 
of MIP-la expression was observed in GM-CSF transgenic leg muscle, compared to 
that of wild type (see figure 6.30, panel A; compare lanes 1-4 with lanes 5-8). Parallel 
analysis of p-Actin expression revealed that this expression was relatively similar 
between normal and transgenic leg muscle (see figure 6.30, panel B; compare lanes 1- 
4 with lanes 5-8). Positive controls were included in lanes 9-11 and 9-10 of panels A 
and B respectively. A Southern blot of the above experiment confirmed those 
observations, but also suggested that there was slight contamination of samples with 
genomic DNA (see figure 6.31) and this was particularly evident in the GM-CSF 
transgenic leg muscle. The impact of this contamination on a particular RT-PCR 
reaction can not be assessed, but it remains a possibility that heavy genomic 
contamination may have sequestered primers and therefore reduced the amplification 
potential of that particular RT-PCR reaction for available MIP-la mRNA templates.
Figure 6.32 shows an RT-PCR analysis of the expression of MIP-la (panel A) 
and p-Actin (panel B) in normal and GM-CSF transgenic peritoneal cells (PC). 
Visible MIP-la expression was only observed in wild type PC after 35 cycles of 
amplification (see figure 6.32, panel A; lane 5). Parallel analysis of p-Actin expression 
revealed that the expression was lower in transgenic PC compared to wild type PC 
(see figure 6.32, panel B; compare lanes 6-10 with lanes 1-5). These differences in p- 
Actin expression may explain why no MIP-la expression was observed in the RT- 
PCR analysis of GM-CSF transgenic PC. Positive controls were included in lanes 11 
and 12. Figure 6.33 shows a Southern blot analysis of the same experiment, with panel
Figure 6.30: RT-PCR analysis of MIP-la expression in wild type and 
GM-CSF transgenic mouse leg muscle.
Panel A, shows the results of an RT-PCR analysis for the detection of 
M IP-la mRNA, resolved by agarose gel electrophoresis. The arrow to the 
left of the gel indicates the position of the MGP-la mRNA product. Lanes 
1-4 show analysis of wild type mouse leg muscle and 5-8 that of GM-CSF 
transgenic leg muscle. They represent PCR reactions performed for 20, 25, 
30 and 35 cycles respectively. Lane 9 is a positive control for the RT 
reaction performed using BMM RNA, lane 10 is a positive control for the 
PCR reaction performed using genomic DNA, whilst lane 11 is another 
positive control performed using genomic DNA Panel B, shows an 
identical analysis, performed in parallel, using primers specific for the 
detection of P-Actin. The lane assignments are as indicated for A above, 
with the exception of positive controls for the PCR performed with 
genomic DNA (lane 9) and p-Actin cDNA (lane 10). This figure represents 
a single experiment.
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Figure 6.31: Southern blot analysis of MIP-la and p-Actin expression 
detected by RT-PCR analysis, in wild type and GM-CSF transgenic leg 
muscle.
Southern blot analyses were performed on the agarose gels shown in figure
6.12.4.1. Panel A, shows a blot hybridised with a probe for MIP-la. The lane 
assignments for lanes 1-9 are exactly as in the legend for figure 6.30, with the 
exception of lanes 10 and 11 which have not been included. The lower arrow to 
the left of the blot indicates the position of the M IP-la band, the upper arrow 
(marked with GC) indicates the expected size of genomic DNA. Panel B, shows a 
blot hybridised with a probe for P-Actin. The lane assignments for lanes 1-8, are as 
indicated in the legend for figure 6.30, The numbers in the table below represent an. 
approximation of the relative levels of M IP-la product, as assessed by scanning 
densitometric analysis and normalisation to calculated P-Actin levels. They 
represent data from a single experiment.
Wild Type GM-CSF transgenic
35 Cycles 1.0 0.60
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Figure 6.32: RT-PCR analysis of M IP-la expression in wild type and
GM-CSF transgenic mouse peritoneal cells.
Panel A, shows the results of an RT-PCR analysis using primers specific 
for the detection of M IP-la mRNA, resolved by agarose gel 
electrophoresis. The arrow to the left of the gel indicates the position of the 
M IP-la mRNA product. Lanes 1-5 show, analysis of.wild, type mouse 
peritoneal cells and 6-10 that of GM-CSF transgenic peritoneal cells. They 
represent PCR reactions performed for 15, 20, 25, 30 and 35 cycles 
respectively. Lanes 11 is a positive control for the PCR reaction performed 
with genomic DNA, whilst lane 12 shows a positive control reaction for 
M IP-la performed using M IP-la cDNA. Panel B, shows an identical 
analysis, performed in parallel, using primers specific for the detection of (3- 
Actin. The lane assignments for lanes 1-10 are as indicated for A above, 
This figure represents a single experiment.
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Figure 6.33: Southern blot analysis of M IP-la and P-Actin expression
detected by RT-PCR analysis, in wild type and GM-CSF peritoneal cells.
Southern blot analyses were performed on the agarose gels shown in figure 6.32 
Panel A, shows a blot hybridised with a probe for MIP-la. The lane assignments 
for lanes 1-10 are exactly as in the legend for figure 6.32. The arrow to the left of 
the blot indicates the position of the M IP-la band. Panel B, shows a blot 
hybridised with a probe for P-Actin. The lane assignments for lanes 1-10 are as 
indicated in the legend for.figure 6.32. The numbers in the table below represent an 
approximation of the relative levels of MDP-la product, as assessed by scanning 
densitometric analysis and normalisation to calculated P-Actin levels. They 
represent data from a single experiment.
Wild Type GM-CSF transgenic
35 Cycles 1.0 0.60
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A showing MIP-a expression and panel B that of P-Actin. This indicates that some 
expression of MIP-la was visible in both normal and GM-CSF transgenic PC after 35 
cycles, although this GM-CSF transgenic expression was not visible in the RT-PCR 
analysis as previously shown in figure 6.32. The southern blot analysis of P-Actin 
expression (as shown in figure 6.33) support the RT-PCR analysis of p-Actin 
expression, confirming lower P-Actin expression in the GM-CSF transgenic PC 
compared to wild type PC. This suggests that differences in the original amount of 
input mRNA may have occurred during the setting-up of the RT-PCR reactions. No 
genomic DNA contamination was detected in any of the lanes. Densitometic analysis of 
the levels of MIP-la expression (see figure 6.33, panel A; compare lane 5 with lane 
10) with thpse of P-Actin expression (see panel B) revealed that essentially the same 
levels of MIP-la expression occurred in PC from GM-CSF transgenic mice, as did in 
PC from normal mice.
In summary, these results indicate that whilst the level of MIP-a expression 
may be elevated in the eye and bone marrow of GM-CSF transgenic mice, compared to 
wild type mice, the level does not appear to be elevated in the leg muscle and 
peritoneal pells. It should be noted, that due to the very limited amount of sample 
material, these experiments were only performed once and therefore the analysis of the 
results can not be totally conclusive. They do however suggest that elevated levels of 
MIP-la may exist in specific tissues within GM-CSF transgenic mice, compared to 
normal mice and a more extensive analysis of these observations would perhaps be 
informative. In the light of the preliminary observations indicated previously in section 
6.11, it was decided to further analyse the expression of M IP-la in GM-CSF 
transgenic tissues, using the technique of in situ hybridisation. Analysis of frozen 
tissue sections from eye, leg muscle and peritoneal cells was performed using this 
technique, but unfortunately proved uninformative.
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CHAPTER 7: DISCUSSION
7.1 Introduction
One of the most obvious conclusions resulting from the research that has 
accumulated over the past 20 years or so, into the functions of the multitude of 
haemopoietic growth factors and cytokines that act upon the immunohaemopoietic 
system, is the enormous complexity of the regulatory mechanisms in which they are 
involved. As discussed previously in section 1.8, there exists a large interacting 
network of cytokines that exhibit a large degree of functional overlap and potential for 
redundancy. Our laboratory is particularly interested in the role of M IP-la in the 
regulation of stem cell proliferation and previous research has attempted to dissect the 
interactive relationship between MIP-la and another inhibitor of haemopoietic stem 
cell proliferation, TGF-pl. As a result of this investigation it is now believed that MIP- 
la  and TGF-pi have an endogenous, reciprocal relationship in the bone marrow, in 
which TGFrpl probably functions to suppress the expression of M IP-la (Maltman et 
al 1993, 1996). A study by Cluitmans et al (1995) has however, demonstrated the 
simultaneous presence of both TGF-Pl and MIP-la in the bone marrow and 
peripheral blood of normal individuals. Clearly therefore, in addition to suppressive 
factors such as TGF-pl, the expression of MIP-la also must be regulated by positively 
acting factors. To date, our understanding of the regulatory mechanisms controlling the 
expression pf MIP-la is minimal, particularly with regard to its regulation within the 
bone marrow. The focus of this thesis has therefore been to attempt to further 
understand the regulation of MIP-la expression, with a particular emphasis on its role 
within this complex network of regulatory cytokines. One very important point that 
must be considered in such an investigation, is that M IP-la (as well as many other 
cytokines involved in this network) functions as both a haemopoietic and inflammatory 
regulator. Any conclusions resulting must therefore consider both these aspects, as 
conclusions regarding inflammatory functions may be informative about haemopoietic 
functions and vice versa. For the purposes of this discussion, although inflammation is 
a natural part of haemopoiesis, they will be considered as being distinct. Thus in this 
discussion, the term haemopoiesis will refer to constitutive and inducible haemopoiesis, 
such as that occurring during the generation of mature end cells. The term
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inflammation will be used in the context of ‘inflammatory functions’, such as histamine 
release, phagocytosis, etc. and particularly with regard to mature immune cells.
The primary source of MEP-la within the bone marrow is considered to be the 
macrophage. Previous studies in our laboratory have successfully used the well 
characterised bone marrow-derived macrophage (BMM) and this was therefore 
selected as a cell system in which to examine the regulation of M IP-la expression. 
The initial investigations sought to identify haemopoietic cytokines as potential 
regulators of MIP-la expression. The results shown in figure 6.1, demonstrate that 
neither G-CSF, IL-6, nor LIF had any visible effects on the expression of M IP-la in 
BMM. Receptors for LIF, G-CSF and IL-6 have all been reported to be expressed on 
macrophages (Hilton et al 1988, Shieh et al 1991, Lotem and Sachs 1987. This 
suggests that the lack of response of BMM to LIF, G-CSF and IL-6 is not due to the 
absence of expression of receptors for these cytokines. In contrast however, figure 6.2 
shows that GM-CSF did affect MIP-la expression, resulting in a marked increase in 
the levels of MIP-la mRNA. Given the many known haemopoietic and inflammatory 
functions of GM-CSF, particularly with regard to cells of the monocyte / macrophage 
lineage, this observation was of considerable interest. It was therefore decided to 
examine the role of GM-CSF and related cytokines in the regulation of M IP-la 
expression, in greater detail.
7.2 Induction of MIP-la Expression by GM-CSF and EL-3
Initial experiments suggested that GM-CSF is a strong inducer of M IP-la 
expression and to confirm this observation, further investigation was therefore 
performed. The results shown in figures 6.3 and 6.4, demonstrate that GM-CSF rapidly 
induces MIP-la expression and that this is dose dependent. It is likely that this 
induction occurs directly, rather than via induction of a secondary cytokine, since the 
induction is visible within 30 minutes. This is however, merely suggestive and remains 
to be determined. The observed induction even at a low concentration of GM-CSF, 
suggests that GM-CSF is relatively potent in its effects. Figure 6.5 demonstrates that 
the continued presence of either serum or L929 CM is not a prerequisite for the 
inductive effects of GM-CSF stimulation. This implies that GM-CSF is not synergising 
with additional factors present in the serum or L929 CM. Kasama et al
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(1993) previously demonstrated that GM-CSF was able to synergise with LPS to 
increase the level of MIP-la expression in neutrophils, but that GM-CSF alone was 
unable to induce MIP-la expression over a wide range of concentrations. This is in 
contrast to the observations shown in figures 6.2 to 6.5, in which GM-CSF rapidly 
induces MIP-la expression over a wide range of concentrations. The fact that addition 
of a GM-CSF-specific neutralising antibody resulted in the substantial abolishment of 
the GM-CSF induced expression of MIP-la expression, shows that GM-CSF was 
indispensable for this induction. Furthermore, because these experiments were carried 
out under conditions which were designed (as far as possible) to be essentially LPS 
free, it is therefore unlikely that LPS plays a role in this observed induction of MIP-la 
mRNA by GM-CSF. The contrast in these results to those of Kasama et al (1993), 
suggest that clear differences exist between neutrophils and macrophages in the GM- 
CSF regulated expression of MIP-la expression. It should also be noted that their 
study was performed using human neutrophils, whilst the macrophages used in this 
study were murine in origin. Although the promoters of murine MIP-la and the 
various forms of human MIP-la (LD78) are similar (Widmer et al 1991), with 
approximately 75 % homology within the first 350 bp of proximal promoter 
sequences, it is possible that differences may exist in the regulatory control of MIP-a 
and LD78 acting in the two species. If so, this could be one explanation for the 
observed differences between this study and that of Kasama et al (1993).
It is recognised that increases in mRNA expression are not always followed by 
a corresponding increase in protein expression, which casts doubt on the physiological 
and functional relevance of any changes in mRNA levels that are not reflected at 
protein level. Efforts were therefore made to examine the expression of MIP-la 
protein, following GM-CSF stimulation. The observation that MIP-la protein was 
only detectable following concentration of BMM supernatants (see figure 6.7) was in 
keeping with previous data from our laboratory by Maltman et al (1993) who 
previously reported that the expression of MIP-la protein in unconcentrated BMM 
medium was undetectable using Western blot analysis. Whilst it is unclear whether or 
not full translation of MIP-la mRNA into protein occurs in BMM following GM-CSF 
stimulation, the level of protein seems low compared to the level of mRNA. It is 
theoretically possible therefore that for full translation of mRNAs to occur, an
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additional signal is required. Indeed there is evidence that such mechanisms may 
operate for the CC chemokine RANTES and other cytokines, during the induction 
phase of T cell anergy (Schall et al 1992). Certainly one can speculate that it may be 
desirable to limit expression of a protein with potent inflammatory effects, such that 
this expression only occurs when strictly needed. Indeed one can stretch this 
hypothesis to suggest that expression could be limited to specific niches and locations. 
One possible hypothetical mechanism for such control, could be through the action of 
adhesion molecules and other matrix associated molecules. Expression of these could 
be limited to particular niches or circumstances, such that only when a cell is 
interacting with them, do they provide the necessary secondary stimulus. Therefore, in 
the context of GM-CSF stimulation (for example in the immediate locale of a 
inflammatory infection), GM-CSF would act to prime cells for increased expression of 
MIP-la, but this would only occur following the appropriate secondary signal. It is 
clear however, that some increased protein expression does result from GM-CSF 
stimulation and suggests that regulation of MIP-la expression by GM-CSF is 
physiologically relevant.
As indicated in the introduction, GM-CSF is in fact a member of a small 
subfamily of cytokines and shares extensive functional homology with IL-3, as well as 
the shared usage of the common p-subunit in their respective receptors. In fact GM- 
CSF and IL-3 receptors have previously been suggested to be co-ordinately regulated 
in macrophages (Fan et al 1992), providing further evidence for linkage in their 
actions. The reported overlap in specific functions of GM-CSF and IL-3 suggested that 
IL-3 might also therefore be a candidate regulator of MIP-la expression. Figures 6.8 
A and 6.8 B, demonstrate that IL-3 did indeed appear to exert a very similar effect 
upon MIP-la expression, as did GM-CSF. The kinetics of this expression were 
identical and as with GM-CSF, the dose of IL-3 required to exert a visible increase in 
MIP-la expression was low. Thus, both GM-CSF and IL-3 appear to be strong 
inducers of MIP-la expression. One interesting possibility, reported during the 
writing of this thesis, was evidence for the expression of a pre-formed human GM- 
CSF receptor complex that could be activated by GM-CSF, IL-3 or IL-5 (Woodcock et 
al 1997). This suggests that it is theoretically possible that the observed induction of 
MIP-la expression by IL-3 could be occurring through such a pre-formed receptor
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complex, rather than through the expected IL-3 receptor complex., GM-CSF As 
indicated below, IL-5 was unable to effect MIP-la expression, which suggests that 
this pre-formed receptor complex is not present on BMM. However it is unknown if a 
similar preformed murine receptor complex actually exists.
7.3 Effect of IL-5 on MIP-la Expression
Given the shared ability of GM-CSF and IL-3 to induce MIP-la expression, 
their shared usage of the common p subunit and because IL-5 is a member of this 
same subfamily, with some similar functions and that it also signals through the 
common p subunit, it was considered a possibility that IL-5 may also be able to 
regulate MIP-la expression, in a similar fashion to that observed for GM-CSF and IL- 
3. However, the results presented in figures 6.9 to 6.11, suggest that IL-5 does not 
regulate MIP-la expression in macrophages, or other cells within the murine bone 
marrow. That IL-5 does not effect MIP-la expression in macrophages is perhaps 
obvious and is clearly due to the absence of functional IL-5 receptors. Indeed, Takagi 
et al (1995) previously reported that the lineage specificity of IL-5 was mainly due to 
the limited expression of IL-5Ra chain. Results not presented in this thesis have 
suggested that IL-5 has no apparent effect on MIP-la expression in murine B cells 
lines. It is possible however, that in the B cell lines examined MIP-la may be 
transcriptionally silent. In hindsight, a more appropriate model would perhaps have 
been to analyse the expression of MIP-la in primary human eosinophils. Attempts 
were in fact made to perform this analysis, though they were unsuccessful, due to the 
logistical difficulties involved in obtaining samples, particularly from patients with 
eosinophilia. Therefore, the question of whether IL-5 functions as a regulator of MIP- 
la  expression remains unanswered. Recent evidence from a report by Li et al (1996) 
does suggest however, that IL-5 may have some limited effects on MIP-la expression 
in basophils, though this was reported to be not significant.
7.4 Induction of other CC chemokines by GM-CSF and IL-3
Previously, Takahashi et al (1993) showed that in monocytes, both GM-CSF 
and IL-3 were potent inducers of IL-8 expression, another member of the chemokine 
superfamily. This suggested the possibility that additional members of the chemokine
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superfamily might also be regulated by GM-CSF and IL-3. As can be seen in figures 
6.12 and 6.13, expression of the CC chemokines MIP-1(3, JE and MARC were all 
elevated following GM-CSF and EL-3 treatment. Current evidence suggests that that 
both JE/MCP-1 and MARC/MCP-1 are functionally important as inflammatory 
cytokines (Huffiiagle et al 1995, Stafford et al 1997). This would suggest that their 
induction by GM-CSF and IL-3 is related to a role in inflammatory functions, though it 
should be noted that this does not preclude the involvement of GM-CSF and IL-3 in 
regulating MIP-la expression in the context of haemopoiesis. Several studies have 
attempted fo define regulatory elements involved in controlling the expression of 
various chemokine genes, such as MIP-la, MCP-1, RANTES and MARC (Grove and 
Plumb 1993, Ray et al 1997, Moriuchi et al 1997, Jarmin et al 1994). Current evidence 
suggests that many of these genes may share the presence of common transcription 
factor bindipg sequences within their promoters. It is certainly feasible therefore, that 
factors such as NF-kB, previously identified as being potentially involved in regulating 
the expression of MIP-la and other CC chemokines (Grove and Plumb 1993, 
Moriuchi et al 1997, Ueda et al 1997), may be involved in the regulation of other 
genes within the same family. If this were indeed the case, it is certainly possible to 
hypothesise that one important function of GM-CSF and IL-3, may be to non- 
specifically ppregulate chemokine expression. As discussed earlier, this may relate to a 
potential priming role of GM-CSF and IL-3. The regulatory control of the GM-CSF 
gene appears to be fairly complex. For instance in T cells, multiple signals appear to be 
required for GM-CSF expression to occur and it is evident that elements containing 
binding motifs for transcription factors such as ETS1, API, NFAT, NFATp and NF- 
kB and NF-icB-like are just a few of those that have been implicated in the regulation 
of GM-CSF expression in a variety of cell types (Jenkins et al 1995, Thomas et al 
1997). Indeed, mice deficient in c-rel (a subunit of the NF-icB-like family of 
transcription factors) exhibit defects in the production of GM-CSF and IL-3 
(Gerondakis et al 1996), underlining the importance of this family of transcription 
factors in the regulation of GM-CSF and IL-3 expression. Also of interest is the 
observation that some of these factors have been shown to be involved in the 
regulation pf chemokine expression. Examples include NFAT, in the control of MARC 
expression in allergically triggered murine mast cells (Jarmin et al 1994,
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Prieschel et al 1995) and as already mentioned above, NF-kB in the regulation of 
other chemokines. If these transcription factors are involved in the regulation of both 
GM-CSF or IL-3 and the genes they induce, then this could provide additional 
amplification.
Interestingly, direct support for the observation that GM-CSF and IL-3 were 
potent inducers of selective chemokine gene expression in BMM had been previously 
reported, in a very similar study by Orlofsky et al (1994). In this report, the authors 
investigated the effects of GM-CSF on expression of the CC chemokine CIO in BMM 
and also noted that expression of MIP-la, JE and RANTES was induced in BMM. 
There are several discrepancies observed, between results reported in this study and 
that of Orlofsky et al (1994). They reported that expression of MIP-la was only 
weakly induced by GM-CSF, whilst in contrast the results reported in this work show 
that expression of MIP-la mRNA was markedly induced by GM-CSF. One possible 
explanation for this is that Orlofsky et al stimulated their BMM for 24 h with GM- 
CSF, whereas the results reported herein were achieved with only 4 h stimulation. The 
results discussed in section 6.3.2 suggest that MIP-la expression had declined within 
6 h, following GM-CSF stimulation. It is therefore quite possible that expression of 
MIP-la in response to GM-CSF had declined by 24 h, as reported by Orlofsky et al. 
Another contrast, is that in this study no expression of RANTES was detectable in 
BMM, in concordance with the previous study of Maltman et al (1996), whilst 
Orlofsky and colleagues reported that RANTES was also induced by GM-CSF. 
However, they did acknowledge that this induction could have been due to LPS 
contamination. During the course of all experiments performed and reported in this 
thesis, precautions were taken to ensure that as far as was possible, no LPS was 
present. The authors also reported similar effects by IL-3, but presented no data. 
Whilst some discrepancies exist between this study and that of Orlofsky et al, 
probably due to experimental differences, they do both suggest that GM-CSF and IL-3 
are stimulators of chemokine expression. Moreover, the results presented herein 
extend previous observations, to include the novel observation that MIP-ip and 
MARC are both induced by GM-CSF and IL-3. Whilst it is probable that the 
widespread expression of chemokines in response to GM-CSF and IL-3 is likely to be 
the result of a role in an inflammatoiy context, confirmation of this may only occur
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when the effects of GM-CSF and IL-3 on the expression of a much wider range of 
chemokines are examined. In fact one such novel chemokine, known as MPIF-2, was 
recently clpned and reported to be weakly induced in GM-CSF-treated macrophages 
(Patel et al 1997), providing further evidence that this GM-CSF/EL-3 mediated 
induction may be relatively widespread amongst members of the chemokine 
superfamily.
7.5 TGF-P 1 Suppression of Members of the MIP-la Superfanuly
As discussed in section 3.6.2, previous work in our laboratory has discovered 
that an endogenous, reciprocal relationship exists in BMM, between TGF-P 1 and 
MIP-la. In the light of the findings raised during the course of the work reported in 
this thesis, the effect of TGF-pl on GM-CSF and IL-3 induced M IP-la expression 
was therefore of significant interest. The results in figures 6.14 and 6.15 confirmed 
that TGF-pl was a suppressor of GM-CSF and IL-3 induced M IP-la expression. 
This suppression was however not complete, suggesting that GM-CSF and IL-3 
might be sufficiently potent in their effects to overcome the endogenous block exerted 
by TGF-pi on M IP-la expression. However, it should be noted that it is also equally 
possible to speculate the reverse, namely that TGF-P is sufficient enough to at least 
partially overcome the inductive stimulus of GM-CSF or DL-3. Either of these may 
hold true, and they are not necessarily exclusive. This finding was however of 
significant interest, given the previous report of Cluitmans et al (1995), suggesting 
that some M IP-la expression was detectable in the bone marrow, despite the 
presence of TGF-P 1. It is therefore possible that in vivo GM-CSF and IL-3 may act to 
overcome this TGF-P 1 mediated block. However, the relationship between TGF-P, 
GM-CSF, IL-3 and M IP-la in vivo, is likely to be dynamic and the precise level of 
M IP-la expression may therefore depend upon the relative levels of GM-CSF, IL-3 
and TGF-P at any given time. Indeed, the constitutive expression of GM-CSF within 
the haemopoietic microenvironment has been reported to be somewhat variable. Some 
reports have suggested that constitutive GM-CSF expression does not occur 
(Cluitmans et al 1995), whilst others have documented expression of GM-CSF by 
adherent c^lls within bone marrow cultures (Charbord et al 1991). Clearly however, 
GM-CSF is expressed by a wide variety of cell types and in response to a variety of
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inducing stimuli. More certain is the observation that constitutive IL-3 expression is 
undetectable. However, as discussed previously in the introduction, it is possible that 
such expression may occur in localised niches within the microenvironment or 
following conditions of extreme stress.
The observations made in figure 6.16, that TGF-pl also suppressed JE and 
MARC expression following GM-CSF stimulation suggests, that the suppressive 
effect of TGF-pl is more widespread and therefore probably represents the well 
recognised ability of TGF-pl to function as an immuno-suppressive factor. However, 
this observation does not preclude the possibility that one role of TGF-pl may be to 
suppress the induction of chemokine expression in the bone marrow 
microenvironment, under non-inflamed conditions.
7.6 Expression of CCR1 in BMM is Regulated Differently to that of CCR5, in 
Response to GM-CSF and IL-3
Recently, a greater understanding of the interaction of chemokines with their 
cognate receptors has been achieved. One of the most important reasons for this recent 
increase in understanding, has been due to the explosion of interest in the roles of 
chemokines and chemokine receptors in the progression of HIV pathogenesis. 
However, one area which has remained poorly understood is that of the regulation of 
chemokine receptor expression. Understanding this is clearly important, not just for 
novel aspects of chemokine biology such as HIV infection, but also for understanding 
inflammatory and haemopoietic aspects of chemokine function.
The data shown in figures 6.17 to 6.19 show that the expression of CCR1 is 
induced by GM-CSF and IL-3 in BMM and splenic cells, whilst CCR5 expression is 
unaltered. This suggests that the expression of CCR1 and CCR5 is regulated 
differently. One inference from these results, is that CCR1 and CCR5 may have 
distinct functions. It is possible that expression Of CCR5 may be under a more 
restricted and constitutive control. The reason for this different regulation of 
expression is unclear, but it may reflect some importance of CCR1 over that of CCR5, 
under conditions in which GM-CSF or IL-3 are expressed (i.e. under inflammatory 
conditions). Indeed evidence from recent studies in which CCR1 was deleted in mice, 
have provided clear evidence that CCR1 has a crucial inflammatory role in vivo (Gao 
et al 1997, Gerard et al 1997). Attempts to demonstrate a functional significance of
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this increase in CCR1 expression, by analysis of potential changes in calcium 
mobilisation, were unsuccessful. However as discussed in the results, this remains to 
be determined and may reflect experimental difficulties, rather than a lack of effect of 
GM-CSF on CCR1 expression, in a functional context. The effect of TGF-pl on 
CCR1 and CCR5 expression appears to be minimal, apparently only affecting the 
basal level of expression. The significance of this observation is unclear. Different 
mechanisms for the regulatory control of chemokine receptor expression is not a new 
observation and several reports were published during the course of these studies, 
demonstrating that IL-2 regulated the expression of CCR1, CCR2 and CCR5, but did 
not alter the expression of CXCR1, CXCR2 or CXCR4 (Loetscher et al 1996b, Bleul 
et al 1997). Several reports have also documented suppressive effects of various 
agents, such as LPS, IFN-y, TNF-a and IL-la on chemokine receptor expression (Sica 
et al 1997, Tangirala et al 1997). In fact, Tangirala et al reported that treatment of 
THP-1 cells with GM-CSF resulted in a marked reduction in the expression of hCCR2 
mRNA. Interestingly, in this same study the authors also reported that differentiation 
of THP-1 cells with phorbol myristate acetate (PMA) resulted in an almost complete 
loss of hCCR2 mRNA expression. As indicated in figure 6.19 B, GM-CSF did not 
appear to affect mCCR2 expression. The reason for the difference between this 
finding and that reported by Tangirala et al is unclear, but may be due to the different 
cell systems used and perhaps the difference in differentiation state of BMM 
compared to THP-1. A recent report, published during the course of writing this 
thesis, has provided further and intriguing evidence of the potential complexity of 
chemokine receptor expression. This report by Mummidi et al (1997), provided 
evidence for multiple transcripts for human CCR5 (derived by alternative splicing and 
usage of multiple transcriptional start sites) and the usage of multiple promoters. 
Previous reports have documented alternative splicing for CCR2 (Charo et al 1994), 
and CXCR4 (Heesen et al 1997), suggesting that a complex regulation of gene 
expression and organisation may occur in other chemokine receptors. Future 
investigation of the promoters of the various chemokine receptor genes will no doubt 
yield further understanding of the regulation of their expression. In the context of the 
results presented in this thesis, a comparative analysis of the promoters for murine 
CCR1 and CCR5 following GM-CSF treatment would be a very useful approach to 
further understanding why they appear to be differently regulated.
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No stem-cell inhibitory specific receptor has been reported for MIP-la as yet, 
and current evidence from our laboratory suggests that the inhibitory actions of MIP- 
l a  are not mediated through any of the reported MIP-la receptors (Graham et al 
1996). It is probable that the observed effects of GM-CSF and IL-3 on CCR1 
expression as reported in this work, relate to involvement in an inflammatory 
mechanism. Further understanding and confirmation of this must however, await 
identification of this stem cell inhibitory receptor.
7.7 Analysis of MIP-la Expression in GM-CSF Transgenic Mouse Tissues
The studies discussed in the previous sections, strongly suggest a potent effect 
of GM-CSF and IL-3 on MIP-la expression in vitro. However they have provided 
little insight into any role of GM-CSF or IL-3 in vivo. As discussed in various sections 
in the introduction, analysis of knock out and transgenic mice have in many cases 
proved a useful approach to further understanding the potential in vivo role(s) of 
growth factors and cytokines. As discussed previously in section 2.12, analysis of 
mice overexpressing GM-CSF, as performed by Lang et al (1987), revealed some 
unusual phenotypic abnormalities particularly with regard to macrophage function. It 
was speculated by us, that the levels of MIP-la might be elevated in these mice as a 
result of over expression of GM-CSF and indeed increased expression was previously 
reported for other GM-CSF inducible growth factors in these transgenic mice (Lang et 
al 1992). MIP-la may therefore be ultimately responsible for aspects of the GM-CSF 
transgenic phenotype. It was therefore decided to perform a brief examination of the 
expression of MIP-la in these mice.
It should be pointed out here, that only a very limited amount of material was 
available for examination and therefore any investigation is, by necessity, of a purely 
preliminary nature. However, as can be seen in figures 6.26 to 6.29, RT-PCR analysis 
and subsequent Southern blot analysis did suggest that the level of MIP-la expression 
was elevated in the eye, and perhaps also in the bone marrow, of a GM-CSF 
transgenic mouse, relative to that observed in a wild type littermate control. The 
precise source of this MIP-la in wild type mice eyes is unknown, but may result from 
MIP-la expressing cells within the vasculature of the eye or perhaps even infiltrating 
leukocytes. The elevated expression in the eye of the transgenic mouse was
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unsurprising, given the potent effect of GM-CSF on MIP-la expression. It must be 
pointed out that this observed increase in MIP-la may simply be the result of an 
overall increase in the number of macrophages within the eye, rather than a change in 
the actual level of expression as a result of GM-CSF over expression. An answer to 
this and a determination of the precise cellular source, will have to await in-situ 
hybridisation studies.
Although, as discussed in section 6.11.4, the analysis of the GM-CSF 
transgenic bone marrow sample was inconclusive, the RT-PCR analysis did suggest 
that MIP-la expression might be elevated in the GM-CSF transgenic bone marrow 
compared to the wild type. If this was indeed the case, then this would be somewhat 
unexpected, for the following reason. In the original characterisation of the GM-CSF 
transgenic mice reported by Lang et al (1987), no expression of the GM-CSF 
transgene was reported in the bone marrow of transgenic mice and therefore an 
increase in MIP-la expression may be unexpected. It should be noted however, that 
this original analysis of transgene expression was characterised by Northern blot 
analysis rather than by the more sensitive technique of RT-PCR analysis and it is 
therefore possible that the GM-CSF transgene is indeed expressed at low levels in the 
transgenic mice. Furthermore, the serum levels of GM-CSF were reported to be 
elevated, by a much as 40-fold in GM-CSF transgenics (Lang et al 1987). This could 
provide a possible explanation, if increased MIP-la expression does occur in 
transgenic bone marrow, relative to that of wild type bone marrow. Clearly the above 
discussion is merely speculative and can only be confirmed by repeating this analysis.
The observation that the level of MIP-la expression was unaltered in the 
striated muscle of a transgenic mouse, as indicated in figures 6.30 and 6.31, is perhaps 
surprising in the light of observations made during the initial characterisation of GM- 
CSF transgenic mice by Lang et al 1987). In this, the authors reported that the 
expression of the transgene did not occur in non-infiltrated muscle of GM-CSF 
transgenic mice. Furthermore, this transgene expression was age dependent and was 
actually reported to follow, rather than precede the development of lesions in 
transgenic mice exhibiting infiltrates in their striated muscle. As a result of these 
observations, the authors proposed that macrophage accumulation was unlikely to be 
the direct cause of local GM-CSF expression and suggested that GM-CSF might
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merely prolong the survival of macrophages already present within the striated 
muscle, thus leading to an indirect accumulation of macrophages. The results 
discussed in section 6.11.5 suggest that MIP-la expression is not elevated in the 
striated muscle of GM-CSF transgenic mice. The reason for the discrepancy between 
this result and that expected is unclear. However, as noted previously in section 
6.11.5, some genomic contamination was present in the GM-CSF transgenic samples 
analysed and this may have resulted in the sequestration of primers. If this is indeed 
the case then this might explain the absence of any elevated level of MIP-la 
expression in striated muscle, particularly if the magnitude of any increase was 
relatively small.
GM-CSF transgenic mice show a very striking increase in the cellularity of 
their peritoneal cavities, with 90 % of these peritoneal cells being of an enlarged 
macrophage phenotype and showing characteristics of a functionally activated state. 
Given the potent effect of GM-CSF on macrophages as described during the course of 
this work and the reported expression of the GM-CSF transgene in the peritoneal 
cavity, one would perhaps expect to see an increased expression of MIP-la in 
peritoneal cells derived from a transgenic mouse, compared to the level of expression 
observed in a littermate control. As seen in figures 6.32 and 6.33, this was apparently 
not the case. It should be noted that BMM were used throughout the course of the 
studies reported herein and these may be quite distinct in comparison to other 
macrophages, such as peritoneal macrophages (reviewed by Gordon 1995). Obviously, 
it would be necessary to first compare the effect of GM-CSF on BMM and peritoneal 
macrophage expression of MIP-la, in order to answer this question. It is therefore 
theoretically possible that peritoneal macrophages may respond differently to GM- 
CSF, compared to resident BMM.
Whilst this examination of MIP-la in GM-CSF transgenic mice is only 
preliminary, it does offer some tentative suggestion that MIP-la expression may be 
elevated in specific tissues of transgenic mice, compared to wild type mice. It should 
however be noted that the results of such RT-PCR analysis should always be treated 
with caution, due to the extreme sensitivity of RT-PCR. These results do however, 
suggest that further examination of larger numbers of GM-CSF transgenic mice would 
be warranted, perhaps in conjunction with in situ hybridisation analysis.
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7.8 The Role of GM-CSF, IL-3 and TGF-P in Regulating the Expression of MIP- 
la  in BMM
Previous work in our laboratory identified an endogenous reciprocal 
relationship between MIP-la and TGF-p in BMM. The studies performed during the 
course of this thesis have added yet another layer of regulation to those previously 
identified. The results suggest, that in addition to the suppressive effects of TGF-p, 
stimulation of MIP-la expression is mediated by GM-CSF and IL-3. Moreover, this 
inductive effect may be potent enough to overcome the suppressive block exerted on 
these cells by TGF-p. Taken together this implies that under the appropriate 
conditions, the expression of GM-CSF and IL-3 may be induced and this may be 
sufficient to overcome the TGF-p block on MIP-la expression.
So are these observations pertinent to the regulation of MIP-la during 
haemopoiesis? BMM are an excellent in vitro model cell system, roughly equivalent 
to the resident bone marrow macrophage population that is believed to be the primary 
source of MIP-la in the bone marrow and therefore are ideally suited to the study of 
the regulation of MIP-la expression. Interestingly, the levels of GM-CSF mRNA have 
been reported to increase in the bone marrow and spleens of mice, during the recovery 
period following sublethal irradiation (Chang et al 1995), whilst the levels of TGF-p 
were reported to remain constant. It would be of interest to determine if the level of 
MIP-la expression was also increased, perhaps with a delayed kinetic response 
relative to that of GM-CSF expression? (see section 7.10). If the expression of MIP- 
l a  was delayed with respect to that of GM-CSF, this may suggest that MIP-la 
expression is induced via GM-CSF. If this were indeed the case, then one could 
speculate a role for MIP-la in ‘dampening down’ the proliferation of haemopoietic 
stem cells following irradiation or cytotoxic drug treatment. One interesting approach 
would be to investigate this relationship in both normal and MIP-la deficient mice 
and compare their recovery. Such investigation, coupled with in-situ hybridisation 
studies would also enable the precise cellular sources of this increased GM-CSF 
expression to be identified.
The previous study of Maltman et al (1996) suggested that the suppressive 
effect of TGF-P was relatively restricted to MIP-la and MIP-lp. Studies reported in 
this work have suggested however, that this suppression is probably more widespread,
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with TGF-pl acting to suppress the GM-CSF/IL-3 induced expression of at least two 
additional chemokines, JE and MARC. Current evidence suggests that JE and MARC 
are not functional as inhibitors of stem cell proliferation and therefore the suppressive 
effect of TGF-p may be related to its widely documented role as an immuno­
suppressive molecule. It is equally possible therefore, that the observed ability of GM- 
CSF and IL-3 to induce the expression of JE and MARC in addition to that of MIP-la 
and MIP-ip, may also be more related to pro-inflammatory processes than to stem cell 
proliferative control. However this observation does not rule out the involvement of 
GM-CSF or IL-3, in stem cell proliferative control. As discussed in the introduction, 
GM-CSF, IL-3 and TGF-p are just three such factors and there are a multitude of 
additional growth factors, cytokines, receptors, adhesion molecules and other 
regulatory mechanisms, that could impinge upon their interactions. One must also 
consider the fact that these factors may function within highly localised niches in the 
bone marrow microenvironment, possibly through interaction with molecules such as 
proteoglycans that may act to sequester or even actively present growth factors and 
chemokines to target cells. Clearly, an in vitro culture system such as BMM can not 
provide a full re-creation of the complex environment of the bone marrow. Additional 
levels of control may also exist, such as through endogenous interactions between 
MIP-la, GM-CSF and IL-3, and between TGF-P, GM-CSF and IL-3 and their 
receptors. Additionally, other cells besides macrophages are likely to be important in 
this co-ordinated regulation. The use of long-term bone marrow cultures, could 
provide a better model system in which to investigate the importance of these 
additional factors and cellular interactions.
The precise implications of the differences observed in the regulation of MIP- 
l a  receptor expression remains unclear. No firm functional support could be observed 
for the observations made regarding the effect of GM-CSF at the level of mRNA 
expression, as determined by comparison of the ability to mobilise calcium in GM- 
CSF treated BMM. This may however, merely reflect technical problems. Indeed, the 
increase in CCR1 mRNA expression was reflected by an increase in the binding of 
MIP-la to BMM, revealing that an increase in the cell surface expression of MIP-la 
receptor numbers did occur in GM-CSF stimulated BMM. The potential effects of a 
2-3 fold increase in receptor numbers on BMM function is unclear and warrants
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further investigation. It is not possible to say with certainty whether the observed 
effects of GM-CSF and IL-3 on CCR1 expression relate to a proinflammatory effect or 
one involved in stem cell proliferative control, but several points suggest that it is 
more likely to be the result of a role in an inflammatory context. Firstly, the MIP-la 
stem-cell inhibitory receptor has not yet been identified. Current evidence from our 
laboratory suggests that it is not CCR1 (Graham et al 1996), although others have 
suggested a role for human CCR1 in BFU-E inhibition (Su et al 1997). Secondly, the 
observation that CCR1 expression was also elevated in splenic cells, suggests that this 
pattern of expression may also occur in B and T cells (since B cells and to a lesser 
extent T cells, are a major cellular component of the murine spleen). A full 
understanding of the involvement of GM-CSF and IL-3 in the regulation of MIP-la 
receptor expression, in the context of stem cell proliferative control, must therefore 
await identification of the receptor through which MIP-la transduces the signal for 
stem cell inhibition.
So what is the function of GM-CSF, IL-3 and TGF-p in the regulation of MIP- 
l a  expression? As discussed above, these studies have implicated GM-CSF and IL-3 
in the regulatory control of MIP-la expression in BMM. In the context of stem cell 
proliferative control, GM-CSF and IL-3 may function as stimulators of MIP-la 
expression, whilst TGF-p may act to suppress this induction of MIP-la. As discussed 
in sections 2.2 and 2.11, GM-CSF and IL-3 clearly function as haemopoietic 
regulators. So if GM-CSF and IL-3 upregulate MIP-la expression, why does this not 
result in inhibition? One explanation maybe that full translation of this increased MIP- 
la  mRNA may not occur and indeed it is uncertain exactly what level of functional 
MIP-la protein would be required to result in inhibition, in either autocrine or 
paracrine situations. In addition, it is always important to consider the many other 
factors that may be present in the bone marrow microenvironment. It is clear that MIP- 
l a  functions within a relatively narrow window within the stem cell compartment and 
it may be speculated that MIP-la acts as a stem cell inhibitor only during occasions of 
extreme stress, such as a systemic infection. During such an infection extensive 
haemopoietic stem cell proliferation may occur and one possible role for MIP-la may 
therefore be to ‘dampen down’ proliferation of these cells.
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7.9 The Importance of MIP-la in Disease Pathology
The work presented in this thesis suggests that a complex relationship exists 
between MIP-la and at least three other haemopoietic growth factors. This has 
important implications not just for the regulation of haemopoietic stem cell 
proliferation, but in the much wider context of a multitude of diseases and 
pathological states. Indeed it is now evident, particularly from the study of mice 
deficient in the functions of GM-CSF, IL-3 and IL-5, that GM-CSF and IL-3 may be 
important mediators of inflammation, as discussed in sections 2.2 and 2.11. For 
instance GM-CSF, IL-3 and MIP-la have been implicated in the functions of mature 
eosinophil, basophil and mast cells. These cells are critical to the development of 
inflammatory disorders such as asthma and in the protection against parasitic 
infections. This complex picture is further complicated by the existence of over 35 
other chemokines (see table 3.1), and others are likely to be identified in the future. 
Results presented in this thesis suggest that the relationship with GM-CSF and IL-3 
appears relatively non-specific and can be extended to other chemokines. Indeed other 
researchers have shown that CIO, MPIF-2 and IL-8 are all inducible by GM-CSF 
and/or IL-3 (Orlofsky et al 1994, Patel et al 1997, Takahashi et al 1993). Clearly this 
results in a very large and complex interacting network of inflammatory cytokines 
with potentially important pathological implications.
As discussed in section 3.6.3, MIP-la is implicated in a wide variety of 
diseases and pathological states. Perhaps the most compelling evidence for the in vivo 
importance of M IP-la is the report by Cook et al (1995). In this report, the authors 
generated mice in which the gene for MIP-la was disrupted and demonstrated that 
these MIP-la'7' mice were resistant to coxsackievirus B3 (CVB3)-induced myocarditis 
and exhibited a reduced pneumonitis following influenza virus infection. The cardiac 
damage resulting from CVB3 infection therefore appears to be the result of the actions 
of recruited inflammatory cells, rather than from a direct effect of the virus. This 
report clearly demonstrated an in vivo role for MIP-la in viral infection and has 
subsequently been followed by a number of other studies. For instance Epstein Barr 
virus (EBV) has recently been reported to induce the expression of MIP-la (and IL-8) 
in human neutrophils, which may result in the chemoattraction of T and B cells and 
therefore enhance the ability of EBV to infect T and B cells (McColl et al 1997).
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Infection of human monocytes with influenza A virus has been shown to result in the 
expression of MIP-la and other CC chemokines (Sprenger et al 1996). A critical role 
for MIP-la in NK cell inflammatory responses against murine CMV (MCMV) was 
also recently reported (Salazar-Mather et al 1998). These studies, combined with the 
mounting evidence from studies on HIV pathogenesis (see section 3.9) suggest that 
this role in viral pathogenesis is likely to be widespread. Indeed this importance is 
further underlined by the emergence of various virally encoded homologues of MIP- 
l a  and chemokine-like receptors (see section 3.10)
MIP-la is implicated in several autoimmune diseases, perhaps most notably 
that of MS. Indeed, administration of anti-MIP-la antibodies results in prevention of 
experimentally induced MS (Karpus et al 1995). Intriguingly, TGF-p may also play a 
protective role in MS (Kuruvilla et al 1991) and given the clear relationship between 
TGF-p and MIP-la, as detailed in this thesis, it is tempting to speculate that these may 
be linked. In a similar way, both GM-CSF and MIP-la have been implicated in the 
development of rheumatoid arthritis (Koch et al 1994, Haworth et al 1991).
The suppressive actions of TGF-p may also reflect an involvement in anti­
inflammatory processes and this suggestion is supported by the suppressive effect of 
TGF-P 1 on other chemokines such as JE and MARC. The observation that MIP-la 
expression is elevated in TGF-P 1 null mice suggests that this suppressive role is likely 
to be important in vivo.
7.10 Conclusions and aspects for further investigation
MIP-la, in addition to its roles in the normal function of the 
immunohaemopoietic system, is clearly implicated in a wide variety of diseases and is 
important in many pathological circumstances. This underlines the need to further 
understand how its expression is controlled under normal circumstances. The aim of 
this thesis was to attempt to further understand the network of regulatory factors 
controlling the expression of MIP-la in the bone marrow. As discussed above, this 
included a previously identified suppressive role for TGF-p. With the observation that 
GM-CSF and IL-3 appear to function as stimulators of MIP-la mRNA expression in 
BMM, yet further complexity is now evident in the existing network of factors 
involved in M IP-la expression. In conclusion, both stimulatory and inhibitory
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mechanisms appear to regulate the expression of MIP-la and other chemokines in 
BMM, forming a complex interacting network between GM-CSF, IL-3, TGF-P, MIP- 
la , other chemokines and perhaps even some of their receptors. Figure 7.1 provides a 
summary of the proposed interactions between MIP-la, TGF-p, GM-CSF, IL-3 and 
other factors in BMM, as suggested by work reported in this thesis.
Many others aspects of these interactions remain in question. For instance, is 
there also a reciprocal relationship between MIP-la and GM-CSF / IL-3 and what 
effect does TGF-p have on the expression of GM-CSF and IL-3? A previous report 
has suggested that TGF-p downregulates the expression of receptors for GM-CSF and 
IL-3 on murine haemopoietic progenitor cell lines (Jacobsen et al 1991a). If TGF-p is 
also able to suppress GM-CSF and IL-3 receptor expression on BMM, then this could 
result in a reduced responsiveness of BMM to GM-CSF and IL-3 (with a subsequent 
reduced expression of MIP-la). TGF-p has also been reported to downregulates TNF- 
a  or IL-1-induced GM-CSF expression in human articular chondrocytes (Alsalameh et 
al 1994). Further investigation is required to ascertain the precise relationship between 
these different factors and how this affects their individual expression, in both 
constitutive and induced circumstances. For instance, it is uncertain whether or not 
BMM constitutively express GM-CSF or IL-3. A study by Temeles et al (1993) 
suggests that BMM do not express mRNA for either GM-CSF or IL-3. This would 
imply that GM-CSF and IL-3 do not function in an autocrine manner to regulate MIP- 
la  expression in BMM. This observation is in agreement with experiments using 
neutralising antibodies against GM-CSF and IL-3, the results of which are shown in 
figures 6.6 and 6.8B respectively. This suggests that under uninduced conditions, 
BMM are not a source of GM-CSF or IL-3 and that they must be produced by other 
types of accessory cells within the bone marrow microenvironment. Although in the 
study reported by Temeles et al (1993), stimulation of BMM with cytokines did not 
result in the induction of GM-CSF or IL-3 expression, it is possible that induction of 
GM-CSF and IL-3 may occur in BMM following an appropriate inductive stimulus 
(such as LPS?). This induced GM-CSF and IL-3 could then operate in an autocrine 
manner to induce MIP-la expression. This potential for ‘induced autocrine’ 
expression is also illustrated in figure 7.1. It is unlikely that this is the whole story, as 
other growth factors within the bone marrow microenvironment are almost certain to
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affect the expression of GM-CSF, IL-3, TGF-P and MIP-la. For example, IL-1, TNF- 
a  and IFN-a have all been reported to affect GM-CSF expression in a variety of cell 
types (Fibbe et al 1986, Gollner et al 1995). This creates the potential for yet further 
complexity in this network.
A molecular analysis of the precise mechanisms, such as transcription factors 
and other downstream signal transduction pathways, through which GM-CSF and IL-3 
achieve induction of MIP-la expression, is also worthy of further investigation. As 
discussed earlier in section 7.4, such an analysis could prove particularly informative, 
if coupled with analysis of other chemokine genes, such as JE/MCP-1. Preliminary 
results, not presented in this thesis, obtained from studies using the protein synthesis 
inhibitor Cyclohextmide have indicated that GM-CSF-induced MIP-la expression is 
at least in part transcriptionally regulated. Analysis of the molecular elements involved 
in the regulatory control of MIP-la expression by GM-CSF and IL-3 is clearly an area 
with extensive potential for further investigation. This could also be coupled with an 
analysis of those pathways involved in TGF-p 1 mediated suppression of MIP-la 
expression, with the aim of determining exactly how TGF-p suppresses MIP-la 
expression. In fact, a recent report has suggested that TGF-P suppreses MCP-1 
expression in macrophages, possibly by downregulating the expression of c-jun, one 
of the components of the AP-1 transcription factor complex (Kitamura et al 1997). It 
would be of interest to examine this observation further in the light of the results 
presented here in this thesis and this might provide further clues as to why GM-CSF, 
IL-3 and TGF-p appear to be so non-specific in their effects on chemokines.
One final area worthy of further attention, is an investigation into the in vivo 
interactions between MIP-la, GM-CSF, IL-3 and TGF-pl. It is assumed that the 
regeneration of the haemopoietic system after sublethal myeloablation involves the 
action of endogenously produced haemopoietic growth factors. Indeed, following in 
vitro irradiation the levels of GM-CSF protein were previously reported to increase in 
murine long-term bone marrow cultures and spleen cell cultures (Naparstek et al 1985, 
Onoda et al 1980). A study reported by Chang et al (1995), demonstrated that a 
marked increase in GM-CSF mRNA occurred during the first two weeks of the 
recovery period following sublethal irradiation. This increase in GM-CSF mRNA 
expression appeared to precede the cellular recovery, which did not appear until
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approximately 2 weeks post-irradiation. Therefore, an analysis of MIP-la expression, 
together with that of GM-CSF, IL-3 and TGF-p, in sublethally irradiated mice could 
prove highly informative. Admittedly such an analysis might however be relatively 
difficult to undertake, given the relatively low levels of cytokines present in bone 
marrow and particularly with the very small numbers of cells that would be present 
during the earlier stages of reconstitution of the bone marrow microenvironment.
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